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ABSTRACT 
 
The role that the human microbiome and metabolome may play in health and disease is well 
established. To date however, research focus has centred on the human gut microbiome. The 
microbiome of the respiratory tract has received substantially less attention. Here, the respiratory 
microbiome of patients with lung cancer and chronic obstructive pulmonary disease, both diseases 
which have unmet clinical needs, was profiled. For lung cancer, several microbiome-derived biomarkers 
were detected that may allow, through a non-invasive sampling technique, for the diagnosis of disease 
status and stage. For chronic obstructive pulmonary disease (COPD), a number of functional differences 
in the lung microbiome of patients were identified, which may help to explain progression of the 
disease. Additionally, for lung cancer, metabolomic fingerprinting of sputum from patients revealed a 
number of metabolites with the ability to differentiate between negative and positive patients, but who 
presented with clinically-similar symptoms. Using the techniques developed in these clinically-focussed 
projects, studies of the human microbiome’s temporal variability and its response to extreme 
physiological and environmental stress were completed. Longitudinal sampling of the saliva of healthy 
individuals over a one year period, showed that the salivary microbiome and metabolome is remarkably 
stable, but that there is some change in bacterial load. Human saliva is considered a valuable source of 
both microbiome and metabolome-derived biomarkers, and this work suggests that the comparison of 
samples collected at different time-points in the year is valid. By sampling members of the Trans-
Antarctic Winter Traverse expedition, an analogy to how the human microbiome and metabolome may 
alter as a result of prolonged human space travel was possible. The salivary microbiome was shown to 
increase in bacterial load and diversity as a result of the environmental and physiological stresses of the 
expedition, whilst the stool microbiome was shown to maintain the individual differences evident 
before the start of the expedition. Additionally, the metabolome of stool, saliva, and blood plasma was 
shown to be stable throughout the expedition. This research project has shown that analysis of the 
human microbiome in areas not frequently studied by the field in general can provide novel insights into 
diseases with unmet clinical needs, and the role that both the microbiome and metabolome can have in 
the body’s response to stress.  
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CHAPTER 1 | Human Microbiomics and Metabolomics in 
Health and Disease 
 
The sequencing of the human genome in 2001 has allowed a unique insight into the interaction 
between the human body and its microbial inhabitants (Relman and Falkow, 2001). At least 223 human 
genes have been identified which have homologues found only in bacteria (Lower, Lower and Kurth, 
1996), suggesting a microbial origin through horizontal gene transfer. This suggests the importance of 
bacteria, viruses, and other microbial organisms, in shaping the genetic evolution of humans and thus, 
the importance of understanding their genomes and the host-microbiome interactions that exist. 
 
It is widely accepted that the majority of microorganisms are not cultureable under normal laboratory 
practices; the exact figure predicted to be between 5% to 15%. As Figure 1.1 shows, since the advent of 
next-generation sequencing technology has allowed for bacterial 16S ribosomal ribonucleic acid (rRNA) 
sequences to be analysed without the need for prior culturing, the number of predicted bacterial 
species has increased significantly (Rinke et al., 2013). 
FIGURE 1.1 | Increasing Disparity Between 16S Sequences from Named Isolates and Clones 
Next-generation sequencing has enabled the analysis of bacteria without the requirement to culture 
them beforehand. This has rapidly increased the number of ‘predicted’ bacterial species (clones) in 
comparison to those which have been cultured (isolates). Figure taken from Rinke et al., (2013). 
[ 2 ] 
The issue of non-cultureable bacteria is paramount in the field of microbiomics as it limits understanding 
of microbial systems, particularly as unculturable bacteria are not evenly distributed across phyla. This 
would bias any analysis approach based on culturing. There are multiple reasons for why certain 
bacteria are considered unculturable, including specific nutrient requirements, pH conditions, 
atmospheric oxygen levels, or the presence of other microorganisms. Although some progress has been 
made in improving culture techniques, such as improved natural environment simulation (Vartoukian, 
Palmer and Wade, 2010), the reliance is still on the use of sequencing techniques to characterise the 
microbiome in all ecological systems (Schloss and Handelsman, 2005). 
 
These issues constituted the driving force behind the creation of the Human Microbiome Project (HMP). 
Focusing on metagenomic analysis of microorganisms from across the human body, Figure 1.2, their aim 
was to build a database of 16S rRNA that characterises a ‘normal’ human microbiome (Peterson et al., 
2009). Identifying this has been difficult, and in fact, may prove impossible. Studies into the gut 
microbiome have found that no single bacterial species was detectable in all gut samples from 154 
humans. It may be however, that a core gut microbiome exists in terms of metabolic functional 
capability rather than taxonomic composition (Kuczynski et al., 2010).  
 
The Human Microbiome Project is developing the resources, both technical and knowledge-based, that 
will enable microbial communities to be used both as a means of treatment for disease, but also 
possibly, in its diagnosis. Furthermore, the microbial components of faeces, saliva, sputum and skin 
swabs have two key features that make it ideal for a diagnostic sample. Firstly, they are easily 
obtainable, and secondly, they hold a significant resource of molecular information relevant to disease 
(Sonnenburg and Fischbach, 2011). The purpose of the Human Microbiome Project is to enable the 
study of variation in the human microbiome and its influence on disease state. One of its most beneficial 
tasks will be to create a standardised data resource that will act as a reference for researchers exploring 
changes in microbial populations (Peterson et al., 2009).  
 
[ 3 ] 
There are a number of social, ethical and legal implications which must be appreciated and overcome 
during the Human Microbiome Project. Limited knowledge of the human microbiome may mean that it 
is hard to fully identify and explain the potential risks and benefits of partaking in studies to participants, 
which has the potential to cause harm to participants and the reputation of the project. Furthermore, 
biasing of sampling may lead to a non-representative population of participants; the current Human 
Microbiome Project only accepts healthy adults between the ages of 18 and 40 as participants. Sampling 
of participants must also be relatively un-invasive so as to minimise discomfort and biasing of results. 
These implications are not unique to the Human Microbiome Project, but they must be appreciated for 






FIGURE 2.1 | The colour coding shows the distribution by body site which have been sequenced under the Human
Microbiome Project, or are currently in the pipeline. These include the eyes (0%), blood (1%), GI Tract (9%), oral area
(26%), skin (21%), airways (14%) and the urogenital system (9%). Figure created with information from Peterson et al.,
(2009).
FIGURE 1.2 | Distribution of Bacteria in the Human Microbiome Sequenced by the HMP 
Colour coding indicates the percentage composition distribution, by body site, of bacteria that have 
been sequenced under the Human Microbiome Project, or are currently in the pipeline. These include 
the eyes (≈ 0%), blood (≈ 1%), gastrointestinal tract (≈ 9%), oral area (≈ 26%), skin (≈ 21%), airways (≈ 
14%), and the urogenital tract (≈ 9%). Figure adapted from Peterson et al., (2009). 
[ 4 ] 
are seeking to complement it (McGuire et al., 2008). 
 
As the field studying microbiomes has established and developed, so too have the terms used to 
describe the range of approaches and study features, Table 1.1. As the field moves towards 
standardisation, to allow for accurate comparisons it is important that consistent terms are used to 
describe studies into the microbiome. It is likely that as the field expands, and new technologies and 
approaches are developed, the terms outlined in Table 1.1 will be further developed (Kuczynski et al., 
2012). 
 
1.1 | Sequencing and Sampling Techniques in Microbiomics 
 
Since the invention of chain-terminating methods (Sanger, Nicklen and Coulson, 1977), deoxyribose 
nucleic acid (DNA) sequencing has been at the forefront of nearly all life science disciplines. Many early 
microbiome sequencing studies employed clone sequencing, whereby the 16S rRNA gene, Figure 1.3, is 
amplified and then cloned to a high copy number plasmid used to transform Escherichia coli. Individual 
colonies would then be picked and used in single capillary sequencing reactions using chain-terminating, 
TABLE 1.1 | Terms in Microbiome Research 
In a move towards standardisation in the field studying microbiomes, the terms used to describe the 





An amplified fragment of DNA from a region of a marker gene, such as 16S 
rRNA, that is generated through polymerase chain reaction (PCR) 
Metabarcoding 
A method for assessing the biodiversity of a system, such as the microbiome, 
usually through sequencing or other molecular analysis of a marker gene 
Metagenomics The study of the collective genome of microorganisms from an environment 
Microbiome The collection of genes that are harboured by microbiota 
Microbiomics The study of the microbiome 
Microbiota The collection of microbial organisms from a defined environment 
Operational 
Taxonomic Units 
Sequences are generally collapsed into these based on sequence similarity, 
usually set at a threshold of 97% 
[ 5 ] 
fluorescently labelled dideoxy nucleoside triphosphates (ddNTPs). Microbiome studies employing 
Sanger sequencing of clone libraries would usually be in the scale of 1-5,000 reads per study (Gill et al., 
2006), and with relatively low numbers of samples due to the sequencing costs involved. Sanger 
sequencing carried the benefits of long sequence reads, up to 1,000 base pair (bp), and accuracy rates in 
excess of 99.9% (Shendure and Ji, 2008), allowing identification to the species level of taxonomy. It is 
however, an expensive method, in both financial and human resources, in comparison to next-
generation sequencing technologies and techniques.   
 
The application of next-generation sequencing technologies to the field of microbiomics has allowed for 
much larger studies, in terms of both sample number and sequence number. One of the main 
technological advancements was the introduction of the 454 pyrosequencing system (Margulies et al., 
2005). This system allowed for the high-throughput sequencing of thousands of 16S rRNA amplicons, 
from multiple samples in one system run. Sequencing using 454 pyrosequencing suffers from a 
drawback in terms of reduced sequencing read lengths, usually around 400 bp, compared to traditional 
Sanger sequencing, and also a high rate of homopolymer errors, making it prone to a higher error rate 
(Shendure and Ji, 2008). However, the substantial increase in sequence volume, and matched reduction 
in sequencing cost, saw it quickly replace Sanger sequencing as the primary technology in the field of 
microbiomics; enabling some of the largest microbiome studies to date to be completed, such as those 
completed by the Human Microbiome Consortium (The Human Microbiome Consortium, 2012b).  
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FIGURE 1.3 | The Structure of the 16S rRNA Gene 
The 16S rRNA gene is central to current microbiome studies. It is a component of the 30S small subunit 
of prokaryotic ribosomes and is essential for bacterial cell function. Because of this, it is found in all 
bacterial genomes, albeit at varying copy numbers. There are nine regions, of various sizes, of the gene 
that are hyper-variable, regions V1 to V9. Sequencing these regions allows for assessment of phylogeny. 
[ 6 ] 
The main limitation of sequencing of the 16S rRNA gene, either through clone sequencing or 454 
pyrosequencing, is that information on the microbiome is limited to its taxonomic composition, and 
usually restricted to the genus level of resolution. The next step in understanding the role that the 
microbiome plays in health and disease is characterising both its species level composition and 
functional capacity. This requires a metagenomic approach to sequencing, whereby the entire microbial 
DNA obtained within a sample is sequenced, rather than just isolated 16S rRNA sequences. As with 
previous advances in the field of microbiomics, this has been allowed through advances in sequencing 
technologies. Although 454 pyrosequencing has been used in metagenomic studies, it is somewhat 
limited by the total number of reads obtainable per run, compared to other available sequencing 
platforms (Loman et al., 2012). This means that sequencing depth may not be sufficient to identify low 
copy number sequences, which may have important biological implications. 
 
Metagenomic sequencing techniques are beginning to be applied to the human microbiome, in both 
health and disease. One of the earliest metagenomic studies catalogued the microbial gene content of 
the gut of 124 European individuals. A total of 3.3 million non-redundant microbial genes were 
identified, approximately 150 times as many as contained within the human genome. Within the 
functional capacity of the microbiome, approximately 40% of genes were common between at least 50% 
of samples, suggesting a significant element of individual differences exist between microbiomes (Qin et 
al., 2010). 
 
Microorganisms which do not have a phylogenetic marker gene, as bacteria do in the 16S rRNA gene, 
such as viruses, can be identified through metagenomic sequencing (Willner et al., 2012b), exploring the 
wider microbiome. A further step in the application of metagenomic sequencing is the emergence of 
metagenome wide association studies. For example, in a study of Type 2 diabetes, the taxonomic 
composition of the gut microbiome varied between individuals, but not between disease and control 
groups (Qin et al., 2012). 
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1.1.1 | Bioinformatic Resources for Microbiome Research 
 
The field of microbiomics has advanced significantly with improvements in sequencing technologies. 
However, advances in this area alone needed to be equalled by advances in sequence analysis methods. 
With Sanger sequencing, analysis is usually refined to basic local alignment search tool (BLAST) (Altschul 
et al., 1990) searching of the nucleotide sequence to assign taxonomy. However, the advent of next-
generation sequencing has substantially increased the number of DNA sequences in microbiome 
studies. Improvements in bioinformatic resources needed to match advances in sequencing ability in 
order to fully utilise the technology in microbiome studies. To this end, a number of bioinformatic 
pipelines, aimed primarily at high-throughput, barcoded 16S rRNA sequences, were developed. 
 
The Quantitative Insights into Microbial Ecology (QIIME) pipeline has allowed for a standardised 
approach to 16S rRNA sequence analysis (Caporaso et al., 2010). The move towards metagenomic 
sequencing of the microbiome has resulted in the development of additional pipelines, backed up by 
sufficient computing power, to enable an entire metagenomic sequencing project to be taken from raw 
sequence to functional and taxonomic alignments in one facility (Meyer et al., 2008).  
 
Although analysis pipelines are important in taking raw sequences to biological interpretation, they rely 
entirely on genomic databases which act as repositories for annotated sequences. For example, 16S 
rRNA analysis pipelines, such as QIIME, use, amongst others, the Ribosomal Database Project (RDP) 
database (Cole et al., 2009), Greengenes (DeSantis et al., 2006), or SILVA (Quast et al., 2013) databases 
to assign taxonomy to sequences. With metagenomic studies, databases which store functional 
annotations are also required. The Metagenomic Rapid  Annotation using Subsystem Technology (MG-
RAST) pipeline, for example, relies heavily upon the M5nr non-redundant database (Wilke et al., 2012), 
which combines protein sequences and annotations from a number of sources. 
 
In addition to the creation and maintenance of annotation databases, an important theme that has 
emerged within the field of microbiomics is open data sharing of sequences, allowing researchers to 
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combine datasets from different experiments to further their work. The three main sequence 
depositories are the European Nucleotide Archive (Leinonen et al., 2011), the DNA Databank of Japan 
(Kosuge et al., 2014), and the National Centre for Biotechnology Information (NCBI) Sequence Read 
Archive (Kodama, Shumway and Leinonen, 2012). 
 
1.1.2 | Sampling the Microbiome 
 
Due to the rapid expansion of the field of microbiomics, a diverse range of sampling methodologies have 
emerged. This diversity has led to difficulties in the comparison of microbiome sequence data from 
different studies; due to potential bias that may have been introduced at different stages of the analysis 
pipeline. The common first step, the selection of sampling material, is important to ensure accurate 
representation of the environment being studied. The oral cavity, for example, offers many sources of 
sampling, including saliva, tongue, tonsils, teeth, cheeks, and hard and soft palates. Sequencing projects 
have shown these areas to consist of a defined microbiome, that is not fully shared with other areas 
(Aas et al., 2005). Therefore, comparing the microbiome of the oral cavity between two studies, one 
using saliva and one using tongue swabs, would not be a valid comparison of the oral microbiome, but 
rather a spatial comparison within. 
 
Extraction of genomic DNA is one of the most important steps in microbiome studies. It is however, one 
of the steps whereby the largest amount of bias can be introduced. For example, if a commercial DNA 
extraction kit is used, the resulting sequence data is unlikely to be comparable between two different 
kits, because of differing levels of extraction efficiency (Vishnivetskaya et al., 2014). Differences in 
sample storage before DNA extraction, however, have been suggested to have minimal impact on 
resulting sequence data. If any slight difference is introduced by storage practices, these are likely to be 
surpassed by differences introduced through DNA extraction technique (Wu et al., 2010). 
 
One of the more recent issues to arise in microbiome studies is that of contamination of experimental 
reagents and kits with microbial DNA. This is a particularly important issue in studies examining 
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microbiomes with low concentrations of microorganisms, or where the microbiome constituent of 
interest is at a low concentration (Laurence, Hatzis and Brash, 2014). Additionally, clinical diagnostic 
techniques using DNA extraction kits could be compromised by contamination with bacteria, such as 
Legionella, during the manufacturing process (van der Zee et al., 2002). 
 
1.2 | Human Microbiomics in Health and Disease 
 
Due to the ease of sample collection, research into the human microbiome originated in the human gut 
and intestinal system. Following this trend, research in this area is generally more advanced, and 
crucially, starting to relate bacterial community diversity to physiological conditions, with some 
explanation of causality. 
 
Sequencing of the core gut microbiome in lean and obese twins has shown that the human gut 
microbiome has a degree of familial similarity, but that each person has a unique bacterial population 
composition at the species level of taxonomy. Furthermore, similar levels of co-variation between 
monozygotic (identical) and dizygotic (non-identical) twins was displayed, though there was a shared 
core microbiome at the gene level. This study further revealed that a move away from the core 
microbiome, in terms of phylum-level change and reduced microbial diversity, altered the bacterial 
genes present and thus resulted in a different physiological state, in terms of obese and lean weights 
(Turnbaugh et al., 2009). 
 
The power of microbiomics to investigate and further understand human diseases was quickly realized 
after early studies into the gut microbiome, and enabled by rapid advancements in sequencing 
technologies, and a reduction in their respective costs. Diseases that affect the gut received the majority 
of focus in terms of the influence of the host-microbiome interaction on disease aetiology, progression, 
and treatment. Crohn’s disease, a chronic idiopathic inflammatory condition of the gastrointestinal tract 
(Beaugerie et al., 2006), is an early example of this. One of the preliminary studies into the microbiome 
of Crohn’s patients, albeit using only six patients and six healthy individuals and early culture-
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independent techniques, suggested that Crohn’s disease is characterised by a reduced diversity within 
the Firmicutes phylum (Manichanh et al., 2006). Later studies utilising advances in sequencing 
technologies have allowed further insights into Crohn’s disease, particularly the phenotypic differences 
that exist within a disease cohort. Spatial differences within the gastrointestinal tract have been shown, 
including the disappearance of Faecalibacterium and Roseburia from the core microbiome in patients 
with ileal Crohn’s disease, and an increase in Enterobacteriaceae and Ruminococcus gnavus compared 
to patients with colon Crohn’s disease (Willing et al., 2010). This highlights the potential power of 
microbiomics in improving clinical outcomes as diseases, such as Crohn’s disease, could have different 
treatment regiments developed, such as antibiotic therapy, that target the microbial element of 
differing phenotypes.  
 
For many diseases, there are evident shifts in the microbiome of affected patients compared to healthy 
individuals. However, the extent to which the microbiome is a causative factor in disease aetiology and 
progression, or whether the change is simply a reflection of disease state, is poorly understood. Ever 
since the link between Helicobacter pylori infection and gastric cancer was identified (The EUROGAST 
Study Group, 1993), the role that the microbiome may play in cancer has received increased attention. 
For example, colorectal tumour tissue has been shown to form a niche for Coriobacteria, whilst showing 
decreased levels of Enterobacteria (Marchesi et al., 2011). However, as the microbiome of colorectal 
tumour tissue was analysed after carcinogenesis, the causative contribution of the microbiome to the 
initiation event is not clear. Further work on colorectal cancer has suggested that Fusobacterium 
nucleatum is significantly increased in abundance in patients with colorectal cancer. Again however, 
sampling of the tumour tissue microbiome after the initiation of tumorogenesis means that a causative 
link with F. nucleatum cannot be established. The pro-inflammatory mechanisms of the bacteria may 
provide a possible causative factor, but the opportunistic infection of an immune-compromised patient 
cannot be ruled out (Castellarin et al., 2012). 
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Approximately 25 diseases and syndromes have been associated with the microbiome of the 
gastrointestinal tract, albeit at a level of correlation rather than causation. These have included oral and 
gastrointestinal cancers (Ahn, Chen and Hayes, 2012), colorectal cancer (Sobhani et al., 2011) and 
Crohn’s disease (Manichanh et al., 2006). Nevertheless, increasing numbers of studies are attempting to 
establish a cause and effect relationship, such as through the application of Koch’s postulates to mouse 
models of inflammatory bowel disease (de Vos and de Vos, 2012). There are multiple mechanisms 
through which the host microbiome could contribute to a carcinogenic event. For example, the 
inflammatory response mediated by the host microbiome may lead to localised DNA damage, which 
may lead to the formation of an oncogene, one of the preliminary stages in carcinogenesis. Additionally, 
the host microbiome may biochemically alter metabolites, increasing or prolonging the presence of 
carcinogens. The oral microbiome, for example, has the capacity to convert ethanol to acetaldehyde; a 
genotoxin capable of causing DNA damage. Normally, ethanol is metabolised to acetaldehyde by alcohol 
dehydrogenase, and then to acetic acid by aldehyde dehydrogenase. However, the microbiome’s 
contribution has the effect of increasing ethanol to acetaldehyde conversion, resulting in prolonged 
periods of elevated acetaldehyde levels in the oral cavity and gastrointestinal tract, which may 
contribute to risk of oral and gastrointestinal cancer risk (Ahn, Chen and Hayes, 2012). 
 
1.3 | Microbiome Changes Associated with Respiratory Diseases 
 
Due to the established link between cystic fibrosis (CF) and the lung microbiome, much of the early work 
in the field of respiratory microbiomes focused on this disease. However, it was not until early culture-
independent were developed that the role of the microbiome in lung disease could be explored. One 
such method, terminal restriction fragment length polymorphism, was first used to identify a number of 
bacterial species previously unconnected to cystic fibrosis, a number of which were strict anaerobes 
(Rogers et al., 2004). 
 
Until relatively recently, it was believed that the human lungs were a sterile environment in terms of 
microbial communities (Charlson et al., 2011). This was commonly accepted until culture-independent 
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microbiological techniques demonstrated that the lungs were in fact colonized, in both healthy and 
diseased individuals, by bacteria (Erb-Downward et al., 2011). These findings have opened a new field of 
microbiome investigation; one which particularly relates to microbial diversity as an indication of 
diseased state. Currently, the majority of research concerning the lung microbiome has focused on 
microbial diversity in relation to the lungs and airways of patients with asthma and cystic fibrosis. 
 
1.3.1 | Microbial Diversity in the Asthmatic Lung 
 
Asthma is a respiratory disease which is characterised by a hyper-responsiveness of the airways to 
various stimuli. This response leads to obstruction of the airways via a combination of bronchial smooth 
muscle spasm and inflammation; resulting in edema of the respiratory mucosa and mucous secretions. 
Asthma is usually diagnosed from coughing, wheezing and dyspnea, and commonly treated with steroids 
inhaled through a nebulizer to reduce airway inflammation (Weinberger and Abu-Hasan, 2007). 
 
Before the wide-spread use of next generation sequencing techniques, studies into the asthmatic lung 
relied heavily upon the use of bacterial culture techniques. Although limited in its sensitivity to 
cultureable bacteria, the technique has suggested that there may be a causative link between the lung 
microbiome and the development of asthma. For example, Bisgaard et al., followed newly born infants 
for five years, finding that neonates who, at one month old, had their hypo-pharyngeal region colonised 
with Streptococcus pneumoniae, Haemophilus influenza or Moraxella catarrhalis, are at an increased 
risk of developing a recurrent wheeze and asthma at an early stage in life (Bisgaard et al., 2007). This 
study suggests, potentially, that the presence of at least one of these three microorganisms may lead to 
the development of asthma. However, as this was not uniformly all cases, it may again be that the 
presence of these microorganisms is an indicator of a predisposed state for asthma, rather than a cause 
of asthma in itself. 
 
Differences between the microbial populations of a non-diseased lung and an asthmatic lung have been 
shown, through 16S rRNA amplicon sequencing of 24 adults with asthma (11 adults), chronic obstructive 
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pulmonary disease (five adults) or no known lung condition (eight adults). A total of 5,054 16S rRNA 
bacterial sequences, corresponding to a mean of around 2,000 bacterial genomes per cm2 surface were 
sampled. The pathogenic Proteobacteria, particularly Haemophilus species, were significantly more 
frequent in the bronchi of adult asthmatics or COPD patients. Furthermore, Bacteroidetes, particularly 
Prevotella species, were significantly more common in control adults than asthmatics or COPD patients 
(Hilty et al., 2010). 
 
The study by Hilty et al., was one of the first to identify a difference between the lung microbiome as a 
whole, rather than individual bacterial species, of an asthmatic and "healthy" individual. However, it was 
not able to identify whether this difference was a cause or a reflection of a diseased state. This question 
has been the focus of subsequent studies to evaluate whether a causative link exists. A possible 
causative link between the lung microbiome and asthma has been suggested by Huang et al., who found 
that when patients with sub-optimally controlled asthma were treated with clarithromycin, they 
displayed a greater bacterial diversity in their lungs compared to their pre-treatment state. They further 
found that the patients who responded to clarithromycin had decreased bronchial hyper-responsiveness 
suggesting that a reduction in bacterial load leads to a lessening of the symptomatic burden of asthma 
(Huang et al., 2011). 
 
1.3.2 | Microbial Diversity in the Cystic Fibrosis Lung 
 
Cystic fibrosis is an inherited disease which is characterised by the production of thick, sticky mucus as a 
result of a single defective gene. The defective gene is found on chromosome seven and is a recessive 
gene, so only homozygous recessive individuals will suffer from the condition. In the lungs, the unusually 
thick mucus impedes air flow and also provides an ideal growth medium for bacteria and other 
microbes. As a result, people with cystic fibrosis tend to experience frequent bacterial infections, which 
are one of the significant causes of mortality (Mahenthiralingam, 2014).  
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The cause of cystic fibrosis is directly known and unlike as previously discussed with asthma, microbial 
diversity in the lungs is highly unlikely to be a cause of cystic fibrosis. However, the diversity may instead 
prove to be a highly valuable diagnostic tool which can be used to aide diagnosis and treatment of 
bacterial infections. Morbidity and mortality in cystic fibrosis patients are primarily associated with the 
symptoms of chronic bacterial infections in the bronchial regions of the lungs. These infections were 
originally thought to be caused by a relatively small number of opportunistic pathogens, such as 
Pseudomonas aeruginosa and Staphylococcus aureus. However, recent work using cystic fibrosis sputum 
samples and next generation sequencing by Guss et al., found a significant number of fermenting 
facultative and obligate anaerobes. These are traditionally difficult bacterial species to identify using 
culture-dependent techniques, and some are significant opportunistic pathogens. Many of the bacteria 
identified in cystic fibrosis samples were also present in control samples (Guss et al., 2011), suggesting 
that the lung microbiome of cystic fibrosis patients is more complex than originally believed; with these 
under-sampled organisms playing a role that is yet to be elucidated. Understanding how these 
organisms interact in symptomatic bacterial infections in cystic fibrosis patients will form an important 
next step in improving treatment options; potentially extending the life expectancy of patients 
(Mahenthiralingam, 2014). 
 
1.3.3 | Considerations in Lung Microbiome Studies 
 
In undertaking lung microbiomic studies, there are some aspects that should be considered to avoid bias 
or over-interpretation of the data.  The enclosed nature of the lungs presents difficulties in terms of 
sample collection; and comparisons between different sample materials may be difficult.  Thus, some 
early studies employed bronhcoalveolar lavage fluids as a sampling medium, which later work has 
suggested samples the lower bronchial mucosal flora, different to that of sputum and bronchial aspirate 
samples, which represent the upper bronchial tree (Cabrera-Rubio et al., 2012b). 
 
The use of sputum offers a non-invasive method of sampling.  Choices are also required into the 
methods through which the microbiome is defined.  Thus, whilst sequencing the hyper-variable regions 
[ 15 ] 
of the 16S rRNA gene is widely used for microbiome assessment, due to the limited sequence variation 
it cannot identify bacteria to a species level. With the advance of sequencing technology and 
bioinformatics analysis, definition of the entire metagenomic make-up of the lung microbiome in 
patients with COPD is now possible – thereby providing definitive species-level bacterial identification 
and insights into the function of the microbiome. These technological advances have already been 
utilised in the human gut microbiome (Qin et al., 2010), but to date, are yet to be applied to the lung 
microbiome in COPD patients. 
 
1.4 | Microbiome Changes Associated with Stress 
 
It is well established that exercise-induced stress, that is of a prolonged and/or strenuous nature, can 
lead to significant perturbations of the human immune system. This is believed to create an ‘open 
window’ of increased risk to infection, particularly upper respiratory tract infections. If this stress is 
combined with other life stresses, such as inadequate nutrition or psychological stress, the overall risk 
can be substantially higher (Gleeson, 2007). This ‘open window’ of increased risk to infection suggests 
that an immune system change reduces resistance to colonisation by opportunistic pathogens. It is 
likely, therefore, that this reduced resistance also affects microorganisms forming the commensal 
microbiome in humans; which is present in health. 
 
The human gastrointestinal tract is a system that can be severely affected by stress, both in the short- 
and long-term. These stressors can be real (physical) or perceived (psychological), and can have an 
external or internal origin. Although the stress response has an evolutionary advantage, it can have 
untoward consequences for the gastrointestinal tract. These can include alteration in gastrointestinal 
motility, changes in gastrointestinal secretions, increased intestinal permeability, reduced regenerative 
ability of the gastrointestinal mucosa, and negative effects on the gastrointestinal microbiome 
(Konturek, Brzozowski and Konturek, 2011). 
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The host response to stress can induce changes in the gastrointestinal microbiome, which can have a 
knock-on, long-term effect on the host’s health. However, the microbiome has been shown be able to 
modulate the host’s immune response, to the benefit of both. In rats, Lactobacillus paracasei has been 
shown to produce metabolites that counteract the stress-induced increase in gut permeability. This 
could have important implications in the pathogenesis of gastrointestinal diseases, such as irritable 
bowel syndrome, as probiotics, such as L. paracasei, could be used as a prophylactic or treatment 
regimen (Eutamene et al., 2007). 
 
One of the emerging questions in human microbiomics is the role that the gastrointestinal microbiota 
plays in the psychological state of the host. Animal studies have suggested that the gastrointestinal 
microbiome may have a role to play in the regulation of anxiety, mood, cognition, and pain (Cryan and 
Dinan, 2012). The interaction between the gastrointestinal microbiome and the host brain is mediated 
through the gut-brain axis; the communication system integrating neural, hormonal, and immunological 
signalling between the two. 
 
The gut-brain axis provides the microbial constituents of the gastrointestinal tract a potential route 
through which to indirectly access the brain through biochemical intermediaries. Many gastrointestinal 
diseases, such as inflammatory bowel disease and irritable bowel syndrome, have a psychological 
component, meaning the disease symptoms can be worsened by stress, anxiety or depression (Collins, 
Surette and Bercik, 2012).  
 
The role that stress has on the human microbiome, and the resultant effect that the microbiome has on 
the host in response, is clearly an important area of research. However, a number of questions still 
remain outstanding, including the role gender differences may have in the host-microbiome interaction, 
the gastrointestinal microbiome’s effect on physical and psychological development, and whether the 
microbiome of other human systems also have a role (Foster and McVey Neufeld, 2013). 
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1.5 | Metabolomics as a Tool for Investigating Disease 
 
In a similar way as the human genome is the collection of all the genes in a human, the human 
metabolome is the collection of all of the metabolites in the human body. As with microbiome research, 
any characterisation of the human metabolome is a statistical approximation of the average from a 
limited pool of individuals. Unavoidably, it may be that individuals have a metabolome that is unique to 
them, but changes in a person’s metabolome may be evident as a result of the body’s response to 
various pressure and changes (Pearson, 2007). 
 
FIGURE 2.2 | The majority of metabolomic studies employ a somewhat similar outline. Although the steps can be
somewhat similar between different studies, the methods that constitute each step can be markedly different. This
will vary depending on the type of mass spectrometry used and the type of starting sample. Figure adapted from
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FIGURE 1.4 | Characteristics of Metabolomic Study Pipelines 
The majority of metabolomic studies employ a somewhat similar outline. Although the steps can be 
somewhat similar between different studies, the methods that constitute each step can be markedly 
different. This will vary depending on the type of technique used, and the starting sample. Figure 
adapted from Madsen, Lundstedt and Trygg, (2010). 
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As with the Human Microbiome Project, metabolomic studies are all united by a similar methodology, 
Figure 1.4, in terms of the steps that are taken from sample preparation to biological interpretation 
(Madsen, Lundstedt and Trygg, 2010). All metabolomic methods generate large amounts of data, but for 
studies interested in identifying disease dynamics within the human metabolome, it is likely that only a 
section of the total metabolome will be altered. For example, mass spectrometry (MS) of saliva samples 
from 215 individuals, with cancers including pancreatic, breast and oral, identified as little as 57 
metabolites which were able to predict disease susceptibility for all three cancers (Sugimoto et al., 
2010). 
 
Although significant work has investigated metabolomic changes as a result of cancer, little work has 
focused particularly on lung cancer. However, respiratory diseases have not been completely neglected, 
with COPD receiving particular attention in regards to the metabolomic differences evident at different 
stages of the disease (Ubhi et al., 2012). Metabolomics is a powerful technique in studying the 
physiological response to, or alterations caused by, disease. It is high-throughput in terms of sample 
number, with minimal costs in terms of human and financial resources. It does suffer however, from 
difficulties in comparing data sets generated by differing techniques. 
 
The use of metabolomics in identifying biomarkers for early diagnosis of disease is by no means limited 
to oncology. In theory, metabolomics could be employed to identify biomarkers for any disease that has 
the effect of altering the human metabolome. Parkinson’s disease, for example, has been suggested as a 
disease that could be detected through the use of metabolomics, with recent work on patient plasma 
indicating that 8-hydroxy-2-doxyguanosine could be a biomarker for disease state (Bogdanov et al., 
2008). Diabetic kidney disease, which affects around a third of Type 1 diabetes mellitus patients, has 
also been detected through the use of metabolomics, suggesting the monitoring of Type 1 diabetes 
mellitus patients through metabolomic analysis of urine could significantly reduce complications 
associated with the disease (van der Kloet et al., 2012). 
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1.6 | Methods for Metabolomics 
 
The field of metabolomics began to rapidly expand after the sequencing of the first human genome in 
2001, which showed that genetic sequencing does not fully detail disease associated changes. As Figure 
1.4 details, there are two main technological approaches employed in metabolomics, nuclear magnetic 
resonance (NMR) and mass spectrometry. Although different, both can be used in the three main 
strategies employed in metabolomics, Table 1.2. Each of these have their own individual benefits and 
drawbacks, and varying degrees of applicability. The ‘Gold Standard’ is arguable defined as 
metabolomics, by which as many metabolites within a biological system are identified and quantified, in 
an unbiased way. This has obvious benefits in that biological pathways can be identified, but it is 
demanding in terms of resources and technical requirements. The two other approaches either target a 
small number of previously identified metabolites, or a classification-based approach without 
identification of metabolites (Madsen, Lundstedt and Trygg, 2010). In the field of metabolomics, there is 
a move towards a standardised approach to metabolomics, from sample collection to data analysis and 
reporting, improving the ability to easily compare results from different studies. Although the 
Metabolomics Standards Initiative has been established since 2007, it is yet to fully create and 
implement a set of standards required for peer-reviewed publication (Fiehn et al., 2007). 
TABLE 1.2 | The Three Main Strategies Used in Metabolomics 
The field of metabolomics is not defined by a single strategy, but rather three main techniques, using 
similar technological methods and sampling, each with its own individual benefits and drawbacks. Table 
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1.6.1 | Metabolomics Using Mass Spectrometry 
 
Mass spectrometry methods in metabolomics determines metabolites based on the mass to charge 
ratio in charged particles. The main technologies used in mass spectrometry metabolomics are liquid 
chromatography mass spectrometry (LC-MS), fourier transform ion cyclotron resonance (FT-MS), and 
gas chromatography mass spectrometry (GC-MS) (Spratlin, Serkova and Eckhardt, 2009).  
 
Mass spectrometry techniques are generally considered more sensitive than NMR, with LC-MS 
considered the most sensitive; able to detect compounds at picogram concentrations (Dettmer, Aronov 
and Hammock, 2007). However, if a particular type of compound is the focus of experimentation, then 
this might impact upon choice of mass spectrometry technique. Polar molecules, for example, may be 
detected using electrospray ionisation, though non polar molecules may require a form of pressurised 
chemical ionisation (Spratlin, Serkova and Eckhardt, 2009). 
 
Volatile organic compounds (VOCs), such as alcohols, ketones, and aldehydes, present issues because 
they will not easily be extracted using liquid, as in LC-MS, leading to an incomplete profile being 
analysed. Therefore, GC-MS may be a more appropriate technology because it uses chemical 
derivitisation, without the need for a liquid extraction method. However, not all metabolites will be 
derivatised equally, or at all, and therefore GC-MS can be a less sensitive profiling technique that only 
considers part of the metabolome (Dettmer, Aronov and Hammock, 2007).  
 
It is likely that metabolome profiling, using LC-MS and GC-MS techniques, or derivatives thereof, will 
only be the first step in ‘Gold Standard’ metabolomics. These approaches will generate data that can be 
statistically modelled and individual mass to charge ratios identified that are sufficiently different to, for 
example, separate disease groups. However, it is unlikely that these methods alone will be sufficient to 
identify the biological metabolite that is responsible for this difference. A method, such as FT-MS, will be 
needed to ascertain accurate masses, usually to four to six decimal places, for firm identification (Favé 
et al., 2011). 
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The nature of the metabolome, in terms of the significantly different chemistries of metabolites, means 
that there is no current mass spectrometry platform alone that is able to build an accurate 
representation of the metabolome from a biological sample. Each mass spectrometry method outlined 
here has its own distinct advantages and disadvantages. With metabolomes, particularly those from 
human samples, generally consisting of thousands of metabolites, there is currently no single 
methodology for analysing them all in an accurate, non-biased way. Therefore, a combination of two or 
more mass spectrometry techniques is likely to be the best method to give an accurate representation 
of the metabolome, albeit in separate snapshots (Zhang et al., 2012).  
 
1.6.2 | Metabolomics Using Nuclear Magnetic Resonance  
 
NMR takes advantage of the unique properties of compounds that contain isotopes with an odd number 
or protons and/or neutrons, and the effect that these properties have on the magnetic spin of the 
compound. In NMR spectrometry, the most commonly studied nuclei are 1H and 13C, although nuclei 
from other isotopes have been studied. NMR has a number of advantages and disadvantages unique to 
the technology. In terms of sensitivity, it is considerably less sensitive than mass spectrometry 
technologies; being able to detect metabolites at concentrations above or equal to 10 µmol/L. The 
instrumentation required for NMR is also considerably more expensive than that needed for mass 
spectrometry (Spratlin, Serkova and Eckhardt, 2009). However, NMR does have a number of advantages 
in regards to the minimal sample preparation requirement, and the non-discriminatory and non-
destructive analysis of the biological sample (Dettmer, Aronov and Hammock, 2007). Arguably one of its 
main benefits is the relative ease of metabolite identification, which allows for identification of the 
biological pathway affected by the perturbation, such as disease state, being studied (Griffin, 2003). 
 
1.6.3 | Data Analysis in Metabolomics 
 
As with technological developments in DNA sequencing in the field of microbiomics, similar degrees of 
advancement in data analysis techniques for metabolomics has matched developments in mass 
spectrometry and NMR methodologies. Developments of available tools to analyse high quantities of 
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mass spectrometry or NMR data has arguably been the most beneficial to researchers, allowing 
unsupervised and supervised approaches to data modelling to be quickly and easily completed 
(Dettmer, Aronov and Hammock, 2007; Jarvis et al., 2006). Additionally, web based analysis pipelines 
have been developed that allow for rapid analysis of large datasets, without the need for significant 
local processing capacity, for both data modelling, such as MetaboAnalyst 2.0 (Xia et al., 2012), or 
biomarker discovery, such as Receiver Operating Characteristic (ROC) Curve Explorer and Testing 
(ROCCET) (Xia et al., 2013). 
 
As with microbiomics, reference databases are also essential in allowing identification of metabolites, 
either through NMR spectra, or mass spectrometry mass to charge ratios or retention times. One of the 
largest such databases, for metabolites identified in the human metabolome, is the Human Metabolome 
Database. This contains collections of metabolites with their respective structure, mass, and biofluid 
location. It also stores the properties of metabolites in regards to which biological pathway they are 
found in, and in what diseases they have been shown to be altered (Wishart et al., 2013).  
 
1.7 | Human Metabolomics in Health and Disease 
 
In a similar fashion as for the Human Microbiome Project, the Human Metabolome Project was 
launched as a coordinated effort to build a knowledge base for the field. Starting from a more 
established foundation of data, as metabolomic research significantly predated the sequencing of the 
human genome, the Human Metabolome Database, as discussed previously, was launched as a 
reference point for metabolomic investigation (Wishart et al., 2007).  
 
1.7.1 | Metabolomics in Biomarker Discovery 
 
One of the key principals in biomarker discovery using metabolomics is that disease has an effect on 
normal bodily function, which translates into a visible difference in the metabolome between those with 
and without the disease. As Figure 1.5 illustrates, these differences can be visible at many stages of the 
[ 23 ] 
pathway from a healthy to a diseased state. For example, biomarkers can be used to detect potential 
disposition to a disease, biomarkers for the onset of disease, early biomarkers of disease effect, and late 
biomarkers of disease effect (van der Greef, Stroobant and van der Heijden, 2004). With cancer being a 
genetic disease, the majority of biomarkers for disease predisposition and risk have a genetic basis. 
These have traditionally been studied through the use of genome wide association studies (GWAS), and 
are usually in the form of single nucleotide polymorphisms (SNPs) at specific loci. For example, prostate 
cancer risk has been shown to be associated with SNPs on chromosomes 3, 6, 7, 10, 11, 19 and X, 
explaining 16% of the familial risk of the disease (Kote-Jarai et al., 2008), and colorectal cancer 
predisposition has been linked to a single SNP at chromosome 8q24, which can lead to enhanced Wnt 
signalling (Tuupanen et al., 2009). 
 
Metabolomics arguably has the greatest potential in identifying biomarkers for the onset of disease, 
early disease effect, or late effects of the disease. In regards to cancer, for example, this is based upon 
the ‘Warburg Effect’. This principle was developed after early observations of energy source utilisation 
by cancerous cells, which showed that, even in sufficient levels of oxygen, they use large amounts of 
FIGURE 1.5 | The Monitoring of the Pathway from Health to Disease with Biomarkers 
Biomarkers can be defined by the stage within the pathway from health to disease at which they are 
either an indicator of predisposition, indicator of disease onset, or of early disease effect, or of late 
disease effect which can be used as a target for treatment monitoring. Figure taken from van der Greef, 
Stroobant and van der Heijden, (2004). 
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glucose and glutamine in the glycolysis pathway rather than utilising energy through oxidative 
phosphorylation (Warburg, 1956). This suggests that the presence of cancerous cells, or fully developed 
tumours, can be detected by the changes that they cause in the level of low molecular weight 
compounds, which can be detected through metabolomic techniques. For example, patients with 
bladder cancer have been shown to have significantly different urine, in terms of metabolomic profiles, 
than those without cancer, which could be used as a screen for early onset of the disease (Issaq et al., 
2008). Urine has also been used as a biofluid for identifying patients with kidney cancer, through the use 
of around 30 potential biomarkers (Kind et al., 2007). 
 
One of the key considerations in metabolomics is the choice of sample to analyse. It is possible that the 
changes in the metabolome caused by disease presence are localised in the human body. For example, 
the effects of bladder cancer may be localised to the metabolome of the bladder, and that urine is the 
best biofluid to use of analysis, rather than blood where metabolomic changes may become diluted to 
an unobservable level. Additionally, sampling should be as non-invasive as possible to increase the 
likelihood of the clinical implementation of the method. 
 
1.7.2 | Metabolomics in Drug Discovery and Treatment Monitoring 
 
In oncology specifically, there is a trend towards therapeutic interventions that target particular 
pathways involved in disease pathogenesis and progression. Biomarkers, derived through analysis of the 
metabolome, are increasingly being used in the clinical development of novel pharmaceuticals, to 
identify new molecular targets, to confirm mode of action, and to measure the responsiveness to 
treatment, drug toxicity, and drug resistance (Spratlin, Serkova and Eckhardt, 2009). 
 
The identification of tyrosine kinase inhibitors (Deininger et al., 1997) as a potential novel therapeutic in 
oncology has quickly been utilised for the development of multiple clinical therapies. Metabolomics has 
been used to study the effects of tyrosine kinase inhibitors, to reveal more detail on their potential 
usefulness. For example, Imatinib, used to treat chronic myeloid leukaemia, has been shown, through 
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NMR analysis, to prevent the production of essential molecules required for survival of cancerous cells, 
through the depletion of substrates used in their synthesis (Gottschalk et al., 2004).  
 
NMR has also been used to detect biomarkers indicative of Imatinib resistance. Through NMR analysis, 
cell lines which show a decrease in mitochondrial glucose oxidation and an increase in phosphocholine 
levels, later show resistance to Imitinib. If these biomarkers could be monitored in patients’ 
metabolomes, this would have clinical usefulness as it would indicate where a change in therapy is 
required to ensure continual management of the disease (Spratlin, Serkova and Eckhardt, 2009). 
 
Although the field of oncology has benefited from metabolomics in the identification and validation of 
novel drug targets, it is by no means the sole example. Microbial infections, such as the Influenza A 
virus, have also been studied with metabolomics. For example, infection of human fibroblast cells with 
Influenza A virus, monitored using LC-MS profiling, showed a significant increase in acetylneuraminic 
acid. This confirms the mode of action of oseltamivir, a leading drug for Influenza A infection, which 
targets viral neuraminidase (Beyoğlu and Idle, 2013).  
 
An important issue in drug development is that of compound toxicity, as this may impact upon the 
usefulness of the drug. Indeed, the use of metabolomics to assess drug toxicity has attracted increasing 
attention. Metabolomics as a field still lags behind both genomics and proteomics in terms of 
publication number (Robertson, Watkins and Reily, 2011). Metabolomics has been used to monitor drug 
toxicity and clearance in both animal and human studies. One of the first studies to establish the ability 
of metabolomics to monitor drug toxicity was performed in rat models of acetaminophen. Using NMR, 
Clayton et al., (2006) profiled the urine metabolome of rats before treatment with acetaminophen, and 
found this correlated with the level of liver injury in rats. Additionally, the urine metabolome predicted 
the degree of drug clearance by the liver through the level of glucoronide levels in the urine (Corona et 
al., 2012). With the power of metabolomics evident in its ability to predict drug toxicity, the Consortium 
for Metabonomic Toxicology (COMET) was created to undertake NMR-based metabolomics of urine and 
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serum to predict the liver and toxicity profiles of novel compounds. The results of resulting COMET 
studies showed that NMR-based metabolomics can predict organ toxicities at a sensitivity of 41% and 
specificity of 100% for the liver, and a sensitivity of 67% and sensitivity of 77% for the kidneys (Claudino 
et al., 2012). 
 
1.8 | Aims and Objectives 
 
The fields of microbiomics and metabolomics offer unique opportunities to study the human body in 
both health and disease. Moreover, as the fields are both still in their formative years of development, 
there are still a high number of diseases for which they have not been fully applied. The respiratory 
diseases lung cancer and chronic obstructive pulmonary disease are two such conditions with an unmet 
clinical need to develop novel methods of diagnosis, treatment, and monitoring. Investigation of the 
microbiome and metabolome may help to further understand these diseases. Additionally, techniques 
from the two fields are rarely combined to understand the host-microbiome interaction in humans.  
 
To this end, the specific objectives of this research project, which each form a subsequent chapter of 
this thesis, were: 
  
1) Employ microbiome and metabolomic techniques to identify and evaluate novel biomarkers in 
diagnosing lung cancer. 
2) Use metagenomic sequencing to elucidate the structure and function of the microbiome 
present in the upper respiratory tract of patients with COPD. 
3) Combine microbiome profiling and metabolomic fingerprinting techniques to gauge the 
variability of the human salivary microbiome and metabolome over time. 
4) Chart the changes in the human microbiome and metabolome associated with extreme 
physiological and environmental stress, as an analogy for human space travel. 
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CHAPTER 2 | Microbiomic and Metabolomic Biomarkers 
for Lung Cancer 
 
CHAPTER SUMMARY: Developing novel detection methods will improve early diagnosis of lung cancer, 
increasing the effectiveness of clinical interventions.  
 
Microbiomic Biomarkers for Lung Cancer | In this pilot study, spontaneous sputum samples were 
collected from ten patients presenting with lung cancer-like symptoms, of which four were diagnosed as 
positive, and six negative. Nextera® metagenomic libraries were constructed and sequenced on the 
HiSeq 2500 platform, with subsequent sequences analysed using the MG-RAST pipeline. Taxonomic 
differences were identified in regards to significant fold changes between negative and positive cases, 
with five species having significantly higher abundances in positive cases. Functional differences, were 
evident across a range of biological functions. Regression analyses identified Granulicatella adiacens’ 
relationship with six other bacterial species as indicative of positive samples, suggesting it as a potential 
biomarker. This study offers a novel insight into the functional capacity and species-level taxonomy of 
the sputum microbiome in patients with lung cancer. Furthermore, it suggests G. adiacens as a novel 
and clinically useful biomarker for lung cancer diagnosis and staging.  
 
Metabolomic Biomarkers for Lung Cancer | The ability of metabolomic fingerprinting to differentiate 
between patients with and without lung cancer was tested. Spontaneous sputum of 23 lung cancer 
positive and 11 lung cancer negative patients, alongside 33 healthy controls, was collected. The 67 
samples were fingerprinted using linear quadrupole ion mass spectrometry (LTQ-MS) and gas-
chromatography mass spectrometry. Analysis based on area under the receiver operating characteristic 
curve revealed differential metabolites for negative and positive lung cancer, in negative LTQ-MS mode, 
that had an AUC value of greater than 0.8. This preliminary analysis suggests sputum is a viable sample, 
and metabolomics has potential as a diagnostic and/or discriminator tool. Furthermore, it can identify 
specific key metabolites that could aid our understanding of the molecular pathogenesis of lung cancer 
and possibly guide treatment targets. 
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2.1 | Introduction  
 
Cancer is not a disease in itself but rather the classification of a group of diseases. These are grouped 
together because they share common characteristics, such as unregulated cell growth and the spread of 
cancerous cells from the primary cancer site, to other sites in the body. Due to their varied origins, 
cancers can have many distinguishing features. Six hallmarks have been identified which are shared by 
most, and likely all, cancers (Hanahan and Weinberg, 2000). As Figure 2.1 explains, these six hallmarks 
have been subsequently re-evaluated and two more have been added. Furthermore, two enabling 
characteristics of cancer, genome instability and mutation and tumour-promoting inflammation, have 
also been included. Understanding these ten hallmarks of cancer will likely prove fundamental in all 












FIGURE 1 | Established and Emerging Hallmarks, and Enabling Characteristics of Cancer | This figure
encompasses the six original hallmarks of cancer, as detailed by Hanahan and Weinberg (2000) , shown in red
boxes, in addition to the two new emerging hallmarks (purple and pink boxes) and the enabling characteristics
(blue and orange boxes) as detailed by Hanahan and Weinberg (2010). Figure adapted from Hanahan and
Weinberg (2010) to incorporate information from Hanahan and Weinberg (2000).
FIGURE 2.1 | Established and Emerging Hallmarks, and Enabling Characteristics of Cancer 
The six original (red) hallmarks of cancer, as detailed by Hanahan and Weinberg (2000), in addition to 
two emerging hallmarks (purple and pink), and the enabling characteristics (blue and orange) as 
detailed by Hanaha  and Wei berg (2011). Figure adapted from Hanahan and Weinberg (2011) to 
incorporate information from Hanahan and Weinberg (2000). 
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In 2008, there were approximately 12.7 million new cancer cases, and a total of 7.6 million cancer 
deaths worldwide (Ferlay et al., 2010). It is commonly accepted that whilst the incidence (new cases) 
and mortality rates (number of deaths) for the majority of cancers is decreasing in more economically 
developed countries, they are rising in emerging economies such as China and India. Interestingly, 
migrant studies have shown that cancer rates in the descendant generations of migrants tend to shift 
towards the cancer rates of the host country. This suggests that environmental risk factors, such as 
smoking and weight, rather than genetic differences are responsible for the global variance in cancer 
statistics (Jemal et al., 2010a). 
 
Lung cancer is a major cause of death in both the developed and developing worlds. It is the leading 
cause of death attributable to cancer in men, and second only to breast cancer in women. Globally, 
there are 1.6 million new cases of lung cancer annually, and 1.4 million deaths, as of 2008. This accounts 
for 12.6% of all cancer incidence and a disproportionate 18.4% of all cancer deaths (Jemal et al., 2010b). 
 
As Figure 2.2 shows, the five year survival rate for lung and bronchus cancer has increased only 
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FIGURE 2.2 | Five Year Survival Statistics for Lung and Bronchus Cancer in USA 
Figure 2.2a shows the substantially lower five year survival rate for lung cancer, compared to the 
average for all cancers. The disparity between the survival rate for all cancers, and lung and bronchus 
cancers is evident, with the latter showing little improvement over the last 30 years, whilst the average 
for all cancers has improved considerably. Additionally, Figure 2b shows the increasing disparity 
between the five year survival rate for lung and bronchus cancers for African Americans compared to 
the average. Figure adapted from Jemal et al., (2010b). 
(a) (b) 
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greater divide between the five year survival rates for different groups of Americans, namely 'White' 
and 'African American' (Jemal et al., 2010b). This gap has increased from one percentage point in 1975 
to 1977 to four in 1999 to 2005, suggesting the importance of developing the means to identify this 
cancer at an earlier stage, and thus, increase the prognostic outlook for patients.  
 
Whilst much research into lung cancer has focused on treatment and genetic susceptibility profiling, 
there is an ever increasing focus on developing the means of identifying patients, with various stages of 
lung cancer, at an earlier time. Recent work using Fourier transform infrared spectroscopy as a potential 
high-throughput screen, has suggested that sputum sampling may offer a non-invasive method of 
screening for lung cancer (Lewis et al., 2010).  
 
2.1.1 | The Cause of Lung Cancer 
 
Lung cancer is one of the few cancers where the major risk factor, in the majority of cases, is clear. In 
the vast majority of lung cancer cases, 90%, smoking is the primary cause. The risk of lung cancer from 
smoking increases in a cumulative fashion, with the main indicator of risk being duration rather than 
quantity of smoking (Cornfield et al., 2009).  
 
The mechanisms of how tobacco smoking can lead to lung cancer were elucidated many years after the 
initial link between tobacco and lung cancer was made. Only a minority of the overall smoking 
population develops lung cancer, suggesting that there is a level of individual differences in 
susceptibility. A study involving 732 clinical patients, half with lung cancer and half without, showed that 
there was a statistically significant, two-fold difference between the DNA repair capacities of lung cancer 
patients to the clinical control group.  This suggests that carcinogenic chemicals damage DNA in such a 
way that cancerous cells form and develop into lung cancer (Wei et al., 2000). Oxidative damage has 
also been shown to cause DNA lesions, such as 8-oxoguanine, which can lead to lung cancer developing 
because of genetic mutations resulting from mis-match repair (Paz-Elizur et al., 2003). These two studies 
are examples of work which have added to the substantial body of evidence that shows a causal 
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relationship between cigarette smoking and lung cancer. The DNA damage caused by carcinogenic 
chemicals in tobacco smoke lead to mutations in the genetic code, which can cause normal cells to 
become cancerous, based on the hallmarks of cancer discussed in Figure 2.1. 
 
Radon gas is the second main cause of lung cancer, albeit a comparatively small number, cases annually, 
and these are mainly concentrated in underground miners, though with some cases of residential radon 
exposure leading to lung cancer. In total, approximately 18,600 cases of lung cancer annually result from 
radon exposure in the United States (Field et al., 2000). 
 
2.1.2 | Types of Lung Cancer 
 
Determining the type of lung cancer that has developed in a patient is a key component of determining 
the correct treatment and management pathway. For lung cancer, two broad classes of classification 
exist: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Patients with SCLC frequently 
differ from those with NSCLC in terms of their clinical presentation, in that their symptoms are related 
to the effects of distant metastases (Travis et al., 2004). 
 
Patients with NSCLC are usually classified as one of three main subtypes: adenocarcinoma, squamous-
cell carcinoma and large-cell carcinoma. Of these, adenocarcinoma is the most common and is 
characterised by overproduction of mucin. Squamous-cell carcinoma is the second most common form 
of lung cancer and typically occurs in the centre of the lungs. Large-cell carcinoma is less common and is 
characterised by cancerous cells that are large, with excess cytoplasm and large nuclei. The extent of 
NSCLCs is reported using the Tumour, Node, Metastases (TNM) format, which is important for prognosis 
and treatment planning. The TNM format ranges from Stage 0 to Stage IV, with the relevant stage 
determined through assessment of the primary tumour, involvement of regional lymph nodes, and the 
extent of distant metastasis against set criteria (Travis et al., 2004).  
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Small-cell lung cancers are less common than NSCLC, with approximately 10% of all lung cancers 
classified as SCLC. These lung cancers are characterised by their small cells, with minimal cytoplasm, and 
poorly-defined cell borders. Cancerous cells are usually rounded, oval and spindle-shaped. Typically, 
patients with SCLC present when the disease has metastasised from the lungs and symptoms frequently 
reflect this. Small-cell lung cancers are staged differently to NSCLC. Although the TNM format can be 
used, it does not predict survival and other outcomes well. Typically, SCLC is staged as either limited or 
extensive disease, with the latter equivalent to Stage IV of the TNM staging format for NSCLC (Travis et 
al., 2004). 
 
2.1.3 | Diagnosis and Screening of Lung Cancer 
 
It is a significant issue in the diagnosis of lung cancer, that the symptoms of the condition are similar, or 
even the same, as those for other less serious conditions. This makes the pre-clinical diagnosis of lung 
cancer particularly difficult because the observed symptoms can be confused with those of other 
respiratory conditions. 
 
There is currently no recommended test for early detection of lung cancer in asymptomatic patients. 
However, because there is a clear cause of lung cancer, tobacco smoking in 90% of cases, some high-risk 
patients may choose to pursue the potential of early diagnosis. However, because of the relatively 
primitive nature of lung cancer screening techniques, the American Cancer Society stresses the 
importance of shared decision making between a patient and clinician (Smith et al., 2010). This is of high 
importance because current methods of early detection for lung cancer can have indeterminate 
findings, and a high rate of false positives and negatives. This poses the possibility of psychological 
distress for a patient, leading to increased anxiety around the condition (Byrne, Weissfeld and Roberts, 
2008). 
 
Lung cancer has a poor prognosis, with the five-year survival percentage being approximately 15%, 
Figure 2.2. This has remained relatively static compared with other cancers, and one of the main reasons 
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for this is that when it is usually diagnosed, the cancer has developed to such a stage where surgical or 
other clinical interventions usually prove ineffective (Baldwin et al., 2011). The mammography 
procedure used commonly in breast cancer screening has arguably been a significant driving force 
behind recent decreases in breast cancer mortality. It has been implemented in many countries because 
it meets the criteria set out by the World Health Organisation (WHO), initially developed by James 
Wilson and Gunner Jungner in 1968. These criteria, Table 2.1, are a set of ten principles which should be 
met by a screening procedure in order for it to be beneficial and cost effective (Andermann et al., 2008). 
 
Currently, possible screening techniques for lung cancer do not meet all of the ten conditions laid out in 
Table 2.1. The majority of the conflicts with the criteria arise in relation to cost, whom to treat as 
patients, whether a suitable test or examination exists, and whether the screening technique is 
acceptable to the population. The latter may be of particular concern as many of the possible screening 
techniques centre on the use of X-Rays, which may be harmful to patients. 
TABLE 2.1 | Wilson and Jungner 1968 Screening Criteria 
Ten criteria were set out by James Wilson and Gunner Jungner when they completed their World 
Health Organisation commissioned report in 1968 on the criteria needed for a national screening 
programme to be successful. Table adapted from Andermann et al., (2008). 
 
1 The condition sought should be an important health problem 
2 There should be an accepted treatment for patients with recognised disease 
3 Facilities for diagnosis and treatment should be available 
4 There should be a recognised latent or early symptomatic stage 
5 There should be a suitable test or examination 
6 The test should be acceptable to the population 
7 The natural history of the condition should be adequately understood 
8 There should be an agreed policy on whom to treat as patients 
9 The cost of case-finding should be economical in relation to possible medical costs 
10 Case-finding should be a continuing process and not a “once and for all” project 
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Identifying a target screening population will be of paramount importance in ensuring any lung cancer 
screen is cost-effective, and remains acceptable to the population at large. Because lung cancer is one of 
the few cancers which has a definitive cause in a vast majority of cases, identifying those at high-risk of 
developing the disease is possible. 
 
Work in the Liverpool Lung Project (LLP) has progressed towards developing a risk model for lung cancer 
patients. By identifying those at the highest risk of developing the disease, the hope is that these people 
would form the screening population for a lung cancer screen and thereby reduce costs and resources 
required. By combining data from 579 lung cancer cases with 1157 age- and sex-matched population-
based controls, a procedure for creating risk profiles was created. For example, a 77 year old male with 
an occupational exposure to asbestos, but who is a non-smoker though with a familial history of lung 
cancer, had an absolute risk of 3.17% for developing lung cancer. By setting a cut-off figure for 
surveillance of 6.0%, a sensitivity of 0.34 and specificity of 0.90 was achieved (Cassidy et al., 2008). This 
suggests that this method could easily be employed to identify a high-risk group of patients for whom 
screening for lung cancer would be beneficial. 
 
Currently, there is a narrow range of large-scale screening procedures which are being trialled in the 
United Kingdom. These focus primarily on the use of X-Rays, usually in the form of computerised 
tomography scans. The use of computed tomography (CT) scans has been trialled in many countries, 
albeit with inconclusive results. For example, a Japanese evaluation of low-dose chest CT (LDCT) scans, 
using a combined total of 61,914 CT scans, found that of 25,385 patients screened for lung cancer, 210 
patients with primary lung cancer were identified. Of these 210, a total of 203 underwent surgery, 
resulting in a five year survival rate of 90% for all patients and 97% for those on stage IA (Nawa et al., 
2012). These results suggest that the majority of lung cancers identified through CT scans were 
treatable, though the cost of completing CT scans to identify only 0.83% of those with lung cancer may 
make the cost of using CT scans prohibitive for a national screening programme. However, the benefits 
of CT scans, such as spiral CT scans, may have been over-estimated. For example, an Italian study 
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showed how spiral CT scans increased the number of Stage I lung cancer patients identified compared to 
a randomised control group. However, a three year follow-up suggested that there was a minimal 
difference between the survival rates of those lung cancer cases identified via spiral CT scans compared 
to those diagnosed by conventional means (Infante et al., 2009). 
 
The potential benefits posed by the use of CT scans in screening for lung cancer cases at an earlier stage 
are inconclusive, and may not prove to be clinically useful. This means that different frontiers for 
screening methodologies for lung cancer need to be explored. 
 
2.1.4 | The Microbiome in Cancer 
 
Since the link between Helicobacter pylori and gastric cancer was identified (The EUROGAST Study 
Group, 1993), the possible links between the host and its microbiome, in terms of response, 
exacerbation or even the initiation of carcinogenesis are receiving increased attention.  Changes in the 
bacterial loads for key species, for example, have been linked to oral squamous carcinoma, colorectal 
cancer and oesophageal cancer (Helicobacter and Cancer Collaborative Group, 2001). Within the context 
of lung cancer, a link between H. pylori seropositivity and risk of lung cancer has been investigated 
through the use of serum samples from patients with lung cancer and age-matched controls (Khan, 
Shrivastava and Khurshid, 2012).  Although, no correlation was reported, it did show that a number of 
people with lung cancer tested seropositive for H. pylori and there is a possibility it could be present in 
the lung cancer microbiome.  The use of serum in this study highlights how the microbiome-cancer links 
have been investigated using cancers, such as oral (Koshiol et al., 2012; Narikiyo et al., 2004; Sasaki et 
al., 1998; Tateda et al., 2000) and colorectal (Shiga et al., 2001; Sobhani et al., 2011; Ohigashi et al., 
2013) where sampling can be minimally invasive. However, the enclosed nature of the lung complicates 
sample collection and has involved sampling using bronchoalveolar lavage fluids, tissue from excised 
lungs obtained during transplantation surgery (Chen et al., 2012), or indirectly through serum (Koshiol et 
al., 2012).  
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Sputum is a complex of mucus, pathogens, cellular debris and other particles trapped in the lungs by 
mucus. It provides a non-invasive method of obtaining upper respiratory tract samples that also involves 
minimal patient discomfort (Lewis et al., 2010). As sputum is symptomatic of inflammatory lung airway 
diseases such as COPD, asthma, chronic bronchitis, and cystic fibrosis, it is often used to provide insight 
into the underlying pathogenesis (Voynow and Rubin, 2009). Indeed, conditions such as asthma (Hilty et 
al., 2010), COPD (Erb-Downward et al., 2011; Pragman et al., 2012; Sze et al., 2012) and cystic fibrosis 
(Willner et al., 2011) have used microbial profiling techniques to reveal potentially important insights 
into the role that microbes may play in disease aetiology, progression and treatment.  
 
Sputum from lung patients has been used to explore, albeit in a culture-dependent method, the 
microbial flora and the level of antibiotic resistance (Li et al., 2013). A further, culture-independent 
study using amplicon sequencing suggested that, in sputum, there are significant differences between 
lung cancer patients and controls, particularly within the Granulicatella, Abiotrophia, and 
Streptococcus genera (Hosgood et al., 2014). However, to date, there has been study into the 
metagenomic composition of the sputum microbiome in lung cancer. Therefore, resolution at the 
species level of taxonomy has not been possible, and the functional capacity of the microbiome has not 
been investigated. 
 
2.1.5 | Metabolomic Insights into Lung Cancer 
 
An alternative screening methodology to radiography is the utilisation of molecular markers, both 
genetic and metabolomic, in biofluids. For example, microRNAs have been widely studied and suggested 
as potential biomarkers for lung cancer in sputum (Xie et al., 2010), plasma (Shen et al., 2011), and 
serum (Foss et al., 2011) samples. In fact, for a number of reasons microRNAs are widely considered to 
be one of the most promising areas for lung cancer biomarkers currently in development. For example, 
microRNAs have been shown to be highly stable in serum and plasma samples, the method for obtaining 
a sample is minimally invasive, and the analysis of microRNAs using quantitative polymerase chain 
reaction (qPCR) is well established. However, a number of questions still remain regarding microRNAs as 
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biomarkers for lung cancer. One of the most pressing is the source of microRNAs, as their cellular origins 
are still unknown, and it is still ambiguous whether they are produced by cancerous cells or by healthy 
cells in response to the presence of cancerous cells (Wittmann and Jäck, 2010).  
 
The ease of analysis of biofluids using mass spectrometry or NMR makes metabolomics a well suited 
methodology for identifying non-invasive biomarkers of lung cancer. The focus, to date, of 
metabolomics in lung cancer has been on the evaluation of serum, urine, or tumour biopsies. Analysis of 
serum, for example, through both LC-MS and GC-MS approaches, has suggested it as a source of 
biomarkers for lung cancer. A small-scale pilot study sampling lung cancer patients before and after 
surgical intervention, alongside patients without lung cancer has suggested approximately ten candidate 
biomarkers for lung cancer, including sphingosine, oleic acid, and serine (Chen et al., 2014). 
 
Urine is arguably one of the least invasive biofluids to collect, and has a proven track record as a source 
of biomarkers for a number of diseases. A large scale study of approximately 500 lung cancer patients 
and 500 population controls employing LC-MS identified creatine riboside and N-acetylneuraminic acid 
as potential biomarkers for early stage lung cancer. Additionally, analysis of the cancerous tissue 
metabolome and the metabolome of nearby non-cancerous tissue confirmed that both metabolites 
were significantly enriched in cancerous tissue; revealing the direct association of the biomarkers with 
lung cancer (Mathé et al., 2014). However, urine has a comparatively low level of metabolite data 
compared to other biofluids. Therefore, potential biomarkers that are present at a low level in the body, 
may be at an undetectably low level in the urine. 
 
One of the least studied biofluids in lung cancer metabolomics is sputum. Sputum is a complex of 
mucus, bronchial cells, and microbial cells that is commonly produced by those with various lung 
conditions, including lung cancer and COPD. Cytological analysis of sputum has long been a diagnostic 
tool in lung cancer, that is commonly paired with radiography, and has a sensitivity of around 60% and 
specificity of >99% (Erkiliç, Özsaraç and Küllü, 2003). The DNA methylation and microRNA profiles of 
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sputum has been suggested as a potential biomarker in lung cancer but these are by no means 
established as reliable biomarkers (Hubers et al., 2013; Guzmán et al., 2012). The microbiome of lung 
cancer patients has not been investigated fully, particularly in regards to the species level of taxonomy 
and functional capacity, which can only be determined through metagenomic techniques. 
 
The fingerprinting approach of fourier transform infrared spectroscopy (FTIR), as a non-invasive 
technology to detect lung cancer in sputum samples, has been carried out. Through this, FTIR was 
shown to have the potential to act as a non-invasive, high-throughput and cost-effective for screening 
sputum samples from patients at high risk of developing lung cancer. Additionally, it supported the role 
that sputum could play as a biofluid for use in lung cancer screening (Lewis et al., 2010).  
 
2.1.6 | Aims and Objectives of Chapter 
 
The microbiome and metabolome of sputum from patients with suspected or confirmed lung cancer 
have received minimal attention to date. The aims and objectives of this portion of work were to: 
 
1) Employ metagenomic sequencing to characterise the species-level taxonomy, and functional 
capability of the lung cancer microbiome represented by sputum. 
2) Explore the lung cancer microbiome as a potential source of novel biomarkers for early-stage 
identification of lung cancer, and possible later clinical staging of the disease. 
3) Characterise the metabolome of patients with suspected lung cancer, using a metabolomic 
fingerprinting approach, to identify novel biomarkers that may be able to differentiate a group 
of clinical patients with suspected lung cancer into those negative and positive for the disease. 
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2.2 | Materials and Methods  
 
The Medlung study received ethical approval from the loco-regional ethical committee 
(05/WMW01/75). Informed consent was obtained from all patients prior to giving a sputum sample. All 
samples and data were link anonymised prior to processing and subsequent data analysis. 
 
2.2.1 | Patient Recruitment and Sampling 
 
Spontaneous sputum was collected from ten clinical patients, who were referred for further diagnostics 
at Prince Phillip Hospital, Llanelli, United Kingdom (UK), after presentation with lung cancer-like 
symptoms at their General Practice, as part of the Medlung observational study (United Kingdom 
Clinical Research Network (UKCRN) ID 4682). Spontaneous sputum samples were taken before 
bronchoscopic investigation for lung cancer diagnosis. All spontaneous sputum samples were confirmed 
as sputum, based on bronchial cell content, by a Consultant Pathologist in the Hywel Dda University 
Health Board Pathology Service. 
 
2.2.2 | Processing of Raw Sputum 
 
After collection, raw sputum samples were frozen at -80°C for up to seven days, at which time they were 
defrosted in ice for approximately one hour. Sputum cells were isolated as described by Lewis et al., 
(2010) through the addition of 0.5 mL of a working solution of dithiothreitol (DTT), made up by adding 
2.5 g of DTT to 31 mL of 30% aqueous methanol, and 5 mL of 30% aqueous methanol, following which 
they were placed on a vortex mixer for 15 minutes. Samples then underwent centrifugation at 1800 x g 
for 10 minutes. The supernatant was then removed and the pellet transferred to a clean 1.5 mL 
microcentrifuge tube and frozen at -80°C. 
 
After processing, those samples undergoing metabolomic fingerprinting were stored at this temperature 
for up to two years, whilst those undergoing total genomic DNA extraction were stored for no more 
than seven days. 
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2.2.3 | Isolation of Total Genomic DNA 
 
Total genomic DNA was extracted from 100 µL of treated sputum using a FastDNA SPIN kit for soil (MP 
Biomedical, Santa Ana, USA) following manufacturer’s instructions. Bead beating was carried out in a 
FastPrep-24 machine (MP Biomedical) with three cycles at speed setting 6.0 for seconds, with cooling on 
ice for 60 seconds between cycles. Genomic DNA was eluted in to 30 µL of DNase/Pyrogen-free water 
(DES) and double stranded deoxyribose nucleic acid (dsDNA) concentration determined using the 
Quant-iT dsDNA High Sensitivity assay kit and a Qubit fluorometer (Life Technologies, Paisley, UK). 
 
2.2.4 | Metagenomic Library Preparation and Sequencing 
 
After extraction of genomic DNA, samples were normalised to 10 ng/µL with PCR grade water (Roche 
Diagnostics Limited, West Sussex, UK) and 50 ng used to create metagenomic libraries using the 
Nextera® DNA kit (Invitrogen, San Diego, USA) following manufacturer’s instructions, except that a 
MinElute PCR purification kit (Qiagen, Ltd Crawley, UK) was used for the clean-up of tagmented DNA. 
Nextera® DNA libraries were quantified using the Quant-iT dsDNA High Sensitivity assay kit, and 
approximate library sizes determined by running on a 2 % agarose gel alongside HyperLadder IV (Bioline, 
London, UK). Sample libraries were pooled in equimolar concentrations and sequenced at 2 x 151 bp 
using an Illumina HiSeq 2500 rapid run, with samples duplicated over two lanes, and following standard 
manufacturer’s instructions at the IBERS Aberystwyth Translational Genomics Facility. 
 
2.2.5 | Metagenomic Sequence Analysis 
 
After sequencing, output files for each lane were combined into one file, using the BioLinux 7 
environment (Field et al., 2006), for each read direction. Sequencing files were uploaded to MG-RAST 
(v3.2) (Meyer et al., 2008) as FASTQ files. Paired-end reads were joined using the facility available within 
MG-RAST, with non-overlapping reads retained. Sequences were dereplicated and dynamically trimmed 
using the default parameters for FASTQ files, and human sequences removed by screening against the 
Homo sapiens (v36) genome, available via NCBI.  The MG-RAST pipeline used an automated BLASTX 
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annotation of metagenomic sequencing reads against the SEED non-redundant database (Overbeek et 
al., 2005). SEED matches can be matched to identity at various taxonomic levels; including genus and 
species levels. Organism abundances were modelled and exported from MG-RAST using the ‘Best Hit 
Classification’ after alignment to the M5NR database, with alignment cut-off parameters set at an e-
value maximum of 1 x 10-5, a minimum identity of 97%, and a minimum alignment of 15. Functional 
abundances were modelled and exported from MG-RAST using ‘Hierarchical Classification’. SEED 
matches can also be related to metabolic information, again at different levels of classification. The 
coarsest level of organization; the generalized cellular function was termed level 1, and the finest, 
individual subsystems level 3. To normalise for potential variations in sequencing efficacy, sequence 
abundances were transformed into percentages based upon the total read abundance for each sample. 
Statistical analysis was completed using the MetaboAnalyst 2.0 (Xia et al., 2012) facility and MINITAB 14 
package. Eukaryotic taxonomic classifications were trimmed based on literature searches to remove 
poorly classified reads. Sequence files can be viewed on MG-RAST via the IDs listed in Chapter 2 
Appendix, Supplementary Table 2.1 and raw sequence files have been deposited at the European 
Nucleotide Archive under primary accession number PRJEB9033 and secondary accession number 
ERP010087. Unless otherwise stated, all P values indicate significance of one-way analysis of variance 
(ANOVA) tests. 
 
2.2.6 | 16S rRNA Quantitative PCR 
 
Quantitative PCR was carried out on neat extracted DNA against standards created by amplifying the 
16S rRNA gene of two randomly selected lung cancer positive and two lung cancer negative samples. 
This was completed through amplification of the 16S rRNA gene in a 20 µL reaction volume consisting of 
10 µL of 2 x BioMix (BioLine), 0.25 µL each of 27f (5’-AGA GTT TGA TCC TGG CTC AG-3’) and 1389r (5’-
ACG GGC GGT GTG TAC AAG-3’) primers (Hongoh, Ohkuma and Kudo, 2003) to give a final concentration 
of 500 nM, 1 µL of neat extracted DNA, and 9.5 µL of PCR Grade Water (Roche). The reaction volumes 
were then subjected to PCR consisting of 94°C for two minutes, 30 cycles of 94°C for 45 seconds, 55°C 
for 45 seconds, and 72°C for 90 seconds, followed by a final elongation step of 72°C for seven minutes. 
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The resulting PCR products were combined and purified using an Isolate II PCR and Gel Extraction 
purification kit (BioLine), following manufacturer’s instructions, and quantified using an Epoch 
spectrometer. 
 
The resulting DNA concentration was used to estimate the total number of 16S rRNA gene copies and 
serial dilutions of 1010, 108, 106, 104, 102, and 100 made. Quantitative PCR was completed on neat 
extracted DNA against standards with each reaction completed in 25 µL volumes, each consisting of 12.5 
µL 2 x SYBR Green Mastermix (Life Technologies), 0.25 µL of each EubF1 (5’-GTG STG CAY GGY TGT CGT 
CA-3’) and EubR1 (5’-ACG TCR TCC MCA CCT TCC TC-3’) primer (Maeda et al., 2003), in a final 
concentration of 400 nM, 11 µL of PCR Grade Water (Roche) and 1 µL of neat DNA extract. Reactions 
were run using a C100 thermal cycler (BioRad, Hercules, USA) and CFX96 optical detector (BioRad), with 
data captured using CFX Manager software (BioRad), under conditions of 95°C for ten minutes, 40 cycles 
of 95°C for 15 seconds and 60°C for 60 seconds, followed by a melt curve consisting of a temperature 
gradient of 60°C to 95°C in 0.5°C increments, each for five seconds. 
 
2.2.7 | Linear Quadrupole Ion Trap Mass Spectrometry (LTQ-MS) 
 
After processing, 20 µL of sputum was added to 20 µL of ultrapure water and 40 µL of ice-cold high 
performance liquid chromatography (HPLC) grade acetone. Samples were placed on a vortex mixer for 
five seconds, cooled on ice for 30 minutes, and then underwent centrifugation at 11 000 x g for five 
minutes. A total of 50 µL of the supernatant was removed and transferred to a glass vial, to which 250 
µL of 70% methanol (made up using HPLC grade methanol and ultrapure water) was added. All vials 
were capped and randomised before injection using an autosampler, with tray temperature kept 
constant at 15°C. For each sample, 20 µL was injected into a flow volume of 60 µL per minute water-
methanol, in a ratio of 70% water and 30% methanol, using a Surveyor liquid chromatography system 
(Thermo Scientific, MA, USA). Data acquisition for each individual sample was conducting, in alternating 
positive and negative ionisation mode, over four scan ranges (15-110 m/z, 100-220 m/z, 210-510 m/z, 
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500-1200 m/z) on an LTQ linear ion trap (Thermo Electron Corporation, CA, USA), with an acquisition 
time of five minutes.  
 
2.2.8 | Gas Chromatography Mass Spectrometry 
 
As with LTQ-MS, 20 µL of processed sputum was added to 20 µL of ultrapure water and 40 µL of ice-cold 
HPLC grade acetone. Samples were placed on a vortex mixer for five seconds, cooled on ice for 30 
minutes, and then underwent centrifugation at 11 000 x g for five minutes, after which 50 µL of the 
supernatant was removed and dried in a DNA SpeedVac at 40°C until all liquid had been removed. After 
drying, 30 µL of a 20 mg/ml solution of methoxyamine in pyridine was added to the sample in a glass 
vial. Vials were capped and incubated at 90°C for 15 minutes. After incubation, 20 µL of N,O-
Bis(trimethylsilyl)trifluoroacetamide (BSTFA) was added to the sample, alongside 5 µL of an alkane mix, 
warmed to 60°C for addition, consisting of C10, C13, C15, C18, C19, C23, C28, C32 and C36 alkanes, each at a 
concentration of 2 µL/mL in pyridine, for alkanes which are liquid at room temperature, and 2 mg/mL in 
pyridine, for alkanes which are solid at room temperature, capped and incubated at 90°C for 15 
minutes. After undergoing derivitisation, samples were run on an Agilent 6890N GC (Agilent 
Technologies, CA, USA) linked to a 5973N MS (Agilent Technologies) with a DB5 equivalent column 
(Agilent Technologies), using a helium carrier gas at a flow rate of 1 mL per minute, set at a constant 
rate. GC-MS heating was set at 80°C for three minutes, rising to 280°C at a rate of 15°C per minute, and 
then to 330°C at a rate of 50°C per minute. The inlet temperature was set at 280°C with a 2:1 split ratio 
and the MS transfer line was set at 330°C, with an isooctane solvent being used to wash the auto-
sampler. Samples were run in duplicate, starting with raw sputum each time and analysed on separate 
GC-MS runs. 
 
2.2.9 | Metabolomic Data Analysis 
 
To normalise the LTQ-MS data, it was exported into Microsoft© Excel™ 2010 and the total ion count for 
each sample was used to transform the intensity value for each metabolite in to a percentage of the 
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total ion count, after the removal of metabolites less than 50 m/z in LTQ-MS profiles. Multivariate 
analyses were then completed using the PyChem (Version 3.0.5g Beta) package (Jarvis et al., 2006), the 
MetaboAnalyst 2.0 online platform (Xia et al., 2012) and the ROC Curve Explorer and Tester (ROCCET) 
online platform (Xia et al., 2013). GC-MS data was exported and the mean values for each data point 
calculated from duplicate sample runs. Retention times of alkane standards were then removed and 
data normalised. Data was then modelled as for LTQ-MS data as previously described. 
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2.3 | Results 
 
Two separate patient cohorts donated samples for this portion of work. A total of ten patients donated 
sputum samples that were analysed through metagenomic sequencing, and 34 clinical patients and 33 
’healthy’ participants donated samples which were analysed through metabolomic fingerprinting. 
 
2.3.1 | Participant Cohort for Lung Microbiome Study 
 
After histological investigation of the ten patients referred with lung cancer-like symptoms, four 
patients were diagnosed with lung cancer (one squamous cell NSCLC, one adenocarcinoma NSCLC, one 
large cell carcinoma NSCLC, and one where a bronchoscopy was not possible and a radiological diagnosis 
TABLE 2.2 | Average Patient Characteristics for Both Negative and Positive Lung Cancer Groups 
Data are means for each either the negative or the positive lung cancer groups. Standard deviations are 
given in brackets. FEV1 % of predicted is forced expulsion volume of lungs in one second, as a 
percentage of the predicted value for that patient. Smoking pack years is individual history normalised 
to 20 cigarettes a day for one year. CO level is carbon monoxide in parts per million concentration. 
 
  Negative (LC-) Positive (LC+) 
Number 6 4 
Age 58.8 (14.8) 73.3 (7.2) 
Gender     
Male 4 2 
Female 2 2 
Smoking Status     
Current 4 3 
Ex 2 0 
Never 0 1 
Smoking Pack Years 57.7 (35.4) 28.8 (24.6) 
Infection Present     
Yes 0 0 
No 6 4 
Antibiotic Use     
Yes 1 0 
No 5 4 
CO Level (ppm) 21.0 (24.5) 7.3 (8.0) 
FEV1 % of Predicted 77.1 (22.3) 69.3 (16.0) 
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was required), and six were found to be negative for lung cancer presence after a one year follow-up 
period. Summarised patient information is shown in Table 2.2, and full individual patient information in 
Chapter 2 Appendix, Supplementary Table 2.1. No discernible differences between the two patient 
groups were observed. 
 
2.3.2 | Preliminary Read Analysis and Bacterial Load 
 
Sequencing statistics, both pre- and post-quality control process are summarised in Chapter 2 Appendix, 
Supplementary Table 2.2, alongside corresponding one-way ANOVA P values. In all but one of the 
sequencing statistics, identified rRNA features, no significant differences were detected. This suggests 
that sequencing with the the HiSeq 2500 platform, along with subsequent bioinformatic analysis using 
MG-RAST did not introduce any bias; which may affect interpretation of results. All ten metagenomes 
sequenced are publicly available via the links detailed in Chapter 2 Appendix, Supplementary Table 2.1. 
 
In regards to estimated bacterial load, no significant difference (P value = 0.616) was observed between 
the Log10 values of estimated 16S rRNA copy number of LC+ (5.63) and LC- (6.06) samples. 
 
2.3.3 | Comparison of Taxonomic Composition of Microbiome 
 
At the taxonomic level, Figure 2.3a, principal component analysis (PCA), created using the MG-RAST 
analysis platform, appears to show some separation, mainly along principal component one, between 
the positive and negative lung cancer groups. Additionally, there appears to be no clustering in regards 
to smoking status, suggesting that lung cancer status may be one of the primary factors in the 
observable separation based on taxonomic composition of the microbiome. 
 
The ‘core’ microbiome of both negative and positive lung cancer patients, to the species level of 
taxonomic classification was investigated, Table 2.3, as this is likely to give greater insight into the 
microbiome than genus. A total of seven species were found to be present in all ten samples, with 
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Streptococcus viridans found to be significantly (P = 0.042) higher in LC+ samples. Six further species 
were found to be present in all LC- samples, but not all of the LC+ samples, but none were significantly 
different in their level of abundance. Furthermore, a total of 16 bacterial species were found in all of the 
LC+ samples but not all LC- samples, with Granulicatella adiacens (P = 0.015), Streptococcus intermedius 
(P = 0.023), and Mycobacterium tuberculosis (P = 0.036) found to be significantly higher in the LC+ 
group. 
 
Additionally, at the taxonomic level, significant (t-Test P value < 0.05) fold changes in regards to species 
abundance between positive and negative lung cancer cases were identified through use of the 
MetaboAnalyst 2.0 platform, Figure 2.4. This reflects differences in the ‘core’ microbiome changes 
shown in Table 2.3, namely significantly higher abundances of G. adiacens, S. intermedius, and M. 
tuberculosis, in positive cases, with additional significant increases evident within Streptococcus viridans 
and Mycobacterium bovis abundances. No significant differences, between LC+ and LC- samples, within 



















































FIGURE 2.3 | Principal Component Analysis of Taxonomic and Functional Classifications 
PCA plots created using the MG-RAST analysis platform, modelling (A) taxonomic, and (B) functional 
classifications, using the sequence cut-offs as detailed previously. PCA plots were drawn using 
normalised values and Maximum distance. Positive cancer samples are coloured green and negative 
coloured red. ■ symbol denotes an ex-smoker, ● a current smoker, and  a never smoker. The code to 
the top-right of each lung cancer positive sample indicates the stage of the lung cancer at the time of 
sampling. 
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TABLE 2.3 | Average Percentage Abundance of Species Present in ‘Core’ Microbiome 
Average percentage abundance of species present in the negative and positive lung cancer groups, with 
corresponding P values from one-way ANOVA, with significant values in bold text. % column shows 
average abundance, St. Dev. column shows standard deviation, and Count column shows the number 
of patients in each group in which the species was found, out of the total number of patients. The top 
division represents species present in all samples, the second division those found in all negative 
samples, and the bottom division those found in all positive samples. 
 
Species 
Lung Cancer Negative Lung Cancer Positive 
P Value 
% St. Dev. Count % St. Dev. Count 
Streptococcus viridans 0.02% 0.01% 6 / 6 0.10% 0.04% 4 / 4 0.042 
Streptococcus thermophilus 1.73% 1.33% 6 / 6 5.96% 2.51% 4 / 4 0.115 
Ochrobactrum anthropi 0.48% 0.20% 6 / 6 0.95% 0.32% 4 / 4 0.188 
Streptococcus pneumoniae 7.30% 1.84% 6 / 6 15.17% 6.72% 4 / 4 0.200 
Enterococcus faecalis 0.10% 0.03% 6 / 6 0.25% 0.13% 4 / 4 0.203 
Salmonella enterica 0.01% 0.00% 6 / 6 0.05% 0.04% 4 / 4 0.271 
Neisseria meningitidis 1.04% 0.73% 6 / 6 0.79% 0.30% 4 / 4 0.756 
Escherichia coli 0.01% 0.01% 6 / 6 0.06% 0.04% 3 / 4 0.207 
Fusobacterium nucleatum 0.16% 0.14% 6 / 6 0.00% 0.00% 2 / 4 0.310 
Haemophilus influenzae 22.29% 17.38% 6 / 6 4.30% 3.70% 3 / 4 0.346 
Streptococcus parasanguinis 9.87% 4.24% 6 / 6 4.75% 4.75% 1 / 4 0.398 
Streptococcus pyogenes 0.24% 0.11% 6 / 6 0.31% 0.12% 3 / 4 0.659 
Veillonella parvula 1.60% 0.64% 6 / 6 2.01% 1.84% 2 / 4 0.805 
Granulicatella adiacens 0.00% 0.00% 1 / 6 0.07% 0.03% 4 / 4 0.015 
Streptococcus intermedius 0.00% 0.01% 2 / 6 0.06% 0.02% 4 / 4 0.023 
Mycobacterium tuberculosis 0.00% 0.00% 5 / 6 0.01% 0.00% 4 / 4 0.036 
Enterococcus sp. 130 0.01% 0.01% 5 / 6 0.06% 0.02% 4 / 4 0.050 
Streptococcus sp. 6 0.01% 0.01% 5 / 6 0.06% 0.02% 4 / 4 0.050 
Acinetobacter junii 0.01% 0.00% 5 / 6 0.03% 0.01% 4 / 4 0.112 
Streptococcus salivarius 0.14% 0.10% 4 / 6 3.23% 2.46% 4 / 4 0.195 
Shewanella spp. 0.00% 0.00% 3 / 6 0.01% 0.00% 4 / 4 0.206 
Streptococcus vestibularis 0.01% 0.01% 5 / 6 1.31% 0.74% 4 / 4 0.208 
Lactobacillus paracasei 0.00% 0.00% 1 / 6 2.61% 2.60% 4 / 4 0.234 
uncultured bacterium 0.00% 0.00% 4 / 6 0.00% 0.00% 4 / 4 0.266 
Lactococcus lactis 0.02% 0.01% 4 / 6 0.02% 0.01% 4 / 4 0.379 
Neisseria gonorrhoeae 0.29% 0.20% 5 / 6 0.17% 0.08% 4 / 4 0.500 
Rhodococcus erythropolis 0.09% 0.11% 3 / 6 0.13% 0.06% 4 / 4 0.628 
Stenotrophomonas maltophilia 0.10% 0.05% 5 / 6 0.20% 0.08% 4 / 4 0.662 
Staphylococcus aureus 0.42% 0.49% 5 / 6 0.20% 0.14% 4 / 4 0.666 
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2.3.4 | Comparison of Functional Capability of Microbiome 
 
With regards to PCA separation of functional classifications, Figure 2.1b, no obvious separation was 
evident. This appeared to be reflected in both lung cancer status, and smoking status. Again, using 
MetaboAnalyst 2.0, significant fold changes in functional alignments were also identified. At the crudest 
level of functional classification, Level 1, no differences were evident. However, at Levels 2 and 3, Table 
2.5, significant differences were observed. At Level 2, four functional classifications, involved in the urea 
cycle, putrescine/gamma-aminobutyric acid (GABA) utilisation, Gram-positive cell wall components, and 
invasion and intracellular resistance, were higher in LC+ samples. At Level 3, seven functional 
classifications were higher in LC+ samples, whilst three were lower, when compared to LC- samples. 
These differences appeared to be across a wide range of biological function, with higher levels of 
classifications observed for methicillin resistance in Staphylococci, iron sidrephore sensor and receptor 
system, amongst others. Lower levels of functional alignments for LC+ samples were observed in the 












































FIGURE 2.4 | Significant Fold Changes in Species Abundance from LC- to LC+ 
Using the online features of MetaboAnalyst 2.0, significant fold changes, as determined by t-Tests with 
P values <0.05, were identified. Five species, from three genera, were all higher in positive lung cancer 
samples, with Granulicatella adiacens and Streptococcus intermedius showing the highest change. 
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2.3.5 | Microbiomic Biomarkers for Lung Cancer 
 
To evaluate the potential of using metagenomics to identify novel biomarkers for lung cancer and lung 
cancer progression, both a species level regression analysis and Level 3 functional regression analysis 
were completed. Those regressions with an R2 value of 80% or more were plotted to identify those with 
differing relationships between negative and positive lung cancer groups. From this, the bacterial 
species G. adiacens was identified as having positive correlations with six other bacterial species, Figure 
2.6, in positive lung cancer samples, which was not evident in in negative lung cancer samples. 
Additionally, when the stagings of positive lung cancer samples were plotted, a pattern with disease 
progression was observable, with a linear relationship seen whereby advances in lung cancer staging 


































Level 2 Level 3
FIGURE 2.5 | Significant Fold Changes in Levels 2 and 3 Functions from LC- to LC+ 
Using MetaboAnalyst 2.0, significant fold changes of Level 2 (grey bars) and 3 (black bars) functional 
alignments, as determined through t-Tests with P values <0.05, were identified. A total of four Level 2 
functional alignments were higher in positive lung cancer, alongside seven Level 3 functions. Three 
Level 3 functional alignments were lower in positive lung cancer samples. 
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FIGURE 2.6 | Regression Analysis Suggests Importance of G. adiacens in LC+ Analysis 
Species regression analyses were completed, and those with an R2 value of greater than 80% were 
plotted to identify differing relationships between negative and positive lung cancers. This type of 
relationship was shown to exist between G. adiacens and six other species, with a strong positive 
relationship present in positive lung cancer samples, and no correlation evident within negative lung 
cancer samples. Normalised percentage abundances are shown on x and y axes. 
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2.3.6 | Patient Cohort for Lung Metabolome Study 
 
Patients and participants sampled as part of this study are summarised in Table 2.4, with full clinical 
information detailed in Chapter 2 Appendix, Supplementary Table 2.3. A total of 34 clinical patients with 
suspected lung cancer were recruited, with 23 confirmed with lung cancer (LC+) (16 NSCLC (nine Stage 4,  
three Stage 3A, one Stage 3B, three Stage 2B, and one Stage 1B), six SCLC (three extensive and three 
limited), and one receiving a clinic-radiological diagnosis made by the lung cancer multidisciplinary 
team), and 11 had no diagnosis of lung cancer after extensive testing and follow up for at least one year 
(LC-). In addition, a total of 33 non-clinical controls were collected from staff and students at Swansea 
University, with no history of clinical lung disease. No discernible differences were observed between 
the information detailed in Table 2.4, except that within the LC- group there was a gender bias towards 
a significantly higher proportion of male patients than female patients. 
 
TABLE 2.4 | Summarised Patient and Participant Information 
Summarised patient information detailing clinical data. Full clinical data for clinically acquired samples, 
and information collected for healthy control participants, are fully detailed in Chapter 2 Appendix, 
Supplementary Table 2.3. nc = data not collected. Smoking pack years is individual history normalised 
to 20 cigarettes a day for one year. 
 
  Non-Clinical Controls (CON) LC Negative (LC-) LC Positive (LC+) 
Number 33 11 23 
Age 55.3 (14.6) 66.5 (14.3) 66.6 (8.1) 
Gender 
   Male 20 10 11 
Female 13 1 12 
Smoking Status 
   Current 15 3 10 
Ex 0 8 10 
Never 18 0 3 
Smoking Pack Years NC 49.0 (34.9) 39.3 (18.9) 
Infection Present 
   Yes NC 3 1 
No NC 8 22 
CO Level (ppm) NC 3.7 (1.3) 4.2 (2.8) 
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2.3.7 | Comparison of LTQ-MS and GC-MS Metabolite Analysis 
 
Preliminary analysis of metabolomic fingerprints acquired through LTQ-MS and GC-MS was conducted 
through principal component analysis. From this, the metabolomic fingerprints acquired in negative 
LTQ-MS mode, Figure 2.7a, showed the greatest degree of separation between the three samples 
groups. This separation was not evident in positive LTQ-MS mode, Figure 2.7b, and only partially present 
in GC-MS profiles, Figure 2.7c. Similar degrees of separation were seen in hierarchical cluster analysis, 
FIGURE 2.7 | Principal Component Analysis Plots for LTQ and GC-MS Fingerprinting 
PCA, based on metabolites acquired in (a) LTQ-MS negative mode, (b) LTQ-MS positive mode, and (c) 
GC-MS, clearly differentiates between the clinically and non-clinically acquired samples, though 
separation of the two clinical groups, lung cancer and symptom controls, does not occur. For (c), 
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based on the top 25 metabolites identified through one-way ANOVAs, LTQ-negative metabolites, Figure 
2.8. Again, clear separation was evident between clinical and non-clinical samples, but not between LC+ 
and LC- groups.  
 
2.3.8 | Identification of Clinically Relevant Biomarkers 
 
Due to the greater degree of separation shown in negative mode LTQ-MS fingerprints, it was decided to 
use this for the identification of clinical relevant metabolomic biomarkers. Initial analysis was completed 
using MetaboAnalyst 2.0’s random forest analysis feature. This showed a number of differential 
metabolites, in LTQ-negative mode, which were altered in LC+ samples, compared to LC- and CON 
samples. This suggested that a number of LTQ-MS metabolites may be useful as biomarkers of lung 
cancer status. Using the online facility ROCCET, univariate analysis was completed to identify potential 
biomarkers based on area under the receiver operating characteristic curve. The top three metabolites 
are listed in Table 2.5, with the area under the curve (AUC) figure for the top differential metabolites 
shown in Figure 2.10. This identified a number of metabolites that had a high AUC value (>0.99) for 
FIGURE 2.8 | Hierarchical Cluster Analysis with Heat Mapping for LTQ Metabolites 
Hierarchical cluster analysis and corresponding heat maps were constructed, based on the top 25 
metabolites identified through one-way ANOVAs, for metabolites identified in LTQ-negative mode. 
Similarly to PCA plots, separation between the clinically and non-clinically acquired samples was clear, 
but separation between LC positive and negative samples was not evident. 
 CON  LC-  LC+
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differentiating between clinically and non-clinically acquired samples. Additionally, a number of 
metabolites were identified with an AUC value of greater than 0.80, a threshold for clinically useful 
prediction. In LTQ-MS negative mode, metabolite 1496.72 showed the highest AUC value. At this value, 
0.85, the metabolite had a sensitivity of 54.5% and a specificity of 69.6%.  
 
TABLE 2.5 | Top Five Area Under Curve Values for LTQ-Negative Mode Metabolites 
Using the online ROCCET platform, the top five metabolites, based on AUC values, for each differential 
group comparison were identified. For clinical and non-clinical comparisons, high AUC values were 
obtained, and for the LC negative and positive comparison, five metabolites with AUC values greater 
than 0.8 were identified. 
 
Differential Metabolite AUC Value t-Test Fold Change 
CON Vs LC- 
67.18/1479.81 1.00 4.47 x 10
-15
 -2.38 
67.18/1560.81 1.00 3.10 x 10
-15
 -2.26 
69.09/1479.81 0.99 6.09 x 10
-15
 -2.25 
LC+ Vs CON 
53.27/75.09 1.00 8.74 x 10
-24
 4.71 
69.09/75.09 1.00 7.42 x 10
-24
 4.69 
189.09 1.00 6.12 x 10
-20
 2.57 
LC+ Vs LC - 
1496.72 0.85 2.93 x 10
-3
 -0.03 
957.36 0.83 4.57 x 10
-3
 0.31 




FIGURE 2.9 | Random Forest Plots for Identification of Key LTQ Metabolites 
Random forests plots were constructed, using MetaboAnalyst 2.0 for LTQ-negative mode, which 
revealed a number of metabolites, in both modes, which may have potential in terms of diagnostic 
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FIGURE 2.10 | Univariate Receiver Operating Characteristic Curve Analyses  
Using the online facility, ROCCET, univariate receiver operating characteristic curves were created, and 
plotted to create area under the curve figures for LTQ-negative mode metabolites. The metabolite with 
the highest AUC value for each differential group is plotted. 
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2.4 | Discussion 
 
Two separate approaches were explored with a view to identify novel biomarkers for lung cancer, 
namely exploring the lung microbiome and the lung metabolome. Overall, both approaches appear to 
have been successful in identifying biomarkers for lung cancer status, and staging in regards to the lung 
microbiome. 
 
2.4.1 | The Lung Cancer Microbiome 
 
The role of the microbiome in a range of respiratory conditions has been well documented; however, 
lung cancer has received only minimal attention. The lung cancer microbiome has been detailed, at the 
genus level, in female non-smokers from Xuanwei, China, through the use of amplicon sequencing. 
Interestingly, significant differences were only detected between sputum samples, and not buccal 
samples, suggesting a localised effect in the bronchial tree of the lung (Hosgood et al., 2014). This study 
suggested a potential role of household coal burning exposure, and its effect on the lung microbiome in 
patients with lung cancer, rather than tobacco smoking, which is the most common cause of lung cancer 
in more economically developed countries (Jemal et al., 2010a). This portion of work looked to address 
this, and to develop a more in-depth view of the microbiome with clinically relevant samples. 
 
2.4.2 | Taxonomic Composition of the Lung Cancer Microbiome 
 
In regards to PCA separation, Figure 2.3, taxonomy appeared to be influenced, to a greater degree than 
function, by lung cancer status. Interestingly, smoking status did not appear to be an influencing factor 
in separation. The effect of smoking on the lung microbiome is still to be firmly established (Erb-
Downward et al., 2011). To date, this is the first study to evaluate the lung cancer microbiome in a 
cohort of patients that contains smokers. It may be that any effect of smoking on the lung microbiome is 
outweighed by changes associated with lung disease, such as lung cancer. 
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The ‘core’, species-level microbiome, Table 2.3, revealed some noteworthy differences between the 
lung microbiomes of patients negative and positive for lung cancer. A significant difference was 
observed for S. viridans, which was found all patient samples, with a five-fold increase in LC+ patients. 
This bacterial species has been cultured from lung cancer patients in recent studies, but to date, it has 
not be identified as a differential bacteria for lung cancer state (Laroumagne et al., 2013). Additionally, 
Granulicatella adiacens, Streptococcus intermedius, and Mycobacterium tuberculosis were identified as 
being significantly higher in LC+ patients, although they were only found in all LC+ samples and not all 
LC- samples. Interestingly, a history of tuberculosis has been associated with an increased risk of lung 
cancer (Shiels et al., 2011), and a significantly shorter survival rate (Heuvers et al., 2012). In this study, 
none of the patients had a history of tuberculosis, as this would have prevented their inclusion in the 
study. It may be that M. tuberculosis is a member of the commensal lung microbiome, and indeed, it is 
predicted that one third of the global population are carriers of latent tuberculosis (Korbel, Schneider 
and Schaible, 2008). Nevertheless, the significantly higher levels of M. tuberculosis observed in LC+ 
patients warrants further study. The significant differences observed in the ‘core’ microbiome, Table 2.3, 
are mirrored in the significant fold changes from the LC- to the LC+ group, Figure 2.4, except that 
Mycobacterium bovis is also significantly higher in LC+ samples.  
 
In this study of the lung cancer microbiome, the focus has been on characterising the bacterial 
component. However, the eukaryotic component of the lung microbiome may also hold important and 
novel insights. The number of eukaryotic microbes in the lung microbiome is likely to be orders of 
magnitude lower than the bacterial component, but nevertheless, may harbour a number of 
opportunistic pathogens (Huffnagle and Noverr, 2013). In this study, no significant differences between 
the eukaryotic portions of the lung microbiome were detected between LC- and LC+ patients. However, 
a high number of alignments were removed because of their classification to the Homo sapiens genome, 
or other non-microbial eukaryotic genomes. This is likely to represent a lack of high-quality databases 
for eukaryotic microbes, which is a severe limitation. 
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2.4.3 | Functional Capacity of the Microbiome 
 
Metagenomic sequencing allows the field of microbiomics to move beyond characterising the 
microbiome simply in terms of its taxonomic composition, and more towards understanding how its 
functional capability shifts in response to disease state. Here a total of four Level 2 classifications, were 
identified that showed significantly higher levels in patients positive for lung cancer, including those 
involved in arginine use, urea cycle, putrescine and gamma-aminobutyric acid utilisation, and invasion 
and intracellular resistance. Interestingly, elevated levels of polyamines, such as putrescine and GABA, 
have been associated with a range of cancers including lung malignancies (Nowotarski, Woster and 
Casero, 2013). Polyamines offer a rich nitrogen source of bacteria, and elevated levels associated with 
lung cancer could explain why there are significantly more associated alignments in positive lung cancer 
cases. 
 
At Level 3 of functional classification, seven functions were significantly higher, and three significantly 
lower, in the positive lung cancers. Some of these increases reflected Level 2 changes, but others, such 
as higher levels of iron siderophore sensors and receptor system alignments, further suggest that 
changes in the cancerous lung are reflected by changes in the lung microbiome. Elevated iron levels are 
associated with lung cancer (Xiong, Wang and Yu, 2014), and as iron is essential for many cellular 
functions in bacteria, it is not unexpected that elevated levels of iron associated with lung cancer would 
result in a selective pressure to reflect this in the microbiome. Functional changes are not unexpected in 
the lung microbiome as a response to malignancy formation, but this study is the first to confirm that 
such synergy exists. 
 
Of the three functional classifications shown to be significantly lower in LC+ cases, two have known 
functions. The biggest reduction in functional classifications was seen in the COG0451 grouping, but to 
date, these have not been assigned a biological function. However, significantly lower levels were also 
seen in functional classifications with known biological function namely RNA methylation and 
glutaredoxins, although the significance of these changes, in regards to lung cancer, is unclear. 
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2.4.4 | The Microbiome as a Source of Novel Biomarkers 
 
One of the key purposes of this portion of work was to identify potential novel biomarkers for lung 
cancer state and stage. To this end, G. adiacens was shown to have a significant positive relationship 
with six other bacterial species, which is only seen in patients positive for lung cancer. The Granulicatella 
genus has been identified as being significantly higher in the sputum of non-smoking lung cancer cases 
(Hosgood et al., 2014), suggesting that it may be a true reflection of lung cancer state, rather than a by-
product of tobacco smoking. The Granulicatella genus, and G. adiacens specifically, is a difficult 
organism to culture, which may be the limiting factor that explains the minimal study that has been 
conducted into it (Woo, 2003). It has however, been associated with endocarditis (Perkins et al., 2003) 
and septicaemia (Bizzarro et al., 2011). G. adiacens may be an opportunistic human pathogen, or a 
commensal bacterium that is able to take advantage of a niche, such as altered sputum composition 
(Hubers et al., 2013), that is present in the lungs of patients with lung cancer. Additionally, the six other 
bacterial species associated with G. adiacens in positive lung cancer patients; do not appear to have 
been linked to lung cancer in the literature. Similarly, it may be that they respond to a selective pressure 
in the cancerous lung, or potentially, that G. adiacens has a synergistic relationship which enables their 
higher abundance. Regardless of the biological basis for these significantly higher abundances seen, they 
nevertheless have the potential to act as biomarkers for lung cancer, in regards to both lung cancer 
status, but also in staging, due to the pattern of abundances seen in Figure 2.6.  
 
The use of spontaneous sputum is a well-established diagnostic medium for lung cancer because of its 
non-invasive collection, and that it is symptomatic of lung cancer as a disease. Therefore, it offers a 
viable alternative to radiography based diagnoses for high-throughput, non-invasive, and low-risk 
screens (D’Urso et al., 2013). However, it should be appreciated that sputum production is localised to 
the upper respiratory tract, and particularly the bronchial tree. As microbiome studies in other 
respiratory diseases have shown, including in COPD (Erb-Downward et al., 2011) and cystic fibrosis 
(Willner et al., 2011), spatial differences can exist within the lungs and therefore, sputum should only be 
taken as representative of the microbiome in the upper respiratory tract. 
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This novel study has expanded upon the knowledge of the microbiome in patients with lung cancer, 
using clinically relevant control samples, particularly in regards to the functional capacity of the 
microbiome, and its taxonomic composition at the species level. Additionally, the strength of using 
metagenomics to identify potential biomarkers for disease state and progression has been 
demonstrated; namely G. adiacens abundance correlations with a range of bacterial species, which 
could have clinical use. However, due to the relatively small sample number in this pilot study, more 
work is needed to confirm these relationships, and whether they are observable in earlier stage lung 
cancers, and other types, such as SCLC. 
 
2.4.5 | The Lung Cancer Metabolome 
 
Since the ‘Warburg Effect’, as it is now know, was first described in 1956 (Warburg, 1956), the 
alterations that cells undergo during carcinogenesis has been a focus of both basic and applied clinical 
research. The concept that these cellular changes could be detected via the subsequent changes in low 
molecular weight compounds has received some attention in the field of lung cancer diagnostics and 
biomarker discovery. For example, GC-MS has been used to identify potential biomarkers for a range of 
cancers in the form of urinary volatile organic metabolites (Silva, Passos and Câmara, 2011). Saliva has 
also been used as a biofluid for metabolomics, with capillary electrophoresis mass spectrometry being 
used to identify specific oral, breast and pancreatic cancer profiles (Sugimoto et al., 2010). Additionally, 
lung cancer has received attention in terms of metabolomics, but these investigations have focussed on 
the cancerous tumours themselves or serum from affected patients, and using a limited range of mass 
spectrometry techniques (Hori et al., 2011). 
 
In this exploratory study, sputum has been suggested as a source of biomarkers for the identification of 
positive or negative lung cancer status of a patient group presenting with lung cancer like symptoms. 
Through the use of ROCCET analysis, a number of negative mode LTQ-MS metabolites that had AUC 
values greater than 0.8, a cut-off for discrimination that may be useful in a clinical setting, were 
identified. The LC+ group consisted of a range of lung cancer stages and histology, including NSCLC and 
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SCLC. This suggests that biomarkers established through metabolomic techniques could have utility as a 
preliminary screen for lung cancer status, identifying patients that require a clinical follow-up for lung 
cancer confirmation, histology and staging.  
 
2.4.6 | Metabolomic Biomarkers for Lung Cancer 
 
As far as it is possible to ascertain, this is the first study to report on the metabolomic fingerprinting of 
sputum acquired from lung cancer patients. The use of sputum, the production of which is a symptom of 
lung cancer, as a biofluid for screening carries the benefit of being non-invasive, high-throughput, and 
low-cost, compared to current conventional methods such as CT scans (Rivera, Mehta and Wahidi, 
2013). 
 
Although the metabolites, with AUC values that suggest their potential clinical usefulness, identified in 
this portion of work, have a false positive rate that would prove problematic in a whole-population 
screen, they could still have utility in the screening of a ‘high-risk’ group, such as smokers. Furthermore, 
it may be that metabolomic biomarkers could be combined with other forms of biomarkers, such as 
circulating miRNAs, to enable an integrated approach to lung cancer screening, as has been suggested 
for other cancers (Laxman et al., 2008). 
 
In this portion of work, three different sample groups were used. In terms of a lung cancer screening 
regiment, it is likely that only ever an ‘at risk’ group of patients would be screened, such as smokers. The 
Control group in this work all have a history of smoking, albeit not all current, which would place them 
at an elevated risk of lung cancer. Here, a number of metabolites, or metabolite ratios, Table 2.5, have 
been shown to have an AUC value of 1.0 between the Control and LC+ group. This would translate into 
sensitivity and specificity percentages of nearly 100%. The main technology currently being proposed for 
lung cancer screening is CT scanning, which does not have sensitivity and specificity as high as shown 
here, and also carries the issue of potential risk to patients through repeated radiation exposure (Bach 
et al., 2012).  
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One of the strengths of this portion of work is the use of patient samples from a group presenting with 
suspected lung cancer, but not all of whom went on to be positively diagnosed with the disease. This 
means that metabolomic biomarkers for lung cancer that were able to differentiate between these two 
patient groups would have clinical use as a preliminary, non-invasive screen. This could, potentially, then 
identify patients who would need follow-up assessment with CT scanning, or another diagnostic such as 
bronchoscopy. Low-dose computed tomography scans are widely considered to be the most effective 
method of screening for lung cancer. However, the cost of LDCT screening currently prevents its 
widespread adoption, with each false-positive estimating to cost $1,000 (Wood et al., 2012). The use of 
metabolomic biomarkers, as described in this portion of work, could be employed to reduce the number 
of patients referred for LDCT, the consequent number of false-positive diagnoses, and thus the cost of 
screening using LDCT. 
 
2.4.7 | Moving from Fingerprint, to Metabolome, to Metabolite 
 
In this portion of work, a metabolomic fingerprinting method was employed to identify potential 
metabolomic biomarkers. However, as previously discussed, metabolomic fingerprinting identifies 
biomarkers without identifying individual metabolites. Although this provides for a fast classification of 
samples based on mass spectrometry, or additionally NMR, it does not provide insight into the biological 
processes involved in altering the metabolome to such an extent that allows for separation between 
disease groups, as seen here (Madsen, Lundstedt and Trygg, 2010). To progress this work further, 
identification of individual metabolites responsible for the high AUC values observed would be required. 
This could be accomplished through the use of a variety of mass spectrometry method. After the 
identification of individual metabolites, the biological pathways that each are involved in could be 
further interrogated to understand aberrations causing a detectable change in the metabolome of 
specific disease states, such as lung cancer presence. The identification of individual metabolites would 
also improve a screening methodology based on a mass spectrometry-based approach. For example, if a 
small number of metabolites have been identified, such as that been demonstrated in breast and 
ovarian cancer (Slupsky et al., 2010). 
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The utilisation of metabolomic fingerprinting to identify potential biomarkers for the identification of 
lung cancer status is novel and promising. However, there are a number of limitations to this portion of 
work. Firstly, the sample size used is relatively small, with minimal early stage lung cancer samples. This 
means that accurate predictions for the applicability of the findings to this group are not possible. 
Furthermore, due to insufficient sputum volume, accurate identification of the biomarkers with 
potential clinical application was not possible. Nevertheless, the power of using metabolomics to 
identify biomarkers, with potential clinical application, to separate those presenting with suspected lung 
cancer, into those positive and negative for the disease, has been shown. 
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2.8 | Conclusions and Future Work 
 
In this portion of work, the lung microbiome and metabolome were investigated to evaluate them as a 
source of novel biomarkers for the identification of lung cancer. To this end, the lung cancer microbiome 
and metabolome have been shown to possess unique characteristics, when compared to those without 
lung cancer, which are sufficient to differentiate disease groups. 
 
For the lung microbiome, a number of bacterial species were identified as being potential biomarkers 
for both lung cancer status and stage. Additionally, for the metabolome, a number of fingerprinting 
metabolites were shown to be able to differentiate between lung cancer positive and lung cancer 
negative patients, to a level that may have clinical usefulness. Both of these approaches employed 
sputum as a sampling biofluid. This is arguably one of the main strengths of both of these portions of 
work because sampling sputum is non-invasive. Furthermore, because it is localised to the lungs, and 
specifically the bronchial tract, the aberrations caused by the presence of lung cancer are likely to be 
concentrated, unlike other biofluids such as blood or urine, where the changes may be diluted to such 
an extent that they are not detectable.  
 
An additional strength of this portion of work is the patient cohort that was investigated. Albeit a small, 
pilot-sized study, the use of patients all presenting with suspected lung cancer, only a portion of whom 
were subsequently diagnosed with lung cancer, means that the changes observed in the lung 
microbiome and metabolome are not simply the result of general lung disorder. 
 
Both the lung microbiome and metabolome portions of work presented here have revealed novel 
insights into lung cancer. Nevertheless, the are both relatively small-scale pilot studies, and future work, 
with a considerably increased cohort of patients, with a variety of lung cancer stages and histologies, will 
be required to verify the findings presented here. Additionally, this presents the opportunity to combine 
microbiome and metabolome investigations towards a systems biology approach for the identification 
of lung cancer biomarkers.  
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CHAPTER 3 | Understanding the COPD Microbiome 
Through Metagenomic Sequencing 
 
CHAPTER SUMMARY | The lung microbiome in COPD has been well-characterised but little is known 
about the functional capacity of the microbiome, which can be revealed through metagenomics. 
Genomic DNA was isolated from spontaneous sputa (sampling the upper respiratory tract) from ten 
control participants and eight patients with moderate (three Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) II) to severe COPD (five GOLD III). Nextera® libraries were constructed and 
sequenced on the Illumina HiSeq 2500 platform. Resulting sequences were then analysed using the MG-
RAST pipeline; an automated analysis platform for metagenomes. Principal component analyses, 
irrespective of smoking status, showed partial separation at the level of bacterial taxon but only to a 
lesser extent based on function.  A core microbiome of eight microbial genera (Haemophilus, 
Lactobacillus, Neisseria, Ochrobactrum, Pseudomonas, Staphylococcus, Streptococcus, and Veillonella) 
and four species (Haemophilus influenzae, Ochrobactrum anthropic, Streptococcus pneumoniae, and 
Streptococcus thermophilus) were found in all 18 samples. Significant differences were observed in the 
abundance of bacterial species between Control and COPD patients, particularly in regards to species of 
the Streptococcus genus. A total of 14 bacterial species were shown to have higher abundance levels in 
COPD patients, and a total of 17 bacterial species were shown to have lower abundance levels in COPD 
patients. In addition, functional differences in the metagenomes from COPD patients were consistent 
with a greater bacterial growth capacity, with higher abundances of genes involved in amino acid, 
carbohydrate, protein, DNA, and RNA metabolism.  Regression analyses correlated COPD severity (as 
indicated by worsening airflow obstruction / lower FEV1% of predicted) with differences in the 
Streptococcus genus, specifically S. pneumonia, and also functional classifications aligned to sialic acid 
metabolism. This pilot study has linked COPD severity to the abundance of S. pneumonia and altered 
bacterial sialic acid metabolism, which could influence the inflammatory response in the lung. Thus, the 
functional capacity of the COPD microbiome may be a factor in bacterial-associated exacerbations and 
raises a number of avenues for further study.  
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3.1 | Introduction  
 
Chronic obstructive pulmonary disease is a leading cause of death and morbidity, leading to an 
estimated 2.75 million deaths worldwide in 2006 (Lopez et al., 2006). COPD is usually caused by smoking 
in the developed world and is an umbrella term for a multisystemic inflammatory state, including 
several diseases such as chronic bronchitis and emphysema. 
 
3.1.1 | COPD Aetiology and Pathogenesis 
 
COPD does not have a single definitive cause, but rather a collection of risk factors. Tobacco smoking 
and certain occupational exposures are the two certain environmental risk factors and α1-antitrypsin 
deficiency is a certain host risk factor. COPD remains as a poorly characterized disease, though the 
central principle is that lung function is limited through a combination of small airways disease and 
parenchymal destruction (Mannino and Buist, 2007). 
 
Tobacco smoking is likely to be responsible for the vast majority of COPD cases worldwide, but there are 
noteworthy differences. For example, in less economically developed countries, a more important risk 
factor for COPD may be household biomass fuel smoke exposure. Indeed, with tobacco consumption 
decreasing in more economically developed countries, Figure 3.1, exposure to household smoke may be 
one of the more significant risk factors globally (Salvi and Barnes, 2010). 
 
Conservative estimates of disease burden suggest that at least 10% of the adult population over the age 
of 40 years is affected by COPD. Additionally, the link between tobacco and COPD is reinforced by the 
considerably higher prevalence in current and ex-smokers compared to non-smokers. COPD prevalence 
is also increased in men, compared to women, which may be somewhat explained by the pattern of 
tobacco consumption described in Figure 3.1 (Halbert et al., 2006). 
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The morbidity of COPD is one of the primary social and economic burdens of the disease. Measures of 
morbidity traditionally cover visits to primary and secondary healthcare, number of prescriptions, and 
overnight hospital admissions. Although exact figures for COPD morbidity are difficult to calculate, 
because of the numerous comorbidities associated with the disease, it is established that COPD-related 
morbidity increases with age (Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2014). In 
addition to the significant mortaility associated with COPD, with recent modelling predicting that COPD 
will be the fourth leading cause of mortality worldwide by 2030 (Mathers and Loncar, 2006), the 
economic burden of COPD makes it a significant global issue.  
 
The pathogenesis of COPD is defined primarily by the inflammatory response of the respiratory tract, 
which is modified in the disease. This in turn is amplified by subsequent exposure to irritants, including 
tobacco and household fuel smoke, which is sustained after exposure is ceased; making COPD an 
irreversible disease. A number of factors can be involved in modification of the inflammatory response, 
including constituents of the lung microbiome, oxidative stress, increased protease levels, and 
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FIGURE 3.1 | Model of the Worldwide Tobacco Epidemic 
This model describes the initial rise and subsequent decline in smoking prevalence which is followed, 
albeit with some delay, by a rise and then decline in the number of deaths caused by smoking. With this 
pattern of tobacco consumption worldwide, it is possible that tobacco smoking may cease to be the 
primary cause of COPD. Figure adapted from Lopez, Collishaw and Piha, (1994). 
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One of the key characteristic of COPD is periods of acute symptom exacerbations, leading to a 
substantial worsening of morbidity and mortality. It is defined as a natural event in COPD which is 
characterized by a change in a patient’s baseline dyspnea, cough, and/or sputum production, which is 
beyond normal day-to-day variations and may warrant a change in regular medication (Global Initiative 
for Chronic Obstructive Lung Disease (GOLD), 2014). Increased levels of inflammation are very common 
in acute exacerbations, and are usually triggered by colonisation of the lower respiratory tract by 
viruses, bacteria, or a combination of both (Wedzicha and Seemungal, 2007). The level of bacterial load 
in COPD acute exacerbations has been shown to be increased compared to baseline COPD, suggesting 
that the microbiome may play a significant role in the initiation of exacerbations, immune response to 
exacerbations, or effectiveness of clinical interventions (Garcha et al., 2012). Therefore, establishing the 
COPD microbiome at a baseline of the disease may have important implications in improving 
understanding of acute COPD exacerbations, and suggesting potential predictors for them. 
 
3.1.2 | Diagnosis and Treatment of COPD 
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FIGURE 3.2 | FEV
1
/FVC Spirometry for Normal and COPD-Affected Lungs 
The use of FEV
1
/FVC spirometry is required for a definitive clinical diagnosis of COPD. A FEV
1
/FVC of less 
than 0.70 confirms the presence of COPD. Figure adapted from Global Initiative for Chronic Obstructive 
Lung Disease (GOLD), (2014). 
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or sputum production, and a history of exposure to COPD risk factors, such as tobacco smoking. A 
definitive clinical diagnosis requires spirometry, the measurement of breath, assessment. A post-
bronchodilator forced expiratory volume in one second (FEV1) over forced vital capacity (FVC) ratio, also 
defined as FEV1% of predicted, the proportion of a patient’s lung capacity that they are able to expel 
within one second (FEV1) as a proportion of the total air that can be expelled from the lungs after full 
inspiration (FVC), Figure 3.2, of less than 0.70 confirms the presence of COPD (Global Initiative for 
Chronic Obstructive Lung Disease (GOLD), 2014). 
 
In addition to clinical diagnosis, spirometry is also used to classify COPD, based on the FEV1/FVC ratio, 
from mild to very severe COPD, Table 3.1. These four COPD classifications carry distinct clinical 
characteristics, in terms of the predicted number of exacerbations and hospitalisations per year, and the 
three-year predicted mortality rate (Global Initiative for Chronic Obstructive Lung Disease (GOLD), 
2014). Although spirometry is the main method of classifying COPD, a weak correlation between the 
FEV1/FVC ratio a patient’s health-related quality of life has been shown. This means that within any of 
the four GOLD classifications of COPD, there is a significant degree of individual variation, with two 
patients sharing the same FEV1/FVC ratio potentially having vastly different health-related qualities of 
life. This suggests that the comorbidities commonly associated with COPD also need to be formally 
TABLE 3.1 | Classification of COPD with Clinical Characteristics of Groups 
COPD is classified into four Global Initiative for Chronic Obstructive Lung Disease (GOLD) categories 
from mild to very severe COPD. This is determined by FEV1/FVC ratio. Clinical characteristics for GOLD I 
(Mild) COPD classifications have yet to be determined. Table constructed using data taken from Global 
Initiative for Chronic Obstructive Lung Disease (GOLD), (2014). 
 
GOLD 







I Mild ≥ 0.80 ? ? ? 
II Moderate ≤ 0.50 to < 0.80 0.70 – 0.90 0.11 – 0.20 11% 
III Severe ≤ 0.30 to < 0.50 1.10 – 1.30 0.25 – 0.30 15% 
IV Very Severe < 0.30 1.20 – 2.00 0.40 – 0.54 24% 
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assessed, as these may also have a significant influence on a patient’s health-related quality of life 
(Jones, 2009). 
 
One of the key treatment options for COPD patients is smoking cessation. This has been shown to be the 
intervention with the greatest degree of benefit in regards to moderating the progression of COPD. This 
benefit is likely brought about through the reduction in irritant exposure, namely cigarette smoke, which 
reduces inflammatory-related damage to the lungs. To date, there has been no medication for COPD 
that has been proven to either prevent, or reverse, the long-term decline in lung function that is 
characteristic of COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2014). 
 
Because no treatment for COPD, to date, has been proven to be effective at improving lung function, 
treatments focus on the management of the symptomatic load of a patient. For stable COPD, there are 
two approaches treatment can take: pharmacological and non-pharmacological therapies. For 
pharmacological therapies bronchodilators such as β2-agonists, anticholinergics, and corticosteroids are 
the main options. The overriding issue in COPD treatment is tailoring the regiment to individual patients. 
There is a significant degree of individual differences within COPD patients, particularly in regards to 
comorbidities, so these must be taken into consideration when treatment options are decided. 
Complications of pharmacological therapies can be significant, with increased risk of pneumonia for 
corticosteroid use for example. Non-pharmacological treatments for COPD can include pulmonary 
rehabilitation, oxygen therapy, or lung transplantation (Global Initiative for Chronic Obstructive Lung 
Disease (GOLD), 2014).  
 
The treatment of acute exacerbations is one of the most challenging areas in managing COPD. What 
constitutes an exacerbation is still poorly defined, and diagnosis and treatment relies on the patient 
presenting themselves with an acute change in their day-to-day symptoms. The majority of COPD acute 
exacerbations are believed to have a viral or bacterial cause, or a combination of both, with a limited 
number of microbial species believed to be the causative factor in the majority of acute exacerbations. 
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Antibiotic treatment has been shown to improve management of acute exacerbations, with the benefit 
enhanced in patients with severe COPD compared to those with moderate (Wedzicha and Seemungal, 
2007). The clinical benefit of using antibiotics in the treatment of acute exacerbations of COPD suggests 
a significant role for the lung microbiome. Understanding the lung microbiome in stable COPD may 
reveal novel insights into the processes preceding acute exacerbations. 
 
3.1.3 | The Lung Microbiome of COPD 
 
It is now clearly established that the lungs are not a sterile environment (Charlson et al., 2011). 
However, although much is known about the microbiomes of lungs in CF and asthmatic patients, 
relatively little is known about the lung microbiome of COPD patients. For example, it has not been 
established whether any changes in the lung microbiome of patients with COPD is a causative factor in 
the disease, or simply a reflection of the altered lung environment. Additionally, the role that common 
pharmaceutical treatments for the disease, such as inhaled corticosteroids, have on the lung 
microbiome have not been defined. Furthermore, because smoking tobacco is a major risk factor in 
developing COPD, the lung microbiome of "healthy" smokers also needs to be established. 
 
To this end, Erb-Downward et al., used 16S rRNA pyrosequencing analysis to examine four participants 
with COPD, seven "healthy" smokers and three participants who have never smoked. Although the 
study did not find a significant difference in lung microbiomes between the three groups, it did conclude 
with three main results. Firstly, that the lung microbiome of "healthy" smokers is distinct to the 
microbiome reported for either the oral cavity or nasopharynx. Secondly, the diversity of the lung 
microbiome is less reduced in participants with decreased lung function, such as COPD, and is usually 
associated with Pseudomonas species. Lastly, the study found that some smokers had a less diverse lung 
microbiome relative to smokers with normal lung function which suggests that changes in the lung 
microbiota may be detectable before there is clinical evidence of reduced lung function via spirometric 
techniques (Erb-Downward et al., 2011). 
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As with CF, studying the lung microbiome of COPD patients may also aid in treatment in addition to its 
potential application in diagnosis. Acute exacerbations of COPD are a significant source of morbidity and 
in 50% of cases, bacterial infections are implicated. Presently, a small number of pathogens have been 
reliably identified in COPD airways, via culture-dependent methods, but the entire community structure 
of the COPD lung microbiome in acute exacerbations is still to be elucidated. Towards this goal, Huang et 
al., used 16S rRNA PhyloChip technology on a cohort of eight COPD patients in an attempt to identify 
significant pathogenic bacteria. They found that 75 taxa of bacteria were detectable in all COPD 
patients, and many of these taxa are known pathogens. Furthermore, they identified pathogenic 
bacteria, even in those patients who were currently undergoing antibiotic treatment for an infection. 
This suggests that improved treatment of exacerbations may be achieved through high-throughput 
identification of pathogenic bacteria to further identify appropriate therapeutic targets (Huang et al., 
2010). 
 
Patients experience acute exacerbations, which may be triggered by infection or environmental 
pollutants.  Approximately 75% of acute exacerbations are attributed to viral or bacterial infection, or a 
combination of both (Han et al., 2012). Characterisation of bacteria cultured from the airways of COPD 
patients has linked exacerbations with pathogens such as Streptococcus pneumoniae, Haemophilus 
influenzae, and Moraxella catarrhalis (Hirschmann, 2000).  
 
Since the advent of culture-independent techniques, especially amplification and sequencing of the 16S 
rRNA gene, the lung microbiome of COPD has been one of the most widely studied amongst respiratory 
diseases. Analysis of the lung microbiome may lead to novel insights into the progression of COPD and 
potential therapeutic interventions. Lung microbiomic analyses based on 16S rRNA amplicon 
sequencing, to characterise bacterial taxonomic composition, compared bronchial alveolar lavages from 
patients with COPD to healthy individuals.  Initial studies suggested that the lung microbiome of patients 
with moderate and severe COPD patients is less diverse than ‘healthy’ controls (Erb-Downward et al., 
2011), although other work suggested this was an underestimation of bacterial diversity (Huang et al., 
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2010). More recent work, with a larger cohort of moderate and severe COPD patients, suggested 
increased microbial diversity in more severe COPD (Pragman et al., 2012). Others have described a core 
COPD lung microbiome that includes Pseudomonas, Streptococcus, Prevotella, Fusobacterium, 
Haemophilus, Veillonella, and the Porphyromonas genera.  
 
3.1.4 | Aims and Objectives of Chapter 
 
COPD is one of the respiratory diseases that have received the greatest degree of attention in regards to 
analysis of the lung microbiome. However, metagenomic analysis of the lung microbiome of stable 
COPD patients has been distinctly limited. The aims and objectives of this portion of work were 
therefore, to: 
 
1) Analyse the taxonomic make-up of the COPD microbiome, in stable patients, to the species 
level, compared to individuals without COPD. 
2) Evaluate the functional capacity of the lung microbiome in stable COPD patients to identify 
potential implications that this may have on disease progression, or management. 
3) Investigate characteristics of the lung microbiome in stable COPD patients to identify any that 
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3.2 | Materials and Methods  
 
The MedLung study received loco-regional ethical approval (05/WMW01/75). Informed consent was 
obtained from all participants at least 24 hours prior to sampling, and at a previous clinical appointment 
for clinical patients. All data was link anonymised prior to analysis. 
 
3.2.1 | Patient Recruitment and Sampling 
 
Spontaneous sputum was collected from patients with a clinical and spirometric diagnosis of COPD from 
two UK hospitals. COPD diagnosis required a history of at least ten smoking pack years, an age of older 
than 40 years, and post bronchodilator FEV1/FVC of less than 0.70. Additionally, spontaneous sputum 
samples were collected from staff members at Swansea University who were either current or ex-
smokers, but had no known lung disease and no symptoms of COPD. All spontaneous sputum samples 
contained bronchial cells as confirmed by a Consultant Pathologist.  
 
3.2.2 | Isolation of Total Genomic DNA 
 
After collection, raw sputum samples were frozen at -80°C for up to seven days, at which time they were 
defrosted in ice for approximately one hour. Sputum cells were isolated as described by Lewis et al., 
(2010) through the addition of 0.5 mL of a working solution of DTT, made up by adding 2.5 g of DTT to 
31 mL of 30% aqueous methanol, and 5 mL of 30% aqueous methanol, following which they were placed 
on a vortex mixer for 15 minutes. Samples then underwent centrifugation at 1800 x g for 10 minutes. 
The supernatant was then removed and the pellet transferred to a clean 1.5 mL microcentrifuge tube 
and frozen at -80°C. After processing, all samples remained frozen for up to two years before total 
genomic DNA was extracted. 
 
Total genomic DNA was extracted from 100 µL of isolated sputum cells within seven days of arrival to 
Aberystwyth laboratories using a FastDNA SPIN kit for soil (MP Biomedical, Santa Ana, USA) following 
manufacturer’s instructions. Bead beating was carried out in a FastPrep-24 machine (MP Biomedical) 
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with three cycles at speed setting 6.0 for seconds, with cooling on ice for 60 seconds between cycles. 
Genomic DNA was eluted in to 30 µL of DES and dsDNA concentration determined using the Quant-iT 
dsDNA High Sensitivity assay kit and a Qubit fluorometer (Life Technologies, Paisley, UK). 
 
3.2.3 | Metagenomic Library Preparation and Sequencing 
 
Extracted genomic DNA was normalised to 10 ng/µL with PCR grade water (Roche Diagnostics Limited, 
West Sussex, UK) and 50 ng used to create metagenomic libraries using the Nextera® DNA kit 
(Invitrogen, San Diego, USA) following standard instructions, except that a MinElute PCR purification kit 
(Qiagen, Ltd Crawley, UK) was used for the clean-up of tagmented DNA. Nextera® DNA libraries were 
quantified as above, and approximate library sizes determined by running on a 2% agarose gel alongside 
HyperLadder IV (Bioline, London, UK). 
 
Sample libraries were pooled in equimolar concentrations following Illumina guidelines and sequenced 
at 2 x 151 bp using an Illumina HiSeq 2500 rapid run, with samples duplicated over two lanes, and 
following standard manufacturer’s instructions at the IBERS Aberystwyth Translational Genomics 
Facility. 
 
3.2.4 | Metagenomic Sequence Analysis 
 
After sequencing, output files for each sample were combined into one file, using the BioLinux 7 
environment (Field et al., 2006), for each read direction. Sequencing files were uploaded to MG-RAST 
(v3.2) (Meyer et al., 2008) as FASTQ files, and paired-end reads joined using the facility available within 
MG-RAST, with non-overlapping reads retained. Sequences were dereplicated and dynamically trimmed 
using the default parameters for FASTQ files, and human sequences removed by screening against the 
Homo sapiens (v36) genome, available via NCBI.  The MG-RAST pipeline used an automated BLASTX 
annotation of metagenomic sequencing reads against the SEED non-redundant database (Overbeek et 
al., 2005). 
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The SEED hits can be matched to identity at various taxonomic levels; e.g. genus or species levels.  
Organism abundances were modelled and exported from MG-RAST using the ‘Best Hit Classification’ 
after alignment to the M5NR database, with only alignments with a maximum e-value of 1 x 10-5, 
minimum identity cut-off of 97 %, and a minimum alignment cut-off of 15 being used. Functional 
abundances were modelled and exported from MG-RAST using ‘Hierarchical Classification’. SEED 
matches can also be related to metabolic information, again at different levels of classification. The 
coarsest level of organization; the generalized cellular function was termed level 1, and the finest, 
individual subsystems level 3. Read abundances were transformed, to normalise for potential variations 
in sequencing efficacy, into percentages based upon the total abundances within each sample. 
Statistical analysis was completed using the MetaboAnalyst 2.0 (Xia et al., 2012) facility and MINITAB 14 
package. Eukaryotic taxonomic classifications were trimmed based on literature searches to remove 
poorly classified reads. Unless otherwise stated, where given, P values represent the significance of the 
result of one-way ANOVA tests. All sequences files are publicly available through the MG-RAST IDs 
detailed in Chapter 3 Appendix, Supplementary Table 3.1. Raw sequence files have been deposited at 
the European Nucleotide Archive under primary accession number PRJEB9034 and secondary accession 
number ERP010088. 
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3.3 | Results 
 
Spontaneous sputum was collected from eight patients (five male: three female) with a clinical and 
spirometric diagnosis of COPD from two UK hospitals, with a mean age of 46, mean smoking pack years 
of 46 and mean FEV1% of predicted of 46%. Of the eight COPD patients, three were classified as GOLD 
stage II and five as GOLD stage III. Ten (six male: four female) spontaneous sputum samples were 
collected from staff members, (mean age = 53) at Swansea University who were either current or ex-
smokers but had no known lung disease and no symptoms of COPD. Individual participant details, 
alongside additional clinical information for COPD patients, are given in Table 3.2. Full participant 
information is detailed in Chapter 3 Appendix, Supplementary Table 3.1. No discernible differences were 
observed between the characteristics detailed in Table 3.1, in regards to age, male to female ratio and 
smoking status. 
 
TABLE 3.2 | Characteristics of Participant/Patients for each Disease Group 
Data are means for each disease group, with standard deviations displayed in brackets. FEV
1
% = 
forced expulsion volume in one second, as a percentage of the predicted value. Smoking pack years is 
individual history normalised to 20 cigarettes a day for one year. GOLD = Global Initiative for Chronic 
Obstructive Pulmonary Disease rating of COPD severity. nc = not collected. 
 
Group Control COPD 
Number 10 8 
Age 52.90 (13.26) 67.75 (5.26) 
Male : Female Ratio 6 : 4 5 : 3 
Smoking Status 
  
Current 4 5 
Ex 6 2 
Never 0 1 
Smoking Pack Years nc 45.57 (12.87) 
FEV
1
% of Predicted nc 45.88 (11.47) 
GOLD Rating 
  
I nc 0 
II nc 3 
III nc 5 
IV nc 0 
Antibiotic Use 0 2 
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3.3.1 | Preliminary Sequence Read Analysis 
 
Genomic DNA sequencing statistics are shown in Chapter 3 Appendix, Supplementary Table 3.2. One-
way ANOVA showed no statistically significant differences in all but one sequencing output. Average 
read lengths were significantly longer (P = 0.001) in control samples, by approximately 4 bp. However, 
because no other read characteristics were shown to be statistically significant, it is likely that 
sequencing with the HiSeq 2500 platform and subsequent metagenomic analysis with the MG-RAST 
pipeline did not introduce any degree of bias that would affect subsequent data analysis. All 18 
sequenced metagenomes are publicly available via the links detailed in Chapter 3 Appendix, 
Supplementary Table 3.1. 
 
3.3.2 | Comparison of the Taxonomy of COPD Microbiome 
 
MG-RAST Principal Component Analysis revealed separation between the control and COPD groups 
when considering taxonomic classification; with five out of the eight COPD samples forming a distinctive 
cluster, Figure 3.3a. However, three COPD samples remained clustered away from the main COPD group 
FIGURE 3.3| Principal Component Analysis of Taxonomy and Functional Classifications 
Using MG-RAST analysis platform, PCA plots were created using (a) taxonomic and (b) functional 
classifications, using the analysis method detailed previously. Control samples are coloured blue and 
COPD red. Triangles indicate patients who are current smokers, and black circles indicate the patient 
has antibiotic use in their medical history prior to giving a sample. PCA plots drawn using normalised 
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with the Control group. There were no unifying characteristics of these three samples, with two being 
GOLD stage III and one GOLD stage II. PCA separation did not appear to be influenced by smoking status 
or reported prior use of antibiotics.  
 
A total of eight bacterial genera were present in all 18 samples, Haemophilus, Lactobacillus, Neisseria, 
Ochrobactrum, Pseudomonas, Staphylococcus, Streptococcus, and Veillonella. At the species level, Figure 
3.4, there are four species present in all 18 samples, Haemophilus influenzae, Ochrobactrum anthropic, 
Streptococcus pneumoniae, and Streptococcus thermophilus. Crucially, four additional species found in 
all of the COPD samples but not all control samples: Staphylococcus aureus, Stenotrophomonas 
maltophilia, Streptococcus agalactiae, and Streptococcus pyogenes.  Significantly, all of these species are 
human pathogens, with S. pyogenes being the most pathogenic Streptococcal bacterium. However, no 
FIGURE 3.4 | Core Microbiome of All Samples, COPD Samples, and Control Samples 
Abundance of the 14 bacterial species that constitute the ‘core microbiome’ in Control participants and 
COPD patients. Four bacterial species were found in all samples from both groups, four species were 
found in all of the COPD samples but not all of the Control samples, and six species were found in all of 
the Control samples but not all of the COPD samples. There was no bacterial species that was common 
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statistically significant differences, between COPD and Control groups, were evident for the four 
bacterial species found in all COPD samples, but not all Control samples, suggesting that individual 
differences may play an important role in determining the level of bacterial species in the ‘core’ 
microbiome. Additionally, six bacterial species were found in all control samples but not in all COPD 
samples; two Enterococcus species, S. rostri and the Streptococcus species S. parauaberis, S. virdans and 
sp.6. Some non-human eukaryotic sequences were identified in metagenomic libraries, but no 
significant differences in species abundance were detected when comparing control and COPD groups. 
Other species which exhibited statistically significant fold changes in abundance between COPD and 
controls were targeted, Figure 3.5. These species included the pathogens Gemella haemolyses, 
Abiotrophia para-adiacens and Glemella sanginis. The Streptococcus genus in particular appeared to 
exhibit many changes in abundance in COPD patient samples, with both increases and decreases 






























FIGURE 3.5 | Significant Changes in Species Abundance from Control to COPD 
Using MetaboAnalyst 2.0, t-Tests and fold-changes were calculated from normalised percentages of 
reads, with only those with a P value of < 0.05 charted. The Streptococcus genus appears to be highly 
dynamic in COPD, with both increases and decreases in species abundance in COPD compared to the 
Control group. On average, COPD samples appear to show a net loss in the abundance of obligate 
anaerobes, but a net increase in the abundance of facultative anaerobes. 
[ 82 ] 
3.3.3 | Comparison of Functional Capacity of COPD Microbiome 
 
Functional classification, Figure 3.3b, appeared to reduce the separation of the two groups, when 
compared to taxonomic classification, Figure 3.3a. However, seven of the control samples clustered 
away from the COPD samples, but three remained clustered with the majority of the COPD samples. As 
with taxonomic classifications, smoking status did not appear to influence PCA separation, but the 
presence of antibiotic use in medical history may be a more significant factor in functional separation 
than for taxonomic separation.  
 
Significant fold changes in gene functional classifications were also considered. At the crudest functional 
classification; Level 1, there were significantly fewer alignments to genes involved in carbohydrate 
metabolism in COPD patients, but an increase in clustering-based subsystems, horizontal gene transfer, 
and nucleosides and nucleotides. At the more resolved Level 2 functional classification, 26 classifications 
exhibited a significant difference, with 22 higher in COPD patients. At the most resolved Level 3, only 
significant increases in COPD patients were observed, Figure 3.6. These alignments appear to centre on 
functional classifications involved in bacterial growth, including bacterial cell division, nucleosides and 
nucleotides, and amino acid, protein and RNA metabolism. Additionally, functional classifications 
involved in the stress response associated with the heat shock DnaK gene cluster were significantly 
higher in COPD samples than Control samples. 
 
3.3.4 | Microbiome Changes Associated with COPD Severity 
 
In assessing the potential influence of our finding on the severity of airflow obstruction (FEV1 % of 
predicted), Table 3.3, a positive correlation with the Streptococcus genus (R2 = 51.8%, P = 0.044), and 
more specifically S. pneumoniae (R2 = 63.6%, P = 0.018) was found. Additionally, functional positive 
correlations were observed with the classification of di- and oligosaccharides (R2 = 50.8%, P = 0.047) at 
Level 2, and more specifically with sialic acid metabolism (functional level 3) (R2 = 51.1%, P = 0.046) at 
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Level 3.  No significant correlation between S. pneumonia and smoking pack years or age was observed, 
suggesting that COPD severity is the main factor influencing the observed correlation. 
 
The genus Neisseria showed a correlation with smoking pack years (R2 = 66.1%, P = 0.014). Notable 
significant positive functional correlations for smoking pack years were also observed with bacterial DNA 
repair, potassium homeostasis and the protease modulator YbbK. With regards to age, the 
Ochrobactrum genus showed a significant positive relationship (R2 = 51.6%, P = 0.045), and specifically 
O. anthropi (R2 = 51.6%, P = 0.045). There were also significant correlations with the associated 
biochemical pathways linked to glutamate and proline metabolism, and separately with quorum sensing 
and biofilm formation which could be associated with monosaccharide production.  
FIGURE 3.6 | Significant Changes in Functional Classification Abundance from Control to COPD 
Using MetaboAnalyst 2.0, t-Tests and fold-changes were calculated from normalised percentages of 
reads, with only those with a P value of < 0.05 charted. Differences at Level 3 appear to centre on 
changes to those reads aligned to those with functional roles in bacterial cell division.  
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TABLE 3.3 | Regression Analysis for COPD Patients using FEV
1
%, Smoking Pack Years and Age 
Regression analysis of FEV1% of predicted, commonly used as a measure of COPD severity, with 
normalised sequence numbers, reveals that the Streptococcus genus, and specifically S. pneumonia is 
positively correlated with FEV1% of predicted, but not smoking pack years or age, suggesting that S. 
pneumonia could act as a biomarker for COPD disease progression. Only those taxonomic or 
functional classifications found in all eight COPD patients, and with an R2 value of >0.5 were used in 
regression analysis. + or – symbols indicate whether relationship is positive or negative respectively. 
Significant regressions are highlighted in bold. P represents P value of significance of correlation seen. 
 
  + / - 
FEV
1
























Streptococcus + 51.8 43.7 0.044 23.1 10.3 0.228 20.6 7.3 0.259 
Neisseria - 2.4 0.0 0.715 66.1 60.4 0.014 6.3 0.0 0.548 





s Streptococcus pneumonia + 63.6 57.6 0.018 8.4 0.0 0.487 40.1 30.1 0.092 











Di- and oligosaccharides + 50.8 42.6 0.047 1.8 0.0 0.752 29.7 18.0 0.162 
Glutamine, glutamate, 
aspartate 
- 47.5 38.7 0.059 8.2 0.0 0.491 78.7 75.2 0.003 
Monosaccharides + 39.2 29.1 0.097 3.8 0.0 0.000 55.2 47.7 0.035 
Quorum sensing and 
biofilm form 





Sialic Acid Metabolism + 51.1 42.9 0.046 18.1 4.5 0.293 40.0 30.0 0.092 
DNA repair, bacterial - 2.4 0.0 0.714 74.8 70.6 0.006 6.5 0.0 0.543 
Potassium homeostasis - 15.0 0.8 0.344 65.6 59.8 0.015 21.1 7.9 0.252 
YbbK - 3.4 0.0 0.662 61.0 54.5 0.022 18.0 4.4 0.294 
Glutamine, Glutamate, 
Aspartate and Asparagine 
Biosynthesis 
- 30.3 18.7 0.157 10.3 0.0 0.439 66.5 60.9 0.014 
Proline, 4-hydroxyproline 
uptake 
- 17.1 3.3 0.309 15.4 1.4 0.335 53.3 45.5 0.040 
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3.4 | Discussion 
 
The role of microbial pathogens in COPD has been well documented, specifically in relation to 
exacerbations (Patel, 2002). However, although there have been studies of microbial changes in patients 
with differing levels of COPD severity (Erb-Downward et al., 2011; Pragman et al., 2012; Sze et al., 2012), 
these have not unambiguously identified the species present, or suggested changes in the functions of 
the bacterial populations. In this portion of work, the first metagenomic study of the lung microbiome in 
patients with COPD, which reveals both its function and structure, down to the species level of 
resolution, was detailed.   
 
In the human gut, metagenomic sequencing has been used to develop novel hypotheses into 
personalised disease risk factors based on gene numbers in the microbiome (Qin et al., 2010), and 
metagenomics has yielded novel insights into the lung microbiome of cystic fibrosis (Lim et al., 2014). As 
DNA sequencing becomes more accessible, metagenomic approaches will be increasingly applied in 
personalised medicine, which could provide avenues for improved methods of diagnosing, monitoring, 
and treating COPD. Any personalised medicine strategy however, needs a minimally invasive sampling 
technique, and thus, spontaneous sputum was used in this work, rather than the more invasive method 
of BAL sampling (Parr et al., 2006).  
 
3.4.1 | Species Composition of the COPD Lung Microbiome 
 
Despite considerable variation between individual samples, significant differences between the COPD 
and control groups were found. These are mostly likely to reflect shifts in the species makeup of the 
lung microbiome, so that they become sufficiently prominent to be detected using metagenomic 
sequencing technology. One of the key aspects of these differences was the noteworthy increases in 
four bacterial species - all pathogens - to above detection limits only in COPD patients. Interestingly, 
none of the eight COPD patients were exacerbating, but S. aureus and S. maltophilia, which are 
commonly isolated from COPD patients with acute exacerbation, were found (Nseir et al., 2006). 
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Furthermore, S. maltophilia has also been linked to exacerbations in cystic fibrosis patients, which 
suggests that it may be an important opportunistic lung pathogen in many morbidities (Ciofu, Hansen 
and Høiby, 2013). Most importantly, besides offering increased understanding of the developing 
underlying pathology, these four bacterial species could act as biomarkers for COPD, which could be 
monitored, in addition to FEV1% of predicted (Agusti and MacNee, 2013).   
 
A large number of bacterial species were shown to be significantly different in Control and COPD 
samples. Interestingly, a higher number of bacterial species show a significantly lower abundance in 
COPD samples, than those that show a significantly higher level. The Streptococcus genus in particular 
showed a high degree of dynamism. The evident flux in the lung microbiome present in COPD patients 
suggests that the environment of the COPD lung poses a selective pressure on the microbiome. This may 
mean that only bacteria with the ability to tolerate the changing environment, such as a reduction in the 
oxygen level, will survive, explaining the changes seen in this portion of work. 
 
Currently, COPD diagnosis relies heavily upon the use of the FEV1/FVC ratio to define airflow limitation. 
However, this has been shown to result in higher levels of COPD diagnosis in elderly patients, and 
possibly under-diagnosis in younger patients, below 45 years, who may have milder disease (Global 
Initiative for Chronic Obstructive Lung Disease (GOLD), 2014). Therefore, additional methods of 
diagnosing COPD, alongside spirometric analysis of FEV1/FVC, may improve COPD diagnosis, and may 
even be able to act as a biomarker before the disease has developed to a stage where it is measurable 
through spirometry. 
 
3.4.2 | Functional Characteristics of the COPD Lung Microbiome 
 
Considering metagenomic revealed changes in function, there were increases in the abundance of 
functional alignments associated with bacterial growth, particularly bacterial cell division, nucleosides 
and nucleotides, and amino acid, carbohydrate, DNA, protein, and RNA metabolism. With increases also 
in factors linked to horizontal gene transfer, this indicates large-scale genetic exchanges and the 
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capacity for rapid bacterial growth may be a characteristic of the COPD microbiome. Similar bacterial 
genomic flux also appears to be a feature of cystic fibrosis patients (Bittar and Rolain, 2010), and 
bacterial load has been linked to periods of COPD exacerbation (Garcha et al., 2012). 
 
Acute exacerbations of COPD can be relatively sudden, and can be precipitated by a number of factors, 
including colonisation by virus, bacteria, or a combination of both. A potential hypothesis of bacterial-
associated exacerbations, which has emerged from this portion of work, is that the microbiome of COPD 
patients has the functional capacity for rapid bacterial growth, which may explain the sudden onset of 
exacerbations seen. Functional alignments shown to have a significantly higher level in the COPD 
microbiome include those involved in DNA replication, protein metabolism, bacterial RNA polymerase, 
and bacterial cell division, amongst others, which are essential factors in bacterial cell growth and 
division. As discussed previously, the COPD lung may provide a selective pressure on the lung 
microbiome, leading to alterations in its functional capability. Therefore, analysis of the functional 
capacity of the lung microbiome in COPD patients may provide for an approach to personalised 
medicine that has the potential to create risk factors for acute exacerbations of COPD. 
 
Functional analysis also revealed the significant increase in alignments to the heat shock DnaK gene 
cluster, which in bacteria, is responsible for producing the heat shock protein Hsp70. Analogues of 
Hsp70 have been shown to have significant anti-inflammatory responses in many inflammatory diseases 
(Borges et al., 2012), and could provide a mechanism for bacterial defence from the inflammatory 
mediators inherent in the environment of the COPD lung. 
 
3.4.3 | Lung Microbiome Characteristics Associated with COPD Severity 
 
Previous COPD lung microbiome studies have reported patients with severe COPD had a high prevalence 
of P. aeruginosa, H. influenzae and S. pneumoniae (Monso et al., 2003; Groenewegen and Wouters, 
2003). Analysis of this portion of work failed to suggest any significant correlation between P. 
aeruginosa and FEV1% of predicted. However, as P. aeruginosa does not appear to be part of the 
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detected core lung microbiome of our baseline COPD patients, it may be that any change in the 
abundance of this opportunistic pathogen is linked to exacerbation rather than COPD progression as 
indicated by measures of FEV1% of predicted (Renom et al., 2010). Conversely, H. influenzae was part of 
the core microbiome but was not changed in abundance in these COPD patients. Taken together, these 
observations indicate that abundance changes in these bacteria species would be poor biomarkers for 
COPD progression. A significant positive correlation, however, was observed with S. pneumonia and 
FEV1% of predicted, suggesting that as airflow obstruction increases, the percentage abundance of S. 
pneumonia decreases in the stable state. S. pneumonia is frequently cultured from the sputum samples 
of patients during exacerbations (Monso et al., 2003; Groenewegen and Wouters, 2003), and it is the 
main target of initial treatment with penicillins. Detecting subtle changes in S. pneumonia loads, may 
allow prediction of COPD progression and allow earlier interventions. 
 
A further, significant, positive correlation was observed between FEV1% predicted, and the percentage 
abundance of genes associated with sialic acid metabolism. Sialic acids are nine carbon sugars backbone 
monosaccharides mainly decorating the outside of vertebrate cells, but also some microbes (Severi, 
Hood and Thomas, 2007; Varki, 2007; Vimr and Lichtensteiger, 2002). Extracellular sialic acid moieties 
have many roles in vertebrate immunology and can act to mask cell surface receptors; or act as 
recognition sites for various lectins and antibodies. These roles including the modulation of leukocyte 
trafficking via selectins and influencing complement activation (Varki and Gagneux, 2012). 
 
Sialic acid binding immunoglobulins (Ig)-like lectins (siglecs) are found in immune cells and will recognise 
different linkage-specific sialic acids. Examples of siglecs are siglec-3/CD33 related-siglecs found on 
haematopoietic cell lineages, siglec-9 on natural killer (NK) cells and siglec-8 only on circulating 
eosinophils. After binding sialyated moieties, siglecs can drive the internalisation of sialyated pathogens 
and crucially, modulate pathogen-/damage-associated molecular patterns-mediated (PAMP/DAMP) 
inflammation along with inhibition of NK cell activation. Sialic acid-Siglec interaction therefore serve to 
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maintain a baseline non-activated state of innate immune cells, and limit inflammatory responses 
activation through PAMP/DAMP recognition (Cao and Crocker, 2011). 
 
The pathological advantages to the pathogen of acquired sialic acid decoration is therefore to augment 
siglec mediated avoidance of PAMP/DAMP recognition (Cao and Crocker, 2011; Chang and Nizet, 2014; 
Carlin et al., 2007). Additionally, the presence of sialylated lipopolysaccharide on the bacterial surface 
can prevent complement activation by binding to the C3 component of the complement cascade 
(Shaughnessy et al., 2009). This portion of work has shown a significant correlation with reduction of 
bacterial sialic acid metabolism with decreasing FEV1 % of predicted scores, which would indicate a shift 
towards a lesser capacity to avoid recognition and thus suppress inflammation – a key feature of COPD.  
Thus, a reduction in sialic acid metabolising bacteria could be an important pathological feature in COPD 
progression.  
 
Sialic acid is also an important carbon source in the respiratory tract, particularly the lungs, for bacterial 
colonisation. Indeed, the bacterial pathogen S. pneumoniae, which has been shown in this portion of 
work to be closely associated with COPD severity, is able to utilise human sialic acid as a carbon source 
for growth. Additionally, its ability to metabolise sialic acid also carries the advantages of being able to 
compete with other bacteria for an environmental niche, aiding the bacteria’s progression through the 
mucin layer, and promoting adherence to epithelial cells (Marion et al., 2011). This portion of work has 
demonstrated a significant correlation between COPD severity and both S. pneumoniae and functional 
alignments involved with sialic acid metabolism. This raises the interesting possibility of the interaction 
between these correlations, either as being causative or reflective of changes in the COPD microbiome, 
and warrant significant further study. 
 
As previously discussed, viral colonisation can be an important event in the onset of acute exacerbations 
of COPD. Many viral infections are initiated through binding to host cell surface receptors, including 
those that contain sialic acid (Stencel-Baerenwald et al., 2014). In this portion of work, sialic acid has 
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been shown to have a significant positive correlation with FEV1% of predicted, and thus COPD severity. 
Although viruses were not looked at in this work, they are nonetheless an important constituent of the 
lung microbiome, particularly in COPD. It may be that the microbiome-associated alterations of the sialic 
acid present in the lung microbiome of COPD will alter the ability of viral pathogens to colonise, thus 
impacting on the risk of acute exacerbations of COPD. Therefore, the measurement of sialic acid within 
the lungs of COPD patients may be able to act as a biomarker for risk of acute exacerbations of COPD. 
Colorimetric methods for measuring sialic acid in both serum and BAL fluid already exist, and may 
provide a potential method of non-invasive risk profiling of acute exacerbations in COPD patients 
(Isitmangil et al., 2001). 
 
The observed significant correlations with FEV1% of predicted were substantiated as similar 
relationships with either smoking pack years, or the age of COPD patients, were not evident. This 
reinforces the concept that these observed changes are as a result of worsening airflow obstruction, 
rather than a direct modulating effect of smoking or age on lung immune function. Nevertheless, this 
portion of work does indirectly identify significant relationships between smoking and the Neisseria 
genus, which has previously been linked to smoking (Morris et al., 2013), and a number of Level 3 
functional classifications, namely bacterial DNA repair and potassium homeostasis.  These features 
possibly reflect smoking linked bacterial genomic damage and a response to the inclusion of potassium 
salts in cigarette papers, respectively (Husgafvel-Pursiainen, 2004; Zawadzki et al., 2005). 
 
Despite its small size, this portion of work describes the first use of metagenomic sequencing to reveal 
novel insights into the microbiome present in the COPD lung. Additionally, potential novel bacterial and 
functional biomarkers for COPD progression were identified. This demonstrated the potential strengths 
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3.5 | Conclusions and Future Work 
 
This portion of work aimed to take advantage of metagenomic sequencing technologies to investigate 
the microbiome of patients with COPD to the species-level of taxonomy, and for the first time, reveal 
novel insights into the functional capabilities of the microbiome. To this end, the species-level 
composition of the lung microbiome in COPD was evaluated, and a core microbiome revealed; 
containing bacterial species that could be used as biomarkers for COPD. Additionally, the significant 
changes observed in the functional capacity of the lung microbiome in COPD may be help to explain the 
role of the microbiome in periods of acute exacerbations. Furthermore, the lung microbiome in COPD 
patients could be used to develop risk profiles of patients in regards to their susceptibility for acute 
COPD exacerbations. 
 
One of the most significant portions of this work was the identification of S. pneumoniae and functional 
alignments to sialic acid metabolism as being positively correlated with FEV1% of predicted, and thus 
COPD severity. The identification of sialic acid specifically may allow for the development of novel 
diagnostic and risk susceptibility techniques, and also suggest targets for therapeutic interventions. 
 
Nevertheless, a number of important questions still remain in regards to the role of the lung 
microbiome in COPD patients. Future work to address these may include the longitudinal monitoring of 
COPD patients to sample the lung microbiome before, during, and after periods of acute exacerbations 
to gauge whether changes in the microbiome are predictive, reflective, or even causative. Additionally, 
mechanistic studies of the role of sialic acid in the lung microbiome, particularly in relation to 
colonisation by microbial pathogens important in COPD, such as S. pneumoniae and H. influenza, may 
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CHAPTER 4 | Defining the Temporal Variability of the 
Salivary Microbiome and Metabolome 
 
CHAPTER SUMMARY | The human microbiome and metabolome are both important components of 
homeostasis, and in the monitoring of health and disease. It is well established that incidence of upper 
respiratory tract infections vary throughout the year, and it may be expected that the salivary 
microbiome would reflect this. To determine this, the saliva of 40 healthy participants was collected 
every two months over a 12 day period, from October 2012 to October 2013, alongside lifestyle 
information. Samples were analysed in terms of bacterial load, through quantitative PCR, measurement 
of pH, and metabolomic fingerprinting using negative mode LTQ-MS. A sub-group of ten participants, 
selected because of their similar lifestyle information, underwent 16S rRNA (V3 to V4) amplicon 
sequencing. Subsequent sequences were demultiplexed, merged, trimmed for quality, and uploaded to 
the MG-RAST online pipeline for taxonomic assignment. Estimated bacterial load was shown to be 
significantly (P < 0.001) higher in February 2013 than at all other sampling time points, with individuals’ 
changes between time points displaying significant (P = 0.003) flux. Salivary pH levels were shown to be 
significantly (P < 0.001) higher in December 2012 than in October 2012 and February 2013, with 
significant (P < 0.001) individual variations seen across the sampling period. In regards to the stability of 
the taxonomic composition of the salivary microbiome, α-diversity values showed significant differences 
between participants (P < 0.001), but not between sampling periods (P = 0.801), and a small, but 
significant positive correlation with salivary pH (R2 = 7.8%; P = 0.019). At the phylum level of 
classification, significant differences were evident between participants in the Actinobacteria (P < 
0.001), Bacteroidetes (P < 0.001), Firmicutes (P = 0.008), Fusobacteria (P < 0.001), Proteobacteria (P < 
0.001), Synergistetes (P < 0.001), and Spirochaetes (P = 0.003) phyla. The salivary metabolome also 
displayed temporal stability, with no separation between participants through principal component 
analysis. The salivary microbiome shows temporal stability in terms of bacterial taxonomic diversity, but 
not load, over a one year period, with individual differences likely to be the main factor in determining 
its composition. This work suggests that comparing the human salivary microbiome and metabolome at 
different time points over the year is valid, as minimal temporal variability is shown.  
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4.1 | Introduction 
 
Investigations of the human microbiome and metabolome have allowed for the importance of both in 
health and disease to be realised. The gut microbiome, for example, has been shown to be an important 
component of gastrointestinal diseases such as Crohn’s (Manichanh et al., 2006). Additionally, the 
human metabolome is an important source of biomarkers for disease (Spratlin, Serkova and Eckhardt, 
2009). However, many of these findings, particularly metabolome-derived biomarkers, are dependent 
upon the principle that the human microbiome and metabolome are temporally stable. To date, this is a 
principle that has not been firmly established. 
 
4.1.1 | The Oral Cavity and Saliva Production 
 
The human oral cavity is a major gateway to the human body, and serves many purposes in both health 
and disease; acting as the main point of entry to both the digestive and respiratory tracts. The oral 
cavity has a number of distinct physical features including the hard and soft palates, the tonsils, uvula, 
tongue, vestibule, gingiva and teeth, Figure 4.1a.  
 
One of the spatial components of the oral cavity, albeit without a fixed position is saliva. Healthy human 
adults produce between 0.5 to 1.5 L of saliva a day, at a rate of 0.5 mL per minute, though a number of 
FIGURE 4.1 | The Structure of the Human Oral Cavity 
The (a) human oral cavity consists of a number of spatially distinct structures, including the tongue, soft 
and hard palates, the gingiva, tongue, tonsils, uvula, and vestibule. Within the human oral cavity, saliva 
is produced by the (b) three salivary glands; the parotid gland, the submandibular gland, and the 
sublingual gland. Figures are copyright free and adapted from Wikipedia.com. 
(a) (b) 
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factors can impair production in terms of both volume and composition (Pfaffe et al., 2011). The 
majority of human saliva is produced by three major salivary glands, Figure 4.1b, complemented by 
minor glands which produce saliva to coat the mouth surface. Many biomolecules found within human 
saliva have their origins in the circulatory system and thus, saliva offers a non-invasive diagnostic tool 
for a number of diseases (Matias et al., 2012). Saliva is predominately water, with only a small amount 
of its volume consisting of biomolecules such as proteins, peptides, nucleic acids, electrolytes, 
hormones, and enzymes. These serves as important modulators in the maintenance of homeostasis 
within the oral cavity, helping to maintain a stable pH and prevent dysbiosis in the microbiome (Pfaffe et 
al., 2011). 
 
4.1.2 | The Oral Microbiome  
 
The human oral cavity consists of a number of defined spatial regions, Figure 4.1a, which have been 
shown to have distinct microbiomes (Aas et al., 2005). A large number of microbial taxa, approximately 
600 at the species level, are present within the human oral cavity, many of which are not associated 
with disease initiation, aetiology, or pathogenesis (Dewhirst et al., 2010). Nevertheless, the host 
microbiome has been shown to be an important part of oral diseases, such as periodontal disease and 
dental caries. 
 
Periodontal disease, for example, affects tooth-supporting structures and can also exacerbate existing 
comorbidities, such as cardiovascular and pulmonary diseases. Analysis of the human oral microbiome 
in patients with and without periodontal disease has revealed a number of metabolic pathways enriched 
in the microbiome which are associated with virulence factors, and a shift from a Gram-positive to a 
Gram-negative taxonomic domination. This suggests the oral microbiome in periodontal disease is an 
important component of the disease, constituents of which are able to exploit host dysbiosis which 
precedes the full clinical manifestation of the disease (Liu et al., 2012). Similarly, dental caries has been 
linked to a shift in the taxonomic composition of the oral microbiome, rather than the emergence of a 
distinct bacterial species (Yang et al., 2012). 
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Advances in understanding periodontal disease and dental caries by approaching the conditions in terms 
of whole-scale changes in the microbiome, rather than a traditional focus on the responsibility of single 
bacterial species have refocused the field of oral microbiology. The role of single species is nevertheless 
important in many oral diseases, such as the mutans group Streptococci in dental caries. However, 
FIGURE 4.2 | Biofilm Formation in the Oral Cavity 
Biofilm formation in the oral cavity follows a cyclical pattern whereby initial colonising bacteria provide 
a scaffold for the attachment of other members of the oral microbiome. On a clean tooth surface, 
colonisation will begin with members of the Streptococcus and Actinomyces genera. Additional 
microbes, such as Veillonella and Porphyromonas genera follow, and because of changes in the 
conditions of the environmental niche, incorporation of anaerobic bacteria such as the Fusobacterium 
genus is encouraged. This creates conditions that allow for incorporation of potential oral pathogens 
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because approximately 50% of oral bacteria are yet to be cultured, the importance of these cultureable 
aetiological agents may be overestimated, and in fact may be dependent upon the actions of a number 
of yet to be cultured microbes (Jenkinson and Lamont, 2005). 
 
The formation of biofilms within the oral cavity, particularly on the tooth surface, exemplifies the 
interdependence of single bacterial species with the oral microbiome as a whole. As Figure 4.2 
illustrates, the formation of biofilms follows a cycle whereby initial colonising bacteria act as scaffolds 
for the attachment of other members of the oral microbiome. Initial colonising bacteria, including 
members of the Streptococcus and Actinomyces genera, are able to do so because they are able to bind 
to salivary receptors that coat uncolonised tooth surfaces (Jenkinson and Lamont, 2005). This is 
particularly evident for Streptococcus bacteria which have been shown to bind to salivary proteins 
including, amongst others, α-amylase, fibronectin, and lactoferrin (Scannapieco, 1994). This cycle of 
colonisation observed on the tooth, which culminates in the addition of Treponema and Candida 
species, shows the importance of the microbiome in oral diseases such as dental caries and periodontal 
disease, for which members of these genera are believed to be causative organisms (Jenkinson and 
Lamont, 2005). Without the proceeding steps in biofilm formation on the tooth, neither Treponema nor 
Candida would be able to attach to the tooth surfaces, and thus would not be able play their role in a 
number of oral diseases.  
 
The role of the wider microbiome in the onset of oral disease, and the interconnectedness of species 
within the microbiome in both health and disease, is not solely due to the creation of a scaffold that 
allows for adhesion of secondary colonisers. Constituents of the oral microbiome are also 
interdependent at a metabolic level. Within the human mouth, one of the main sources of nutrition for 
the microbiome is saliva, but its constituents are not readily accessible to bacteria. As a result of the 
diverse range of enzymes required to degrade salivary proteins and glycoproteins, it is unlikely that a 
sole bacterium would possess these in isolation. Co-culture studies have shown that when ten oral 
bacterial species are grown in an artificial salivary medium, the total accumulated biomass is 
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significantly greater than when five bacterial species are grown (Bradshaw et al., 1994). Additionally, 
specific salivary proteins, such as MUC5B have been shown to only be utilisable as a nutrient source for 
bacteria when degraded by a complex of oral bacteria, rather than individual isolates from the same 
complex (Wickström and Svensäter, 2008). 
 
The microbiome found within human saliva is distinct from the microbiomes of other oral structures, 
such as the tongue, tonsils, throat, and gingiva. Because of its ease of sampling, saliva has been one of 
the most widely studied oral features in humans. The microbiome of saliva is dominated by the 
Firmicutes, Bacteroidetes, Proteobacteria, Fusobacteria, and Actinobacteria phyla, with the 
Streptococcus, Veillonella, Prevotella, Neisseria, and Fusobacterium genera accounting for the majority 
of the microbiome found using culture-independent sequencing (Segata et al., 2012). Interestingly, 
analysis of the salivary microbiome has shown there to be a high degree of individual differences within 
populations, with no observable geographical effect on its structure and composition. Additionally, 
variations within the salivary microbiome of a population appear to closely align with the degree of 
genetic differences that are commonly found within a population, approximately 13.5% (Nasidze et al., 
2009). Following this trend, longitudinal samples of the salivary microbiome of monozygotic and 
dizygotic twins suggest that the environment is more important than host genetics whilst shaping its 
structure and composition (Stahringer et al., 2012). 
 
4.1.3 | The Oral Metabolome 
 
Saliva is around 99.5% water, containing a number of important biomolecules that aide in digestion and 
other bodily functions. Many of these biomolecules have origins in the circulatory system and for this 
reason, and because it is an easily accessible biofluid, with a non-invasive collection method, it is 
considered a potentially useful source of metabolomic biomarkers for human disease (Matias et al., 
2012). Primarily, saliva has been suggested as a novel biomarker pool for oral, head, and neck cancers, 
due to its localisation at the site of carcinogenesis. Indeed, metabolomics has identified altered levels of 
valine, lactic acid, and phenylalanine as being indicative of oral cancer, with sensitivity and specificity 
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frequencies above 80% (Wei et al., 2011). Additionally, saliva has been shown to have promise for the 
detection of cancers not localised to the oral cavity, but nevertheless detectable because many salivary 
metabolites are derived from the circulatory system. Cancers that have shown particular promise 
through the identification of metabolome-derived biomarkers include those of the breast, pancreas, and 
lungs (Sugimoto et al., 2010; Bonne and Wong, 2012).  
 
Saliva is a promising biofluid for the identification of metabolome-derived markers for a number of 
diseases, including obesity (Matias et al., 2012), dental caries (Yang et al., 2012) and oral, breast, and 
pancreatic cancers (Sugimoto et al., 2010). However, the oral metabolome is still relatively poorly 
understood in terms of gender and lifestyle-associated differences. Additionally, differences between 
stimulated and non-stimulated saliva could have important implications in the applicability of 
metabolome-derived disease biomarkers to clinical use (Neyraud et al., 2012). Although limited to the 
use of 1H NMR spectroscopy, metabolome differences between stimulated and non-stimulated saliva 
have been shown, particularly that metabolite concentrations are higher in non-stimulated saliva 
(Takeda et al., 2009). This is likely a dilution effect of stimulated saliva containing a higher percentage of 
water than non-stimulated. Levels of fatty acids have also been shown to be increased in stimulated 
over non-stimulated saliva, reinforcing the importance of potential differences in stimulated and non-
stimulated saliva when evaluating candidate disease biomarkers (Neyraud et al., 2012). Furthermore, 
gender differences have been shown in the salivary metabolome, with a number of metabolites 
significantly higher in concentration in male saliva compared to female saliva, including acetate, glycine, 
lactate, pyruvate, and taurine. Changes in the salivary metabolome associated with tobacco smoking 
have also been shown, with metabolites including citrate, pyruvate, and sucrose showing significantly 
higher levels in male smokers compared to male non-smokers (Takeda et al., 2009). As discussed 
previously, NMR is a useful technology for metabolome profiling, but it is limited in its detection 
sensitivity of low concentration metabolites. To date, limited work has been completed using mass 
spectrometry approaches to understand the salivary metabolome, and how it changes in association 
with physiological, environmental, and temporal changes. 
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Although saliva has received a large amount of attention in regards to its metabolome, and changes 
associated with a number of factors including disease, it is by no means the only feature of the oral 
cavity analysed through metabolomic techniques. For example, the metabolome of supragingival 
plaques, the site that is affected by dental caries, has been investigated through capillary 
electrophoresis mass spectrometry. This showed the close interplay between the metabolomes of the 
supragingival plaque and inhabiting oral bacteria, including the genera Streptococcus and Actinomyces, 
after the in vitro addition of glucose (Takahashi, Washio and Mayanagi, 2010). Additional work on the 
effects of glucose addition to microbial biofilms in the oral cavity, has further helped to elucidate the 
mechanistic role of the oral microbiome in disease (Washio, Mayanagi and Takahashi, 2010). 
 
4.1.4 | Seasonal and Temporal Changes in the Human Body 
 
The regulation of the human body in response to, or in anticipation of, changing environmental 
conditions is an evolutionary advantage; allowing for physiological and behavioural changes to occur. 
Physiological and behavioural responses, including weight and reproductive changes, in relation to 
seasonal alterations are well established in mammals, with melatonin the responsible hormone (Barrett 
and Bolborea, 2012). Melatonin has also been shown to be responsible for seasonal changes in the 
human immune system, namely cytokine production, neutrophil activity, and the differentiation and 
proliferation of lymphocytes (Klink et al., 2012).  
 
Hormonal-driven seasonal changes are not solely confined to the actions of melatonin, with a large 
number of human hormones displaying altered seasonal levels, which could have important implications 
on the human immune system. It is well established that vitamin D3 is linked to immune function, and 
variations in its production can be largely contributed to ultraviolet light exposure. Recently, changes in 
vitamin D3 levels in line with seasonal changes, are also associated with altered human peripheral T cell 
compartment function, and could explain some of the seasonal variation seen in human immune 
function (Khoo et al., 2012). Additionally, testosterone levels have been shown, in both men and 
women, to vary considerably over a one year period, with a peak level being reached in the autumn 
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months, which can be twice the level of testosterone reached at the lowest level in the summer months 
(Stanton, Mullette-Gillman and Huettel, 2011). Temporal variations are not only observed in human 
hormonal levels, and fluctuations can be over short, medium, and long term periods. The human 
metabolome, for example, has also been shown to have a circadian rhythm, over a 24 hour period. Mass 
spectrometry of blood plasma and saliva samples, taken over a 40 hour period, suggested that 
approximately 15% of human metabolites are under circadian control (Dallmann et al., 2012). 
 
The human microbiome is closely linked to the physiological state of the host, and the state of the 
immune system in particular can have substantial effects on its structure and function. Early work on 
temporal and spatial differences in the human microbiome, from several body sites, found that spatial 
differences were significantly more substantial than temporal differences, though samples were only 
collected over a small time period, with the first and last collection separated by four months (Costello 
et al., 2009). The human gut microbiome has recently been shown to drive hormone-dependent 
regulation of autoimmunity in mice, with male gut microbiome transplantations to females able to 
increase testosterone levels and affect progression of type 1 diabetes (Markle et al., 2013). The 
microbiome of human milk has also been shown to have a temporal element to its composition, which 
may also be altered by hormonal levels present during birth (Cabrera-Rubio et al., 2012a). 
 
To date, the human microbiome and metabolome have tended to be studied separately, and at single 
time points, or at time points over multiple years. Seasonal changes in the human salivary microbiome 
and metabolome have not been measured. With increasing interest in the use of saliva-derived 
microbiome and metabolome biomarkers in a range of diseases, from oral conditions such as dental 
caries to cancers of peripheral organs, it is important to establish the degree of seasonal variation 
present to aide in the validation of such approaches. Additionally, it is well established that rates of 
upper respiratory tract infections is highest in the winter months, which may be linked to reduce 
immune function (Jones et al., 2014). Consequently, seasonal variability in immune function may also 
lead to seasonal variability in the salivary microbiome. 
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4.1.5 | Aims and Objectives of Chapter 
 
Establishing the temporal variability of the human microbiome and metabolome could be an important 
step in validating our understanding in terms of their relationship with health and disease. To date, this 
has not been accomplished over an annual period with frequent and regular sampling periods. In this 
portion of work, human saliva, which is arguably one of the easiest human biofluids to sample, was 
collected from 40 participants over a 12 month period, with collections every two months. Using these 
samples, the following will be determined to establish the temporal variability of the human salivary 
microbiome and metabolome: 
 
1) Changes in total bacterial load over the 12 month period, using quantitative PCR. 
2) Using a subgroup of ten participants, changes in taxonomic composition of the salivary 
microbiome over a 12 month period through 16S rRNA amplicon sequencing. 
3) Metabolomic fingerprinting of saliva to monitor whether any observed bacterial changes are 
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4.2 | Materials and Methods 
 
This study received ethical approval from the Aberystwyth University Research Ethics Committee. 
Informed consent was obtained from all participants at least 24 hours before the first sample was taken, 
and additional consent forms were obtained before each subsequent sample was donated. All 
participant information obtained was link anonymised prior to subsequent data analysis. 
 
4.2.1 | Participant Recruitment and Sampling 
 
Stimulated saliva samples were obtained from 40 participants, consisting of staff and students at 
Aberystwyth University, over a one year period, from October 2012 to October 2013. During this period, 
a total of seven samples were collected every two months, each over a twelve day period, including 
October 2012 (10/09/2012 to 21/09/2012), December 2012 (10/12/2012 to 21/12/2012), February 2013 
(11/02/2013 to 22/02/2013), April 2013 (08/04/2013 to 19/04/2013), June 2013 (10/06/2014 to 
21/06/2014), August 2013 (12/08/2013 to 23/08/2013), and October 2013 (14/10/2013 to 25/10/2013). 
Participants donated 5 mL of saliva into a sterile 50 mL centrifuge tube, and stimulated saliva through 
jaw movement if necessary. Participants were not restricted in eating or drinking prior to donating a 
saliva sample. At the same time, information on oral hygiene practice, antibiotic use, smoking history 
and diet was collected. 
 
4.2.2 | Sample Processing and Total Genomic DNA Extraction 
 
All saliva samples were normalised to ensure 5 mL volume and underwent centrifugation at 10,000 x g 
for 20 minutes, at 4°C, after which 2 mL of the saliva supernatant was transferred to a PCR grade 
microcentrifuge tube. The remaining saliva supernatant was removed and destroyed, and the saliva 
pellet transferred to a PCR grade microcentrifuge tube. The saliva pellet was stored at -80°C for a 
maximum of seven days, after which it underwent DNA extraction. The saliva supernatant was stored at 
-80°C until collection at all sampling time points had been completed. Subsequent metabolomic 
fingerprinting was completed at one time point. 
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Total genomic DNA was extracted from 200 µL of the saliva pellet using a FastDNA SPIN kit for soil (MP 
Biomedical, Santa Ana, USA) following manufacturer’s instructions. Bead beating was carried out in a 
FastPrep-24 machine (MP Biomedical) with three cycles at speed setting 6.0 for seconds, with cooling on 
ice for 60 seconds between cycles. Genomic DNA was eluted with 50 µL of DES and dsDNA 
concentration determined, in duplicate, using 2 µL on the Epoch spectrometer system (BioTek). 
 
4.2.3 | 16S rRNA Quantitative PCR 
 
Quantitative PCR was carried out on neat extracted DNA against standards created by amplifying the 
16S rRNA gene of five randomly selected October 2012 samples. This was completed through 
amplification of the 16S rRNA gene in a 20 µL reaction volume consisting of 10 µL of 2 x BioMix (BioLine), 
0.25 µL each of 27f (5’-AGA GTT TGA TCC TGG CTC AG-3’) and 1389r (5’-ACG GGC GGT GTG TAC AAG-3’) 
primers (Hongoh, Ohkuma and Kudo, 2003) to give a final concentration of 500 nM, 1 µL of neat 
extracted DNA, and 9.5 µL of PCR Grade Water (Roche). The reaction volumes were then subjected to 
PCR consisting of 94°C for two minutes, 30 cycles of 94°C for 45 seconds, 55°C for 45 seconds, and 72°C 
for 90 seconds, followed by a final elongation step of 72°C for seven minutes. The resulting PCR 
products were combined and purified using an Isolate II PCR and Gel Extraction purification kit (BioLine), 
following manufacturer’s instructions, and quantified with an Epoch spectrometer as previously 
described. The resulting DNA concentration was used to estimate the total number of 16S rRNA gene 
copies and serial dilutions of 1010, 108, 106, 104, 102, and 100 made. 
 
Quantitative PCR was completed on neat extracted DNA against standards with each reaction 
completed in 25 µL volumes, each consisting of 12.5 µL 2 x SYBR Green Mastermix (Life Technologies), 
0.25 µL of each EubF1 (5’-GTG STG CAY GGY TGT CGT CA-3’) and EubR1 (5’-ACG TCR TCC MCA CCT TCC 
TC-3’) primer (Maeda et al., 2003), in a final concentration of 400 nM, 11 µL of PCR Grade Water (Roche) 
and 1 µL of neat DNA extract. Reactions were run using a C100 thermal cycler (BioRad, Hercules, USA) 
and CFX96 optical detector (BioRad), with data captured using CFX Manager software (BioRad), under 
conditions of 95°C for ten minutes, 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds, followed 
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by a melt curve consisting of a temperature gradient of 60°C to 95°C in 0.5°C increments, each for five 
seconds. Where shown, P values represent the significance of one-way ANOVA tests. 
 
4.2.4 | Selection of Participants for 16S rRNA Amplicon Sequencing 
 
Of the 40 recruited participants in this study, a subgroup of ten was selected for 16S rRNA amplicon 
sequencing of all seven monthly samples collected. This subgroup was selected based on supporting 
information given at each bi-monthly sample, with a view to selecting a group of participants with 
minimal differences. Participants were selected for 16S rRNA amplicon sequencing based on oral 
hygiene practices (no history of mouthwash but a history of flossing at least weekly), smoking history 
(no current smokers and past smokers with a cessation period greater than ten years), allergen history 
(no asthma or hay fever), diet (meat-eaters only), antibiotic exposure (no antibiotic use within sampling 
period and six months prior to start), with no restriction on age or gender. 
 
4.2.5 | 16S rRNA Amplicon Preparation 
 
Sequencing of the 16S rRNA gene was carried out via amplification of the V3 to V4 region and 
subsequent amplicon sequencing on the Illumina MiSeq platform. Firstly, the V3 to V4 region of the 16S 
rRNA gene was amplified through duplicate PCR with locus specific primers, alongside negative water 
controls. In a 25 µL reaction volume, 12.5 ng of extracted DNA, or 2.5 µL of PCR grade water for negative 
controls, was added to 12.5 µL of 2 x Accuzyme Mix (BioLine) and 5 µL each of a 1 µM concentration of 
319f primer (5’– CCT ACG GGN GGC WGC AG–3’) with Illumina forward overhang adapter sequence (5’ – 
TCG TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG-3’) and 806r primer (5’–GAC TAC HVG GGT ATC TAA 
TCC–3’) with Illumina reverse overhang adapter sequence (5’- GTC TCG TGG GCT CGG AGA TGT GTA TAA 
GAG ACA G-3’) as detailed by Klindworth et al., (2013). The reaction mix underwent PCR consisting of 
95°C for three minutes, followed by 25 cycles each of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C 
for 30 seconds, followed by a final elongation step of 72°C for five minutes. Each duplicate PCR volume 
was confirmed through visualisation on a 2% agarose gel, after being run for 120 minutes at 100 volts (≤ 
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80 mA) in 1% tris base, acetic acid, and ethylenediaminetetraacetic acid (TAE) buffer. Following 
confirmation of PCR success, corresponding reaction volumes were combined and purified using an 
Isolate II PCR and Gel Extraction kit (BioLine), following manufacturer’s instructions, with elution into 20 
µL of kit buffer. Following purification, a second PCR was completed to attach Illumina adaptors to 
amplified products to allow for multiplexed amplicon sequencing on the Illumina MiSeq platform. To 
make a final reaction volume of 25 µL, 2.5 µL of purified PCR product from the previous step was added 
to 12.5 µL of 2 x Accuzyme Mix (BioLine), 5 µL of PCR Grade Water (Roche) and 2.5 µL each of the 
relevant Nextera XT Index Primer 1 (N7##) and Nextera XT Index Primer 2 (S5##) (Illumina) as detailed in 
Chapter 4 Appendix, Supplementary Table 4.1. The reaction mix underwent a limited cycle PCR 
consisting of 95°C for three minutes, eight cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C 
for 30 seconds, followed by a final elongation step of 72°C for five minutes. To remove non-combined 
adaptors, the entire reaction volume was run on a 2% agarose gel, in TAE buffer, for 120 minutes at 100 
volts (≤ 80 mA). The gel was visualised using a DR195M Transilluminator (Clare Chemical Research, 
Colorado, USA) and each PCR product excised using a sterile scalpel blade. PCR products were purified 
using an Isolate II PCR and Gel Extraction kit (BioLine), following manufacturer’s instructions, with 
elution into 20 µL of kit buffer. Purified PCR products were quantified using a Quant-iT dsDNA High 
Sensitivity assay kit and a Qubit fluorometer (Life Technologies). 
 
4.2.6 | 16S rRNA Amplicon Sequencing and Analysis 
 
Individual sample libraries were pooled together in equimolar concentration and sequenced, along with 
20% PhiX DNA as a control for low diversity, on the Illumina MiSeq platform using MiSeq v3 reagents for 
a 2 x 300 bp run at the IBERS Translational Genomics Facility, Aberystwyth University. After sequencing, 
sample reads were demultiplexed and trimmed for quality, with overlapping reads merged using FLASH 
(Magoč and Salzberg, 2011). Merged reads were analysed using the MG-RAST metagenomics analysis 
pipeline (Meyer et al., 2008). Taxonomic alignments of sequences was completed using the Ribosomal 
Database Project (Cole et al., 2009) facility, with only those sequences with a minimum alignment 
identity of 97%, maximum e-value of 1 x 10-5, and a minimum alignment cut-off of 15 being used. 
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Sequences were analysed using the PCA facility and α-diversity measure, based on the Shannon diversity 
index, within MG-RAST, and exported into Microsoft Excel 2010 and MINITAB 14 for further analysis, 
with multivariate statistics completed using MetaboAnalyst 2.0 (Xia et al., 2012). Sequence numbers for 
each sample were normalised as a percentage composition of the total volume of sequences for each 
taxonomic level of classification. Where shown, P values represent the significance of one-way ANOVA 
tests. All sequence files are available under the MG-RAST project ID 11549: ‘Charting Temporal 
Variability in the Salivary Microbiome’. Raw sequence files were deposited at the European Nucleotide 
Archive under primary accession number PRJEB9010 and secondary accession number ERP010064. 
 
4.2.7 | LTQ-MS Metabolomic Fingerprinting 
 
Saliva supernatant was thawed at 4°C and 200 µL transferred to a sterile 2 mL microcentrifuge tube, to 
which 30 mg of ≤ 106 µM acetone-washed glass beads (Sigma-Aldrich, Dorset, UK) were added. To this, 
1520 µL of a solvent mix of HPLC grade methanol and chloroform, in a ratio of 4:1, was added.  To 
homogenise the mixture, samples were placed on a vortex mixer for five seconds and then milled for 30 
seconds at 30 Hz. Following this, samples were shaken for 20 minutes at 4°C and then stored at - 20°C 
for 20 minutes to precipitate protein. Samples then underwent centrifugation at 11 000 x g for six 
minutes at 4°C. The resulting supernatant was removed and transferred to a sterile 2 mL 
microcentrifuge tube. From this, 70 µL was transferred to an LTQ-MS vial and sealed. Samples were 
stored at -20 °C until run, in a randomised order using an autosampler, with tray temperature kept 
constant at 15°C. For each sample, 20 µL was injected into a flow volume of 60 µL per minute water-
methanol, in a ratio of 70% water and 30% methanol, using a Surveyor liquid chromatography system 
(Thermo Scientific, MA, USA). Data acquisition for each individual sample was conducting, in alternating 
positive and negative ionisation mode, over four scan ranges (15-110 m/z, 100-220 m/z, 210-510 m/z, 
500-1200 m/z) on an LTQ linear ion trap (Thermo Electron Corporation, CA, USA), with an acquisition 
time of five minutes. Individual metabolite m/z values were normalised as a percentage of the total ion 
count for each sample. Normalised abundances were subsequently analysed using MetaboAnalyst 2.0 
(Xia et al., 2012) and PyChem (Jarvis et al., 2006). 
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4.2.8 | pH Measurements of Saliva 
 
Measurements of the pH of saliva supernatant was carried out after processing of each saliva sample 
and using a B-212 Twin pH Meter (Horiba, Kyoto, Japan) after two point calibration using pH 7 and pH 4 
buffers. For pH measurements, 200 µL of saliva supernatant, after thawing at 4°C, was used. After 
stabilisation of reading, pH value was recorded and the sensor washed with ultrapure water, and blotted 
dry. Data analysis was completed using Microsoft Excel 2010 and Minitab 14. Where shown, P values 
represent the significance of one-way ANOVA tests.  
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4.3 | Results 
 
Saliva samples were collected from a total of 40 participants over a one year period, with sampling 
occurring over a two week period every two months, from October 2012 to October 2013. Participant 
information for the complete sample group is detailed in Table 4.1, alongside the characteristics of the 
sub-group of ten participants selected for 16S rRNA amplicon sequencing. The sequencing sub-group 
was specifically selected based on their lifestyle similarities. Full participant information is detailed in 
Chapter 4 Appendix, Supplementary Table 4.2. 
 
TABLE 4.1 | Lifestyle History of Whole Sample Group and Sequencing Sub-Group 
Group summaries of whole sample group (n=40) and sequencing sub-group (n=10). Relevant group 




Whole Group Sequencing Sub-Group 
Age 41.75 (13.14) 44.90 (14.86) 











Current 4/40 0/10 
Smoking Pack Years 2.19 (2.10) - - 
Past 9/40 2/10 
Smoking Pack Years 9.47 (8.24) 10.50 (6.36) 
Average Cessation (Years) 14.80 (10.42) 27.50 (3.54) 
Never 27/40 8/10 
Asthma History 3/40 0/10 












e Mouthwash Use 19/40 0/10 
Antibacterial Mouthwash Use 17/19 0/10 
Manual Toothbrush Use 23/40 3/10 
Electric Toothbrush Use 17/40 7/10 
Flossing 26/40 10/10 




Meat Eater (1 – 3 days) 9/40 4/10 
Meat Eater (4 – 7 days) 26/40 6/10 
Vegetarian 5/40 0/10 
[ 109 ] 
4.3.1 | Temporal Changes in Bacterial Load 
 
The estimated bacterial load of the saliva was measured through qPCR, targeting the 16S rRNA gene, 
using population standards taken from five randomly selected October 2012 samples. Average 
estimated bacterial loads for all 40 participants, at each time point, are given in Figure 4.3a, alongside 
average individual changes from one time point to the next, and from October 2012 to October 2013, 
Figure 4.3b. One-way ANOVAs show that the February 2013 time point had a significantly (P < 0.001) 
higher estimated bacterial load than all other time points. Additionally, when individual changes in 
estimated bacterial load are calculated, changes can be seen with February 2013 to April 2013 and June 
2013 to August 2013 changes showing a significant (P < 0.001) net decrease in an individual’s estimated 
bacteria load. Overall, there was no net change in estimated bacterial load over the entire sampling 
period. However, substantial and significant, flux was observed over the time course; particularly 








































































































































































FIGURE 4.3 | Estimation of Salivary Bacterial Load 
Estimated bacteria load was measured through qPCR targeting the 16S rRNA gene. Average estimated 
bacteria loads by (a) time point show a significantly (P < 0.001) higher bacterial load in February 2013 
than at all other time points. Additionally, average (b) individual changes from one time point to the 
next show a significant (P < 0.001) level of flux, with net decreases shown only in the February 2013 to 
April and June 2013 to August 2013 time point. Error bars in figures show one standard deviation 
around the mean. 
(a) (b) 
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4.3.2 | Temporal Changes in Taxonomy of Salivary Microbiome 
 
Amplicon sequencing statistics are detailed in Chapter 4 Appendix, Supplementary Table 4.3, and show 
no significant differences in total sequence base pairs by participant (P = 0.268), or month (P = 0.537), or 
total sequence number by participant (P = 0.247) or month (P = 0.542). However, sequence length by 
participant were significantly different (P < 0.001), with a range of approximately 15 bp. However, no 
such differences were seen in sequence length by month (P = 0.101). The GC content of sequences was 
also significantly different by participants (P < 0.001), but not by month (P = 0.896). 
 
Using the MG-RAST online platform, principal component analysis was completed using taxonomy 
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SV071 SV055 SV048 SV044 SV035 SV026 SV012 SV005 SV004 SV003
FIGURE 4.4 | Principal Component Analysis of 16S rRNA Taxonomy 
Using the MG-RAST online platform, principal component analysis was completed, using taxonomy 
classifications from the RDP database, at a 97% similarity alignment, with other parameters at default. 
Resulting plots show partial separation by (a) participant, but not by (b) sampling month. 
(a) 
(b) 
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default values. Partial separation was seen by participants, Figure 4.4a, but not by month, Figure 4.4b. 
Separation by participant was notably stronger in certain participants, such as SV048, SV004, SV003 and 
SV055, compared to others. 
 
Analysis of species diversity within a sample at each time point was calculated using the MG-RAST online 
platform. Averages of α-diversity are given in Figure 4.5 by (a) participant and (b) month. Significant 
differences were seen between participants (P < 0.001) but not between sampling months (P = 0.801).  
 
From principal component analysis and α-diversity values, it is evident that the variation between 
participants is substantially, and significantly, greater than that seen between sampling time points, 
suggesting the presence of relative temporal stability within the salivary microbiome, in terms of 
taxonomic diversity. Although macro-level differences are not seen within the taxonomic diversity of the 
salivary microbiome, micro-level changes, at the genus level may nonetheless be evident. Using the 
MetaboAnalyst 2.0 online platform, one-way ANOVAs were completed to identify genera that may be 
significantly altered in their abundance over the sampling time course. The genera Rhodococcus (P = 






















FIGURE 4.5 | α-Diversity Values by Participant and Month 
Species diversity within a sample at each time point was calculated using the MG-RAST online platform, 
with averages of α-diversity given by (a) participants, and by (b) month. Significant (P < 0.001)  
differences were observed between participants, but not between sampling months (P = 0.801). Errors 
bars display one standard deviation around the mean. 
(a) (b) 
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course of sampling. However, both of these genera displayed very low abundance levels, and were 
present in less than 50% of all samples, with Variovorax only present in two samples. Therefore, it is 
likely that these significant values are statistical artefacts of the genus’s low abundances, as they were 
not reproducible in additional statistical packages. 
 
After establishing that individual differences in the taxonomic composition of the salivary microbiome 
are more significant than any seasonal effect which may exist, the phylum level differences between 
participants were established. The Firmicutes phylum was the largest of the phyla, although the number 
of unclassified sequences, with a suspected bacterial origin, contributed a substantial proportion of the 
total bacterial reads, up to 50% of reads in some samples. Within the phylum level of classification, 
Figure 4.6, the Actinobacteria (P < 0.001), Bacteroidetes (P < 0.001), Firmicutes (P = 0.008), Fusobacteria 
FIGURE 4.6 | Average Phylum Level Taxonomy for 16S rRNA Sequencing Sub-Group 
Individual differences have been shown to be more substantial in determining the taxonomic 
composition of the salivary microbiome than any temporal or seasonal factors. At the phylum level of 
classification, these individual differences are pronounced, with a number of phyla displaying 
significantly different abundances between participants. Significance thresholds, as determined through 





























● Actinobacteria *** ● Bacteroidetes *** ● Cyanobacteria ● Deinococcus-Thermus
● Firmicutes ** ● Fusobacteria *** ● Proteobacteria *** ● Unclassified (Bacteria)
● Synergistetes *** ● Tenericutes ● Thermotogae ● Unclassified (Unknown)
● Spirochaetes ** ● Unassigned
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(P < 0.001), Proteobacteria (P < 0.001), Synergistetes (P < 0.001), and Spirochaetes (P = 0.003) were 
shown to be significantly different between participants. 
 
4.3.3 | Temporal Changes in Salivary pH 
 
The pH of any environment can be an important factor in the ability of microorganisms to inhabit and 
grow. As with estimated bacteria load, the pH of saliva samples was measured at each time point, and 
the time point average, Figure 4.7a, and average individual time point difference, Figure 4.7b, was 
calculated. Salivary pH was shown to be significantly (P = 0.003) higher in December 2012 compared to 
October 2012 and February 2013 time points. As with estimated bacterial load, an individual’s salivary 
pH levels were also shown to be in flux throughout the sampling period. Although over the one year 
period there was no net overall change, there were significant (P < 0.001) changes from one point to the 
next, Figure 4.7b. 
 

































































































































































FIGURE 4.7 | Salivary pH Levels 
Salivary pH average for each (a) time point, and (b) individual changes between each time point, were 
measured. The December 2012 time point was shown to have a significantly (P = 0.003) higher pH than 
the October 2012 and February 2013 time points only. Individual differences between time points were 
significant (P < 0.001), though there was no overall net change over the entire sampling period. Error 
bars shown are one standard deviation around the mean.  
(a) (b) 
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with estimated bacterial load, or any measured LTQ-negative metabolite. However, salivary pH levels 
were shown to have a small but significant positive correlation with α-diversity values (R2 = 7.8%, P = 
0.019).  
 
4.3.4 | Temporal Changes in Salivary Metabolome 
 
The chemical composition of saliva may be an important component in determining the taxonomic 
composition of the salivary microbiome. For all 40 participants, at all time points, metabolomic profiles 
were generated using negative mode LTQ-MS. Principal component analysis, Figure 4.8, showed no 
separation of profiles based on sampling time point. Additional modelling, not shown, also showed no 
separation between participants based on negative mode LTQ-MS metabolomic profiles.  
 
Additional analysis of all negative mode LTQ-MS metabolites showed no significant correlations 
between estimated bacterial load nor salivary pH levels. However, a number of metabolites did exhibit 
significant correlations with seven bacterial genera, Table 4.2, using the 70 samples that underwent 16S 
rRNA amplicon sequencing. A total of 11 correlations were observed with significant regression values 
above a R2 value of 90%. However, all significant correlations were observed between negative mode 
FIGURE 4.8 | Principal Component Analysis of Negative Mode LTQ-MS Metabolites 
Principal component analysis of negative mode LTQ-MS metabolite profiles was completed in PyChem, 
with samples classified by collection time point. Minimal variation was observed between samples, and 
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LTQ-MS metabolites and genera which were found in only one of the 70 samples that underwent 16S 
rRNA amplicon sequencing. 
 
   
TABLE 4.2 | Regression Analysis of Genera Taxonomy and Negative Mode LTQ-MS Metabolites 
Significant correlations were observed between seven bacterial genera and a total of seven metabolites 
derived from negative mode LTQ-MS fingerprinting. Genus count refers to the number of samples that 
underwent 16S rRNA amplicon sequencing in which sequences aligned to that genus are found. 
 




-adjusted (%) P Value Genus Count 
Janibacter 
269 92.4 92.3 < 0.001 1 / 70 
431 97.3 97.2 < 0.001 1 / 70 
432 96.4 96.4 < 0.001 1 / 70 
539 96.5 96.5 < 0.001 1 / 70 
593 91.2 91.1 < 0.001 1 / 70 
Cellulophaga 39.18 99.8 99.8 < 0.001 1 / 70 
Bradyrhizobium 161.9 98.7 98.7 < 0.001 1 / 70 
Desulfovirga 161.9 98.7 98.7 < 0.001 1 / 70 
Alkalispirillum 161.9 98.7 98.7 < 0.001 1 / 70 
Klebsiella 161.9 98.7 98.7 < 0.001 1 / 70 
Acholeplasma 39.18 99.8 99.8 < 0.001 1 / 70 
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4.4 | Discussion 
 
The human microbiome and metabolome are important components of homeostasis, and their 
dysbiosis has been linked to disease in both cause and effect. In understanding their role, the temporal 
variability of the human microbiome and metabolome has not been definitively established. Due to 
sampling ease, saliva has been suggested as a source of biomarkers for a number of diseases, including 
oral, breast and pancreatic cancers (Sugimoto et al., 2010), obesity (Matias et al., 2012), and dental 
caries (Yang et al., 2012). Whether the human salivary microbiome and metabolome displays temporal 
variability is likely to determine the usefulness of disease biomarkers derived from the microbiome or 
metabolome. In this portion of work, the salivary microbiome and metabolome of 40 people was 
sampled over a one year period, every two months. For all participants, the estimated salivary microbial 
load and pH was measured, and metabolomic profiles constructed through negative mode LTQ-MS. 
Additionally, a group of ten participants, selected because of their lifestyle similarities, underwent 16S 
rRNA amplicon sequencing to determine the taxonomic composition of their salivary microbiome. 
 
4.4.1 | Temporal Stability of the Salivary Microbiome 
 
The bacterial load of human saliva has been suggested as an in vivo marker of immunity, and previous 
work has shown an increase in salivary bacterial load over the winter months (Jones et al., 2014). 
However, the focus of this study was not the temporal stability of the microbiome, and looked only at 
the salivary microbiome of physically-active males. Nevertheless, a similar pattern of salivary bacterial 
load was seen in this portion of work. The sampling period February 2013 displayed the highest level of 
estimated salivary bacterial load. When the change in bacterial load is calculated for an individual, it can 
be seen that bacterial load appeared relatively stable over the 12 month sampling period. However, 
there are considerable net increases and decreases from one time point to the next.  It has been 
suggested that there may be a link between salivary bacterial load and de novo plaque formation 
(Dahan et al., 2004), although this has been disputed by others (Rowshani, Timmerman and Van der 
Velden, 2004). Salivary bacterial load has also been shown to not be associated with common dental 
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conditions such as gingivitis and periodontal disease (Mantilla Gomez et al., 2001). However, these 
studies relied on the use of culture-dependent techniques such as counting of colony forming units. It 
may be that there is no link between the bacterial load of cultureable bacteria and common dental 
diseases, but a link with difficult-to-culture bacteria cannot be dismissed.  
 
No relationships were seen between estimated salivary bacterial load and salivary pH level, α-diversity 
of the salivary microbiome, nor any negative mode LTQ-MS metabolites. This suggests that the variable, 
or variables, associated with changes in salivary bacterial load were not measured in this portion of 
work. Salivary bacterial load has been suggested as an in vivo measure of immunity and it may be that 
markers of the human immune system, such as immunoglobulin factors, may show an association. 
Although not measured in this portion of work, markers for the human immune system were measured 
by Jones et al., (2014) who did not find any association with salivary bacterial load. 
 
The focus of many microbiome studies is in characterising its taxonomic composition, and there are 
multiple methods which can be used to accomplish this. In this portion of work, the culture-independent 
sequencing of 16S rRNA amplicons was used, allowing for taxonomic classifications to the genus level. 
Analysis of the salivary microbiome through principal component analysis, Figure 4.4, showed that 
individual samples separated by participants rather than collection time point. The samples of particular 
participants appeared to cluster more closely than others, suggesting that individual differences 
between participants are the greatest determinant of the salivary microbiome. The measure of species 
diversity used in this portion of work, α-diversity, was also shown to be determined more by participant 
than by sampling time point, Figure 4.5. Significant differences were observed between participants, but 
not sampling time points. The standard deviations of α-diversity values for participants suggest that 
species diversity within the salivary microbiome is constant throughout the sampling period. 
Interestingly, no relationship between α-diversity and estimated salivary bacterial load was observed, 
suggesting that the increase in salivary bacterial load seen in the February 2013 time point is an equal 
increase in all bacteria, rather than specific taxa. A significant correlation was however observed 
[ 118 ] 
between α-diversity and salivary pH, though only 7.8% of variation in diversity was explained. Due to its 
impact on enzyme function, salivary pH is an important determinant in bacterial colonisation, and 
growth. The positive correlation between salivary pH and bacterial diversity suggests that as saliva 
become increasingly acidic, the range of bacteria able to tolerate these conditions decreases. Lower 
salivary pH levels have been linked to oral diseases, such as dental caries (Humphrey and Williamson, 
2001), and it could be that a corresponding reduction in bacterial diversity is an additional factor. 
 
In regards to differences between sampling time points within individual genera, only Rhodococcus and 
Variovorax were significantly different between time points using the MetaboAnalyst 2.0 online 
platform. However, these genera were present in only a minority of samples, with Variovorax present 
only in two. Furthermore, the significant differences shown in the MetaboAnalyst 2.0 platform were not 
reproducible in additional statistical packages. Therefore, it was determined that the significance 
displayed was an artefact of their low abundance. As with bacterial diversity, significant differences 
were only evident between participants, rather than sampling time point. At the phylum level of 
classification, seven phyla were seen to have significantly different abundances between participants. 
The large number of unclassified bacterial sequences evident in samples, with an average range of 
between 30% and 50%, is noteworthy. It may be possible that significant differences are indeed present 
within the taxonomic composition of the salivary microbiome, but that these differences exist within 
poorly defined taxa.  
 
The taxonomic composition and diversity of the salivary microbiome in this portion of work appeared to 
be determined by individual differences, rather than temporal changes over the one year sampling 
period. This is in line with other work into the human salivary and oral cavity microbiome, although over 
different temporal periods. For example, Stahringer et al., (2012) found that the human salivary 
microbiome appears remarkably stable once in adulthood, which may be as a result of a stabilisation in 
diet, oral hygiene, and other lifestyle factors. Over a shorter time period, namely three months, the oral 
cavity and other body sites displayed a high degree of temporal stability (Costello et al., 2009). The 
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sampling time period in this portion of work appears to be unique within the published literature, and is 
the first to suggest that comparing salivary microbiome composition, but not bacterial load, from any 
time point within the year is valid. 
 
It has been suggested that a core microbiome in healthy individuals exists in the form of metabolic 
function, rather than taxonomic composition (Turnbaugh et al., 2009). Through sequencing of the 16S 
rRNA gene in this portion of work, only the taxonomic make-up of the salivary microbiome could be 
established. To establish the functional capacity of the salivary microbiome, metagenomic sequencing of 
the entire DNA found within a sample would be required. This method of sequencing however requires 
substantial resources which were not available to this project. Additionally, metagenomic sequencing 
allows for the assignment of species or even strain-level taxonomy, and it may be that temporal 
variation exists within these classifications (Weinstock, 2012). 
 
One of the current limitations of microbiome research is the common focus of only characterising the 
bacterial component, as was the case in this portion of work. This is arguably associated with the ease of 
classifying bacteria based on sequencing of the 16S rRNA gene, and although the same technique can be 
used for the eukaryotic 18S rRNA gene, it is complicated by the high abundance of host sequences, 
particularly in humans. The lack of curated databases for eukaryotic microbes is also an issue, which 
complicates the biological interpretation of sequence data (Grice and Segre, 2012). As with the 
eukaryotic microbiome, the viral microbiome is also a neglected area of human microbiome research. In 
saliva, bacteriophages have been shown to be a significant reservoir of bacterial pathogenic gene 
function, which is temporally instable. However, it may be that the virome is constantly in a state of flux, 
rather than reflecting a composition associated with the time of year (Pride et al., 2012). 
 
4.4.2 | Temporal Stability of the Salivary Metabolome 
 
Based on negative mode LTQ-MS profiles, no detectable temporal differences were evident within the 
salivary metabolome of all 40 participants in this portion of work, and additionally no differences were 
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evident between participants, based on principal component analysis. In addition to consumed food 
present within the oral cavity, saliva acts as the main growth medium for the human salivary 
microbiome. It is therefore expected that temporal stability in the human salivary microbiome is 
reflected in the salivary metabolome. However, the differences evident between participants in the 
salivary microbiome do not appear to be reflected in the salivary metabolome. This suggests that 
additional factors than those found in the salivary metabolome may be the causative factor in 
determining the taxonomic composition of a participant’s salivary microbiome, such as immunoglobulin 
factors (Jones et al., 2014) or salivary antimicrobial compounds (Peters, Shirtliff and Jabra-Rizk, 2010). 
    
Saliva has been extensively studied using a variety of metabolomic techniques, with the focus being on 
identifying disease biomarkers. However, minimal work has evaluated the temporal stability of the 
salivary metabolome over a prolonged period of time. The collection time of saliva, namely morning and 
afternoon, has been shown to influence the salivary metabolome; though differences in age was 
believed to be a significant contributory factor to the observed changes (Sugimoto et al., 2012). The 
human circadian rhythm has also been suggested to influence the salivary metabolome, though only 
approximately 15% of metabolites were under direct or indirect control by the circadian clock 
mechanism (Dallmann et al., 2012). These findings suggest that the salivary metabolome is in a 
continuous state of flux, with its composition determined by more than one factor. 
 
Through comparison of individual negative mode LTQ-MS metabolites and genus-level taxonomic 
assignments for the ten participants selected for the sub-group used in 16S rRNA amplicon sequencing, 
a number of significant correlations were observed. A total of seven bacterial genera displayed a 
significant relationship with at least one of seven negative mode LTQ-MS metabolites, which explained 
over 90% of the variation observed. However, these genera could be considered low abundance, as they 
appear in only one of the 70 samples that underwent 16S rRNA amplicon sequencing. It may be that 
these significant regression analyses are statistical anomalies of the low abundance, but it may also be 
that these metabolites are essential for the growth of these genera. The combination of microbiome 
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and metabolome profiling is not common, though several studies have attempted small scale proof-of-
concept studies. Celiac disease, for example, has been studied through both of these methods, with 
metabolomics providing biomarkers for the disease, and microbiomics providing a possible mechanism 
for the disease (Sellitto et al., 2012). The combination of microbiome and metabolome profiling in 
humans has the potential to unravel the mechanisms behind disease, and to provide possible targets for 
treatment. Nevertheless, these two techniques only account for a portion of the approaches needed for 
a systems biology approach in human health and disease. Proteomics and transcriptomics techniques 
are also required to fully elucidate the host-microbiome interaction (Kinross, Darzi and Nicholson, 2011). 
 
4.4.3 | Impact on Saliva-Derived Biomarkers for Disease  
 
Due to the ease of collecting saliva, and how it can reflect most of the compounds found in blood, it is 
considered to be a great promise in the identification of novel biomarkers for disease. As population-
based screening programmes usually require a single sampling time point to measure an individual or 
panel of biomarkers, saliva-derived biomarkers will only be of use if their levels do not fluctuate over 
time. In this portion of work, the salivary metabolome has been shown to be stable over a one year 
period, based on a large sample size of 40 participants giving a total of seven samples each. This finding 
suggests that the salivary metabolome is sufficiently stable to make saliva-derived disease biomarkers 
plausible. Additionally, the majority of studies of the salivary metabolome have focused on the use of 
NMR spectroscopy, which has a lower sensitivity than mass spectrometry based approaches. Therefore, 
this portion of work has suggested that low abundant metabolites, which may not be detected using 
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4.5 | Conclusions and Future Work 
 
This portion of work aimed to characterise the variability of the human salivary microbiome and 
metabolome over time, namely a one year period with sampling every two months. With the fields of 
microbiomics and metabolomics showing promise in helping to understand health and disease, and to 
provide biomarkers for a range of human disorders, understanding their temporal variability is 
fundamental in establishing their usefulness and validity. To this end, this portion of work has shown 
that the human salivary microbiome displays temporal stability in terms of bacterial diversity but not 
load, over a one year period. The salivary metabolome showed a similar degree of temporal stability. A 
significant positive relationship between pH and the α-diversity of the microbiome in a sub-group of ten 
participants was also observed, which may have implications in oral diseases associated with increased 
salivary acidity. 
 
Saliva was chosen as the biofluid in this portion of work because it is non-invasive to collect and shows 
promise as a source of novel biomarkers for disease. Although the salivary microbiome, in terms of 
bacterial diversity, and metabolome have been shown to be temporally stable, this finding cannot be 
extended to the microbiome and metabolome found in other human systems, such as the 
gastrointestinal tract. Furthermore, the participants in this portion of work may not be accurate 
representatives of the microbiome and metabolome found under disease conditions. It may be disease-
related biomarkers, in both the microbiome and metabolome, are under a greater degree of instability 
than that found in healthy individuals. 
 
Although the salivary microbiome, in terms of bacterial diversity, and metabolome have been shown to 
be temporally stable using the methods employed in this portion of work. As previously discussed, the 
use of metagenomic sequencing may reveal species-level taxonomic or functional capability changes 
that are not visible using 16S rRNA amplicon sequencing. Furthermore, metabolomics can only reveal 
changes in relatively low molecular weight compounds, usually those below 1.5 kDa, and it may be that 
temporal instability exists in the proteome or lipidome of human saliva.  
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CHAPTER 5 | Humans and Their Hidden Companions 
Cross Antarctica 
 
CHAPTER SUMMARY | The effects that prolonged human space travel could have on the human 
microbiome and metabolome are unclear, and could potentially impact the successful outcome of 
manned space travel, such as to Mars. In this portion of work, the expedition members of the Trans-
Antarctic Winter Traverse (TAWT) gave stool, saliva, and blood plasma samples for each of the eight 
months of travel, in addition to a preliminary baseline sample. The bacterial diversity of the salivary and 
stool microbiomes was determined through amplicon sequencing of the V3 to V4 region of the 16S rRNA 
region, and bacterial load through quantitative PCR. Metabolome profiles of raw saliva, saliva 
supernatant, stool, and blood plasma were constructed using negative mode LTQ-MS. Additionally, stool 
water content and the pH of saliva supernatant, raw saliva and blood plasma was determined. 
Significant (P < 0.001) differences were seen between baseline salivary bacterial load and all other time 
points, but not between participants. Additionally, bacterial diversity was significantly (P = 0.002) lower 
in Baseline samples than all other sampling months, though individual differences were also significant 
(P = 0.016). At the taxonomic level of classification, significant differences in the Bacteroidetes (P = 
0.008) phylum, and the Desulfotomaculum (P = 0.013), Veillonella (P = 0.016), Prevotella (P = 0.022), 
Megasphaera (P = 0.041), Bacillus (P = 0.047), and Rothia (P = 0.047) genera were evident between 
sampling months. The stool microbiome showed no significant differences in bacterial load between 
participants (P = 0.131) or sampling month (P = 0.867), but bacterial diversity was significantly (P < 
0.001) different between participants. Stool water content (P < 0.001), pH of raw saliva (P < 0.001), and 
saliva supernatant (P = 0.001) all showed significant differences between participants. No differences 
were evident in the metabolomes of any of the four biofluids profiled by either participant or sampling 
month. Overall, the human salivary microbiome shows significant alterations in bacterial load and 
diversity as a result of the TAWT expedition. However, the stool microbiome and metabolomes of all 
four biofluids studied do not. Therefore, the human microbiome and metabolome is differentially 
affected based on sample site, which could have important implications for future space travel. 
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5.1 | Introduction 
 
The human microbiome and metabolome have both been shown to be an important component of 
health and disease. A number of stresses that involve deviations from a person’s normal lifestyle can 
lead to changes in the human microbiome and metabolome. Long-term exploration, such as that 
envisioned for future human space travel, such as manned travel to Mars, could have significant 
implications for the human microbiome and metabolome. This could impact upon the health of 
participants, and the potential success of expeditions. 
 
Due to the nature of human space travel, analogous terrestrial expeditions to the isolation and 
environmental and physiological stress that may be experienced during space travel have to be held to 
gauge the effects that they may have on the human microbiome and metabolome. Concurrent to the 
TAWT expedition, the White Mars scientific project aimed to utilise the unique stressors that expedition 
members experienced to explore how the human body is affected. 
 
5.1.1 | The Human Stress Response 
 
Stressful stimuli, including physiological, environmental and psychological, and the corresponding stress 
response are central to the maintenance of homeostasis. However, the stress response can also lead to 
adverse consequences in humans, with a number of diseases including obesity, heart disease, and 
depression, having stress as a risk factor (Groeneweg et al., 2011). 
 
The term stress can refer to a range of conditions and responses, where the stimulus can range from 
mild to severe, which lead to a host response, such as the release of hormones. However, an emerging 
concept in the field of stress research is that the term stress should only refer to a situation in which the 
demand of a stimuli exceeds the natural regulatory ability of the organism to maintain homeostasis, and 
in particular where these stimuli are unpredictable and uncontrollable (Koolhaas et al., 2011).  
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In response to stressful stimuli, the human body employs physiological and behavioural systems, 
including the central nervous system and the peripheral adaptive response. The human stress response 
is predominately a hormonal one, relying on the endocrine system to produce hormones to maintain 
homeostasis and adapt to the stressful stimuli (Groeneweg et al., 2011). Stress is also able to increase 
the permeability of the gut, Figure 5.1, leading to increased levels of pro-inflammatory cytokines, such 
as interferon gamma (IFNγ) and interleukin six (IL-6). In turn, these can alter activity of indoleamine 2,3-
dioxygenase activity in the liver, lowering tryptophan availability to the brain and altering levels of 5-
hydroxytryptamine, also known as serotonin. Altered serotonin levels can lead to increased levels of 
corticotrophin-releasing factor (CRF) and arginine vasopressin in the adrenal cortex, resulting in higher 
levels of cortisol (Dinan and Cryan, 2012). 
FIGURE 5.1 | Stress Effects on Human Gut Permeability 
Exposure to environmental, physiological, or psychological stressors can lead to increased human gut 
permeability, allowing bacteria and bacterial antigens to cross the gut epithelial layer. This can result in 
an immune response leading to increased pro-inflammatory cytokines, affecting a number of systems, 
including the brain; altering hormonal levels. Certain probiotic bacteria have been shown to alter the 
gut permeability following stress. Figure taken from Dinan and Cryan, (2012). 
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Alterations in the gut-brain axis have been linked to a range of psychological and physiological disorders, 
including depression and inflammatory bowel disease (Konturek, Brzozowski and Konturek, 2011). 
Additionally, there is a high incidence of co-morbidity between stress-related psychiatric symptoms, 
such as anxiety, with gastrointestinal disorders. However, to date, the exact mechanisms involved in the 
gut-brain axis, and the bidirectional communication between the gut and brain are still to be elucidated. 
Ongoing investigations into elucidating these mechanisms include assessing the impact of probiotics, 
antibiotics, and pathogen-induced dysbiosis on the gut-brain axis (Cryan and O’Mahony, 2011). 
 
5.1.2 | Space Travel and the Human Microbiome and Metabolome 
 
The human microbiome has been shown to be an essential component in the maintenance of 
homeostasis. Furthermore, it has been shown to modulate the stress response, either through the 
production or alteration of metabolites. To date, the field of medicine interested in the effect of 
prolonged space travel has  focused on improving the provision of artificial life-support systems, and the 
human microbiome has received only minimal attention (Saei and Barzegari, 2012). This may be 
important as the stress of microgravity has been shown to alter host-microbiome interactions and even 
increase the virulence of a number of human pathogens. Microgravity could alter the human 
microbiome to an extent that overall dysbiosis gives rise to a number of diseases that are not associated 
with a single microbial agent (Foster, Wheeler and Pamphile, 2014).  
 
The environment that astronauts would experience during prolonged space travel offers a number of 
unique characteristics. For example, the environmental microbiome found on the International Space 
Station appears to consist of a large number of human-associated microbes, with around 90% of 
pyrosequenced reads associated with Actinobacteria. Interestingly, members of this phylum have been 
associated with structural damage to buildings, and to allergic-respiratory conditions which may impact 
upon inhabitants (Venkateswaran et al., 2014). As well as posing unique environmental conditions, 
prolonged space travel has inherent environmental stressors, such as microgravity, but also in exposure 
to radiation, which is considered one of the primary barriers to a manned mission to Mars. Work with 
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mice exposed to whole-body radiation, with samples taken after exposure to a LD50 and LD30 dose 
showed that the gut microbiome shifts significantly. Of particular note was the shift in the gut 
microbiome after irradiation to one which included increased levels of Enterobacteriaceae, which 
contains a number of known pathogens (Karouia et al., 2014).   
 
Space travel itself is not the sole means of investigating how prolonged space travel could affect the 
human microbiome. Recent isolation studies that attempt to mimic the isolation and physiological and 
psychological effects of prolonged space travel have measured changes in the structure and function of 
the human gut microbiome. In the Mars-500 study, changes in the taxonomic composition of the gut 
microbiome were seen within the first 14 days, but no such changes were seen in its core functional 
capacity, with a reversion to the initial microbiome composition beginning to be seen within two weeks 
of the study ending. Although slight taxonomic changes were observed in the microbiome, no adverse 
effects were consequently seen in the host, suggesting that the microbiome is highly adaptable to the 
environmental conditions and stressors that may be involved in prolonged space travel (Mardanov et 
al., 2013).  
 
The human metabolome reflects changes in the body’s metabolism, and how it has altered to adapt to 
stressors. As an analogy to prolonged space travel, the environmental and physiological conditions 
presented by the Antarctic have previously been shown to alter the blood plasma metabolome, 
reflecting changes associated with altered liver and kidney function (Yadav et al., 2014). 
 
Radiation is considered to be one of the biggest environmental stressors facing those attempting 
prolonged space flight (Chancellor, Scott and Sutton, 2014). As with the human microbiome, the 
metabolome has also been shown to be significantly affected by radiation. Although limited to animal 
studies, long-term exposure to radiation has been shown to alter the intestinal metabolome of mice, 
with nucleotide and amino acid metabolism being significantly affected. Interestingly, the type of 
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radiation exposure was also shown to have preferential effects on the gut metabolome, with 56Fe 
radiation leading to particularly altered dipeptide metabolism (Cheema et al., 2014). 
 
The use of metabolomics to investigate the human metabolome and how it is affected by prolonged 
space travel, has given rise to the prospect of personalised medical approaches to counter the negative 
consequence of the induced stress response. Metabolomics, in combination with other ‘omic 
FIGURE 5.2 | Antarctic Conditions Facing TAWT Expedition  
The Antarctic poses a highly inhospitable environment, in terms of (a and b) temperature, (c) wind 
speed, and (d) lack of sun light. Black dotted line displays the approximate planned route of the TAWT 
expedition before abandonment part-way through. X displays approximate location of stationary phase 
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technologies such as proteomics and genomics, is able to assess how individuals respond differently to 
the same level of environmental or physiological stressor, such as radiation. Additionally, metabolomics 
could be used to tailor individualised countermeasures to a range of stressors that could be used to 
reduce the negative effects of prolonged human space travel (Schmidt and Goodwin, 2013). 
 
5.1.3 | The Trans-Antarctic Winter Traverse 
 
Considered to be the last major polar challenge, the Trans-Antarctic Winter Traverse expedition aimed 
to travel the 2,000 miles required to cross the Antarctic in the winter (March to September), from 
Crown Bay to the Amundsen-Scott South Pole Station, and then to Ross Island. Environmental 
conditions in the Antarctic include temperatures reaching down to -90°C and near complete darkness, 
Figure 5.2. The five man team travelled predominately on the polar plateau, which averages 2,160 m in 
thickness. In addition to the inhospitable environmental conditions, the terrain can also be dangerous 
with crevasses posing particular threat. 
 
The initial plan for the TAWT expedition was to complete the Antarctic crossing from March 2013 to 
September 2013, with several months either side to prepare for the expedition and subsequent uplift. 
However, in June 2013 after travelling approximately 300 km, and climbing from sea level to an altitude 
of 3,000 m, the TAWT expedition team decided to abandon the rest of the distance. This was because of 
a range of technical and logistical issues, as well as the danger posed by an unexpected crevasse field 
ranging up to 100 km in the proposed distance of travel. Nevertheless, the environmental and 
physiological conditions that the five man expedition team were in for the remainder of the time period 
in Antarctica still provide for a rare analogous situation to prolonged space travel. 
 
5.1.4 | Aims and Objectives of Chapter 
 
The prospect of prolonged human space travel poses a number of novel questions for the role of the 
human microbiome and metabolome in health and disease. From laboratory in vitro and preliminary, 
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pilot-stage in vivo studies, the human microbiome and metabolome have been suggested to be 
important in maintaining the health of participants in prolonged human space travel. However, with 
prolonged human space travel not currently being envisaged, terrestrial-based analogies to the 
environmental and physiological stresses which may be encountered may help to elucidate the response 
of the human body to them, and reveal important information that may aid in the planning and 
implementation of prolonged space travel. To this end, the participants of the Trans-Antarctic Winter 
Traverse expedition conducted during 2013/2014 will provide samples and meta-data to help explain: 
 
1) The effects of physiological and environmental stress on the human salivary and stool 
microbiome. 
2) The effects of physiological and environmental stress on the human salivary, stool, and blood 
plasma metabolome. 
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5.2 | Materials and Methods 
 
The White Mars project, from which samples were received for this study, formed part of the TAWT 
expedition, which took place from December 2012 to September 2013. The White Mars project was 
hosted by King’s College London’s Centre of Human and Aerospace Physiological Sciences, who gained 
the necessary ethical approval to collect samples. This component of the White Mars project, that forms 
the contents of this Chapter, received additional ethical approval from the Aberystwyth University 
Research Ethics Committee. Informed consent was obtained from all study participants, and all 
participant information was link anonymised by the expedition doctor. 
  
5.2.1 | Participant Recruitment and Sampling 
 
A total of five participants took part in the White Mars element of the TAWT. All sampling was 
completed by the expedition doctor, and samples stored at ≈ -40°C throughout the expedition. For stool 
and saliva, a baseline sample was taken from all participants prior to the start of the expedition and 
stored at -30°C until all samples had returned from the TAWT expedition. During the expedition, stool, 
saliva and plasma samples were taken at monthly intervals, over an eight month period, alongside 
individual physiological information and measurements. Samples were stored at King’s College London 
at -30°C for approximately two weeks, until transferred to Aberystwyth laboratories on dry ice, over a 
six hour period. 
 
Throughout the TAWT expedition, all participants consumed a similar high-calorie diet of freeze-dried 
food and consumed similar liquid intake. At night, all participants sheltered within the expedition 
transport caboose. 
 
5.2.2 | Sample Processing 
 
Upon arrival at Aberystwyth laboratories, the 4 mL raw saliva samples were thawed at 4°C, vortexed to 
homogenise mixture, and separated into 2 mL aliquots in sterile 2 mL microcentrifuge tubes. One 
[ 132 ] 
aliquot was immediately frozen at -80°C and treated as raw saliva, and the remaining aliquot underwent 
centrifugation at 11,000 x g for ten minutes at 4°C. The resulting supernatant was removed and 
transferred to a sterile 2 mL microcentrifuge tube and immediately frozen at -80°C for approximately 
one month until analysed using LTQ-MS. The remaining pellet was also immediately frozen at -80°C until 
used for DNA extraction, which was completed within seven days receipt at Aberystwyth laboratories. 
 
Blood samples were thawed at 4°C and underwent centrifugation at 11,000 x g for ten minutes at 4°C to 
ensure no separation (indicative of mixed blood) of sample, and 2 mL transferred to a sterile 2 mL 
microcentrifuge tube and immediately frozen at -80°C. Stool samples were transferred to sterile, pre-
weighed glass vials, and weighed to determine wet weight. Stool samples were frozen at -20°C and 
transferred to a freeze-drier set at -50°C. Stool samples were then weighed every 24 hours until they 
had reached a stable weight, determined as a weight reduction, over a 24 hour period, of less than 5%. 
After freeze-drying, 100 mg of each stool sample was transferred to a sterile 2 mL microcentrifuge tubes 
and stored at -80°C, with the remaining stool sample transferred to a separate sterile 2 mL 
microcentrifuge tube and stored at -80°C. Total genomic DNA extraction was completed on the 100 mg 
aliquot within seven days of receipt at Aberystwyth laboratories, and the remaining sample analysed 
using LTQ-MS within one month. 
 
5.2.3 | Total Genomic DNA Extraction and Purification 
 
For saliva samples, DNA was extracted from the saliva pellet using a FastDNA SPIN kit for Soil (MP 
Biomedical). DNA extraction was completed following manufacturer’s instructions, with bead beating 
carried out in a FastPrep-24 machine (MP Biomedical) with three cycles at speed setting 6.0 for 30 
seconds, with on ice for 60 seconds between cycles. Genomic DNA was eluted with 50 µL of DES and 
dsDNA concentration determined, in duplicate, using 2 µL on the Epoch spectrometer system (BioTek). 
For stool samples, DNA was extracted from 100 mg of freeze-dried stool using a FastDNA SPIN kit for Soil 
(MP Biomedical), as previously described, except that an additional wash step was completed, and 
genomic DNA was eluted with 100 µL of DES. DNA extracts from stool underwent an additional 
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purification step to remove humic acid, which can be a common contaminant that inhibits downstream 
PCR. To 100 µL of extracted DNA from stool, 10 µL of a 3 M (pH 5.2) solution of sodium acetate was 
added. After vortexing for ten seconds, 275 µL of ice-cold, HPLC grade ethanol was added, and the 
mixture cooled on ice for 30 minutes. The cooled mixture then underwent centrifugation at 11,000 x g 
for 15 minutes at 4°C and the supernatant removed. An additional 1 mL of ice-cold, HPLC grade ethanol 
was added and the sample placed on a vortex mixer for ten seconds before undergoing centrifugation at 
11,000 x g for 15 minutes at 4°C. The samples were then air dried in a sterile laminar flow hood for ten 
minutes, after which the DNA was reconstituted in 100 µL of DES buffer. DNA concentration was 
determined, in duplicate, using 2 µL on the Epoch spectrometer system (BioTek). Due to variations in 
DNA loss caused by this additional purification step, samples were concentrated in a DNA 120 Speed Vac 
(Savant Instruments, New York, USA) through complete removal of DES buffer. Samples were then 
reconstituted in DES buffer to reach the same DNA concentration as after initial DNA extraction. 
 
5.2.4 | 16S rRNA Quantitative PCR 
 
Quantitative PCR was carried out, in duplicate, on neat extracted DNA against standards created by 
amplifying the 16S rRNA gene of the five baseline samples, separately for stool and saliva samples. This 
was completed through amplification of the 16S rRNA gene in a 20 µL reaction volume consisting of 10 
µL of 2 x BioMix (BioLine), 0.25 µL each of 27f (5’-AGA GTT TGA TCC TGG CTC AG-3’) and 1389r (5’-ACG 
GGC GGT GTG TAC AAG-3’) primers (Hongoh, Ohkuma and Kudo, 2003) to give a final concentration of 
500 nM, 1 µL of neat extracted DNA, and 9.5 µL of PCR Grade Water (Roche). The reaction volumes were 
then subjected to PCR consisting of 94°C for two minutes, 30 cycles of 94°C for 45 seconds, 55°C for 45 
seconds, and 72°C for 90 seconds, followed by a final elongation step of 72°C for seven minutes. The 
resulting PCR products were combined and purified using an Isolate II PCR and Gel Extraction 
purification kit (BioLine), following manufacturer’s instructions, and quantified using an Epoch 
spectrometer as previously described. The resulting DNA concentration was used to estimate the total 
number of 16S rRNA gene copies and serial dilutions of 1010, 108, 106, 104, 102, and 100 made.  
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Quantitative PCR was completed on neat extracted DNA against standards with each reaction 
completed in 25 µL volumes, each consisting of 12.5 µL 2 x SYBR Green Mastermix (Life Technologies), 
0.25 µL of each EubF1 (5’-GTG STG CAY GGY TGT CGT CA-3’) and EubR1 (5’-ACG TCR TCC MCA CCT TCC 
TC-3’) primer (Maeda et al., 2003), in a final concentration of 400 nM, 11 µL of PCR Grade Water (Roche) 
and 1 µL of neat DNA extract. Reactions were run using a C100 thermal cycler (BioRad, Hercules, USA) 
and CFX96 optical detector (BioRad), with data captured using CFX Manager software (BioRad), under 
conditions of 95°C for ten minutes, 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds, followed 
by a melt curve consisting of a temperature gradient of 60°C to 95°C in 0.5°C increments, each for five 
seconds. Where shown, P values represent the significance of one-way ANOVA tests. 
 
5.2.5 | 16S rRNA Amplicon Preparation 
 
Taxonomic identification of bacterial component of the microbiome was carried out through sequencing 
of the V3 to V4 regions of the 16S rRNA gene on the Illumina MiSeq platform. Firstly, the V3 to V4 region 
of the 16S rRNA gene was amplified through duplicate PCR with locus specific primers, alongside 
negative water controls. In a 25 µL reaction volume, 12.5 ng of extracted DNA, or 2.5 µL of PCR grade 
water for negative controls, was added to 12.5 µL of 2 x Accuzyme Mix (BioLine) and 5 µL each of a 1 µM 
concentration of 319f primer (5’– CCT ACG GGN GGC WGC AG–3’) with Illumina forward overhang 
adapter sequence (5’ – TCG TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG-3’) and 806r primer (5’–GAC 
TAC HVG GGT ATC TAA TCC–3’) with Illumina reverse overhang adapter sequence (5’- GTC TCG TGG GCT 
CGG AGA TGT GTA TAA GAG ACA G-3’) as detailed by Klindworth et al., (2013). The reaction mix 
underwent PCR consisting of 95°C for three minutes, followed by 25 cycles each of 95°C for 30 seconds, 
55°C for 30 seconds, and 72°C for 30 seconds, followed by a final elongation step of 72°C for five 
minutes. Each duplicate PCR volume was confirmed through visualisation on a 2% agarose gel, after 
being run for 120 minutes at 100 volts (≤ 80 mA) in 1% TAE buffer. Following confirmation of PCR 
success, corresponding reaction volumes were combined and purified using an Isolate II PCR and Gel 
Extraction kit (BioLine), following manufacturer’s instructions, with elution into 20 µL of kit buffer. 
Following purification, a second PCR was completed to attach Illumina adaptors to amplified products to 
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allow for multiplexed amplicon sequencing on the Illumina MiSeq platform. To make a final reaction 
volume of 25 µL, 2.5 µL of purified PCR product from the previous step was added to 12.5 µL of 2 x 
Accuzyme Mix (BioLine), 5 µL of PCR Grade Water (Roche) and 2.5 µL each of the relevant Nextera XT 
Index Primer 1 (N7##) and Nextera XT Index Primer 2 (S5##) (Illumina) as detailed in Chapter 5 
Appendix, Supplementary Table 5.1. The reaction mix underwent a limited cycle PCR consisting of 95°C 
for three minutes, eight cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds, 
followed by a final elongation step of 72°C for five minutes. To remove non-combined adaptors, the 
entire reaction volume was run on a 2% agarose gel, in TAE buffer, for 120 minutes at 100 volts (≤ 80 
mA). The gel was visualised using a DR195M Transilluminator (Clare Chemical Research, Colorado, USA) 
and each PCR product excised using a sterile scalpel blade. PCR products were purified using an Isolate II 
PCR and Gel Extraction kit (BioLine), following manufacturer’s instructions, with elution into 20 µL of kit 
buffer. Purified PCR products were quantified using a Quant-iT dsDNA High Sensitivity assay kit and a 
Qubit fluorometer (Life Technologies). 
 
5.2.6 | 16S rRNA Amplicon Sequencing and Analysis 
 
Individual sample libraries were pooled together in equimolar concentration and sequenced, along with 
20% PhiX DNA as a control for low diversity, on the Illumina MiSeq platform using MiSeq v3 reagents for 
a 2 x 300 bp run at the IBERS Translational Genomics Facility, Aberystwyth University. After sequencing, 
sample reads were demultiplexed and trimmed to remove primer sequences. Overlapping paired-end 
reads were merged using the MG-RAST metagenomic analysis pipeline, dereplicated and trimmed for 
quality using default parameters (Meyer et al., 2008). Taxonomic alignments of sequences was 
completed using the Ribosomal Database Project (Cole et al., 2009) facility, with only those sequences 
with a minimum alignment identity of 97%, maximum e-value of 1 x 10-5, and a minimum alignment cut-
off of 15 being used. Sequences were analysed using the principal component analysis, α-diversity 
measurement using the Shannon diversity index, and taxonomic assignment facility within MG-RAST, 
and exported into Microsoft Excel 2010 and MINITAB 14 for additional analysis, with multivariate 
statistics completed using MetaboAnalyst 2.0 (Xia et al., 2012). Sequence numbers for each sample were 
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normalised as a percentage composition of the total volume of sequences for each taxonomic level of 
classification. Where shown, P values represent the significance of one-way ANOVA tests. All sequence 
files are available under the MG-RAST project ID 11838: ‘White Mars’. Raw sequence reads were 
deposited at the European Nucleotide Archive under primary accession number PRJEB9027 and 
secondary accession number ERP010081. 
 
5.2.7 | LTQ-MS Metabolomic Fingerprinting 
 
For raw saliva, saliva supernatant and blood plasma, samples were thawed at 4°C, and 200 µL 
transferred to a sterile 2 mL microcentrifuge tube, to which 30 mg of ≤ 106 µM acetone-washed glass 
beads (Sigma-Aldrich) were added. To this, 1520 µL of a solvent mix of HPLC grade methanol and 
chloroform, in a ratio of 4:1, was added. For stool samples, freeze-dried stool was reconstituted at a 
concentration of 100 mg/mL in a solvent mix of water, methanol and chloroform, in a ratio of 2:5:2 
respectively.  To homogenise the mix, samples were placed on a vortex mixer for five seconds and then 
milled for 30 seconds at 30 Hz. Following this, samples were shaken for 20 minutes at 4°C and then 
stored at - 20°C for 20 minutes to precipitate protein. Samples then underwent centrifugation at 11 000 
x g for six minutes, at 4°C. For raw saliva, saliva supernatant and blood plasma samples, the resulting 
supernatant was removed and transferred to a sterile 2 mL microcentrifuge tube. For stool samples, the 
resulting supernatant was removed and diluted by 50% in the same water, methanol and chloroform 
solvent mix detailed earlier. From these, 70 µL of sample was transferred to an LTQ-MS vial and sealed. 
Samples were kept at -20°C until run, in a randomised order using an autosampler, with tray 
temperature kept constant at 15°C. For each sample, 20 µL was injected into a flow volume of 60 µL per 
minute water-methanol, in a ratio of 70% water and 30% methanol, using a Surveyor liquid 
chromatography system (Thermo Scientific, MA, USA). Data acquisition for each individual sample was 
conducted, in alternating positive and negative ionisation mode, over four scan ranges (15-110 m/z, 
100-220 m/z, 210-510 m/z, 500-1200 m/z) on an LTQ linear ion trap (Thermo Electron Corporation, CA, 
USA), with an acquisition time of five minutes. Individual metabolite m/z values were normalised as a 
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percentage of the total ion count for each sample. Normalised abundances were subsequently analysed 
using MetaboAnalyst 2.0 (Xia et al., 2012) and PyChem (Jarvis et al., 2006). 
 
5.2.8 | pH Measurements of Saliva and Plasma 
 
Measurements of the pH of saliva supernatant was carried out using a B-212 Twin pH Meter (Horiba, 
Kyoto, Japan) after two point calibration using a pH 7 and pH 4 buffer. For pH measurements, 200 µL of 
saliva supernatant, after thawing at 4°C, was used; ensuring equal coverage of the two sensor points. 
After stabilisation of reading, pH value was recorded and the sensor washed with ultrapure water, and 
blotted dry. Data analysis was completed using Microsoft Excel 2010 and Minitab 14. Where shown, P 
values represent the significance of one-way ANOVA tests.  
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5.3 | Results 
 
The TAWT expedition did not complete its initial intention to cross Antarctic during the winter (March to 
September). Due to the dangers posed by unexpectedly large crevasse fields, the expedition was halted 
in Month 4. This was preceded by three months of traversing, where a total distance of 300 km was 
travelled. After three months of remaining in their stationary position, the TAWT expedition took a 
further two months of traversing back to their original starting point. 
 
The TAWT expedition team consisted of five males, with an average age of 37 (range 28 to 54). Table 5.1 
gives each individual team member’s physiological information, along with their anonymised participant 
identifier. Their weight, body mass index, and body fat percentage is given as a mean of their weekly 
measurements over the expedition period. Physiological information for each weekly measurement, for 
each participant, is given in Chapter 5 Appendix, Supplementary Table 5.2. 
 
TABLE 5.1 | Participant Physiological Information 
Individual participant information is detailed for each of the five members of the TAWT expedition. For 
weight, body mass index and body fat percentage (%), participant information is given as a mean of the 
weekly measurements taken with standard deviations shown italicised in brackets. 
 
 
A B C D E 
Age 30 28 34 39 54 
Gender Male Male Male Male Male 
Weight 77.0 (3.0) 80.2 (2.4) 81.1 (1.2) 64.3 (0.7) 65.8 (2.0) 
Body Mass 
Index 26.8 (1.0) 27.8 (1.0) 25.6 (0.4) 21.4 (0.2) 22.4 (0.6) 
Body Fat % 17.3 (0.8) 13.2 (1.5) 16.8 (1.2) 12.5 (0.7) 24.2 (0.9) 
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5.3.1 | Stool Water Content 
 
Each monthly stool sample was freeze-dried until a stable weight was reached. This weight was then 
used to calculate the original water content of the stool sample. Figure 5.3 shows that stool water 
content maintains individual differences between participants over the nine monthly samples. 
Participant B was shown to have significantly (P < 0.001) lower stool water content than Participants A, 
D, and E and Participant C lower stool water content than Participant A only, Figure 5.3a. No significant 
(P = 0.865) differences were evident between sampling months. 
 
5.3.2 | pH of Plasma and Saliva 
 
The pH of saliva supernatant, raw saliva, and blood plasma was measured for each participant at each 
sampling month, Figure 5.4. No discernible pattern was evident for any of the three biofluids in regards 
to changes between sampling months. However, as with stool water content, individual differences 
were present between participants.Participant A was shown to have significantly (P = 0.001) lower saliva 
supernatant pH than Participants C and D. Additionally, Participant A’s raw saliva pH was significantly (P 
< 0.001) lower than Participants C, D, and E. No such significant (P = 0.054) differences were evident 
FIGURE 5.3 | Stool Water Content 
Stool samples were freeze-dried and weighed every 24 hours until they reached a stable weight. Mean 
stool water content is shown by (a) participant and (b) sampling month. Significant (P < 0.001) 
differences were seen between participants, but not between sampling months. In (b), shading signifies 
activity of sampling period with orange showing baseline, green showing periods of traversing, and red 
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between the blood plasma pH of participants. Additionally, no significant differences were evident in 
regards to sampling month for saliva supernatant pH (P = 0.134), raw saliva pH (P = 0.054) and blood 
plasma pH (P = 0.432).  
 
 
FIGURE 5.4 | Saliva Supernatant, Raw Saliva, and Blood Plasma pH Levels 
Individual participant values for pH of (a) saliva supernatant, (b) raw saliva, and (c) blood plasma are 
shown for each sampling month. No discernible pattern is evident for any of the three biofluids in 
regards to sampling month, though Participant A had significantly (P = 0.001) lower saliva supernatant  
pH than Participants C and D, and significantly (P < 0.001) lower raw saliva pH than Participants C, D, 
and E. No such differences were observed between the blood plasma pH of participants. In all figures, 
shading signifies activity of sampling period with orange showing baseline, green showing periods of 
























































[ 141 ] 
5.3.3 | Changes in Salivary Microbiome 
 
To gauge changes in the salivary microbiome over the period of the TAWT expedition, both bacterial 
load and diversity was measured. The former was measured using quantitative PCR targeting the 16S 
rRNA gene, Figure 5.5. In regards to salivary bacterial load, no significant (P = 0.495) individual 
differences between participants, Figure 5.5a, was evident. However, significant (P < 0.001) differences 
were present between sampling months, with baseline samples showing lower bacterial load than at all 
other sampling points. Additionally, no relationship was shown to be present between salivary bacterial 
load and both saliva supernatant pH (R2 = 6.4%, P = 0.093) and raw saliva pH (R2 = 6.4%, P = 0.095). 
 
Bacterial diversity in the salivary microbiome was measured through amplicon sequencing of the V3 to 
V4 regions of the 16S rRNA gene. Amplicon sequencing statistics for saliva are given in Chapter 5 
Appendix, Supplementary Table 5.3, and show no significant differences between sequence number by 
participant (P = 0.326) or month (P = 0.792), or base pair number by participant (P = 0.385) or month (P 
= 0.748). However, significant differences were seen between sequence length between participants (P 
< 0.001) with Participant A having longer reads than all other participants by approximately four base 
FIGURE 5.5 | Estimated Bacterial Load of Saliva 
Means of the estimated bacterial load of saliva by (a) participant, and (b) sampling month are given. No 
significant (P = 0.495) differences were observed between participants. Significant (P < 0.001) 
differences were evident between sampling months, with the estimated bacterial load of saliva in the 
baseline sample lower than at all other sampling months. In (b), shading signifies activity of sampling 
period with orange showing baseline, green showing periods of traversing, and red showing stationary 
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pairs. No significant (P = 0.363) differences were evident between sequence length by sampling month. 
 
Bacterial diversity within the salivary microbiome was measured through α-diversity calculated by the 
MG-RAST analysis pipeline, Figure 5.6. In regards to individual differences between participants, 
Participant A was shown to have significantly (P = 0.016) lower α-diversity than Participants B, D, and E, 
Figure 5.6a. Analysis by sampling months shows that, as with salivary bacterial load, α-diversity is 
significantly (P = 0.002) lower in baseline samples than at all other sampling months. No relationship 
was observed between α-diversity and both saliva supernatant pH (R2 = 0.2%, P = 0.752) and raw saliva 
pH (R2 = 0.0%, P = 0.900). A significant relationship was however, observed between α-diversity and 
salivary bacterial load (R2 = 18.5%, P = 0.003). 
 
Using the MG-RAST online platform, principal component analysis of the salivary microbiome, using 
classifications from the RDP database, was completed, Figure 5.7. No separation was evident between 
participants, Figure 5.7a, and sampling month, Figure 5.7b.  
 
FIGURE 5.6 | α-Diversity of Salivary Microbiome 
Means of α-diversity, calculated by MG-RAST analysis pipeline, of the salivary microbiome are shown by 
(a) participants, and (b) sampling month. Participant A was shown to have a significantly (P = 0.016) 
lower mean α-diversity than Participants B, D, and E. In regards to sampling month, the baseline 
samples were shown to have a significantly (P = 0.002) lower mean α-diversity than all other sampling 
months. In (b), shading signifies activity of sampling period with orange showing baseline, green 
showing periods of traversing, and red showing stationary periods. Error bars show one standard 
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To this point, analysis of the salivary microbiome appears to suggest that changes between sampling 
months are important in determining its composition. To this end, phylum and genus-level taxonomic 
changes were analysed to identify those which significantly differed between sampling months. This 
revealed one phylum and six genera which were significantly different, Figure 5.8. At the phylum level of 
classification, Bacteroidetes was significantly (P = 0.008) lower in baseline samples than all other 
sampling months except Month 2. At the genus level of classification, Desulfotomaculum was 
significantly (P = 0.013) higher in Month 7 samples than in baseline and Month 1, 3, 5, and 8 samples. 
Veillonella was significantly (P = 0.016) lower in baseline samples than Month 1, 4, 5, 6, and 7 samples. 
Prevotella was significantly (P = 0.022) lower in baseline samples than in Month 1, 4, 5, 6, 7, and 8 
samples. Megasphaera was significantly (P = 0.041) higher in Month 5 samples than in baseline and 
Month 1 samples. Bacillus was significantly (P = 0.047) higher in Month 4 samples than in baseline, 
Month 1, 3, and 7 samples. Finally, Rothia was significantly (P = 0.047) higher in baseline samples than in 
Month 1, 3, 4, and 7 samples. Of these phylum and genus-level taxonomic changes, no discernible 
pattern was seen in regards to activity during sampling month, namely traversing or stationary.  
 
FIGURE 5.7 | Principal Component Analysis of Salivary Microbiome Composition 
Using the MG-RAST online platform, principal component analysis was completed, using taxonomy 
classifications from the RDP database, at a 97% alignment, with other parameters at default. Resulting 
plots show no discernible separation by either (a) participant, or (b) sampling month. In (b), legend 
colour signifies activity of sampling period with orange showing baseline, green showing periods of 
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FIGURE 5.8 | Significant Phylum and Genus-Level Salivary Microbiome Changes by Month 
Sampling month appears to have a significant impact on a number of salivary microbiome features. In 
regards to individual taxonomic changes, one phylum (red bars) and six genera (blue bars) showed 
significantly (* = P < 0.05, ** = P < 0.01) different levels of percentage composition, particularly in 
regards to baseline samples. In all figures, shading signifies activity of sampling period with orange 
showing baseline, green showing periods of traversing, and red showing stationary periods. Error bars 
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5.3.4 | Changes in Stool Microbiome 
 
As with the salivary microbiome, both bacterial load and diversity was measured. Bacterial load of stool 
was measured using quantitative PCR, Figure 5.9. In regards to individual changes between participants, 
no significant (P = 0.131) differences were observed, Figure 5.9a. Additionally, no significant (P = 0.867) 
differences were observed between sampling months, Figure 5.9b. No relationship was observed 
between the bacterial load of stool and stool water content (R2 = 1.2%, P = 0.473). 
 
Bacterial diversity in the stool microbiome was measured through amplicon sequencing of the V3 to V4 
regions of the 16S rRNA gene. Amplicon sequencing statistics for stool are given in Chapter 5 Appendix, 
Supplementary Table 5.4. Significant (P = 0.003) differences were seen in regards to total base pair 
numbers, with Participant A having a higher total than Participants C and E. 
 
No such significant (P = 0.946) differences were seen between sampling months. Additionally, significant 
(P = 0.003) differences were seen in total sequence number, with Participant A having a higher total 
than Participants C and E. No such significant (P = 0.946) differences were seen between sampling 
FIGURE 5.9 | Estimated Bacterial Load of Stool 
Means of the estimated bacterial load of stool by (a) participant, and (b) sampling month are given. No 
significant (P = 0.131) differences were observed between participants. Additionally, no significant (P = 
0.867) differences were evident between sampling months. In (b), shading signifies activity of sampling 
period with orange showing baseline, green showing periods of traversing, and red showing stationary 
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months. Furthermore, significant (P < 0.001) differences were seen in regards to average sequence 
length, with Participants A and B having shorter reads, by approximately one base pair, than Participants 
C, D, and E. No such significant (P = 0.993) differences were evident in regards to sampling month. 
 
The bacterial diversity of stool was analysed through α-diversity values calculated using the MG-RAST 
analysis pipeline, Figure 5.10. In regards to individual differences, significant (P < 0.001) differences were 
evident, with Participant A showing a lower α-diversity than all other participants, and Participants B 
and D showing a lower α-diversity than Participants C and E, but higher than Participant A, Figure 5.10a. 
No such significant (P = 1.000) differences were evident in regards to sampling month, Figure 5.10b. No 
significant relationship was observed between the α-diversity of the stool microbiome and stool 
bacterial load (R2 = 4.5%, P = 0.162) nor stool water content (R2 = 6.1%, P = 0.102). 
 
Using the MG-RAST online platform, principal component analysis of the composition of the stool 
microbiome was completed, Figure 5.11. Partial separation was seen in regards to participants, with 
Participants A and C showing the greatest degree of separation, Figure 5.11a. No separation was seen in 
FIGURE 5.10 | α-Diversity of Stool Microbiome 
Means of α-diversity, calculated by MG-RAST analysis pipeline, of the stool microbiome are shown by 
(a) participants, and (b) sampling month. Significant (P < 0.001) differences were observed between 
participants, with Participant A’s α-diversity the lowest of all participants, and Participants C and E’s α-
diversity the highest. In regards to sampling month, no significant (P = 1.000) differences were 
observed. In (b), shading signifies activity of sampling period with orange showing baseline, green 
showing periods of traversing, and red showing stationary periods. Error bars show one standard 
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regards to sampling month, Figure 5.11b. 
 
Analysis of the stool microbiome, through principal component analysis and α-diversity values, appears 
to suggest that individual differences between participants are more substantial factors in determining 
the composition of the stool microbiome, than any changes associated with sampling month. Thus, 
phylum and genus-level changes between participants were analysed, Table 5.2, showing a total of four 
phyla and 38 genera significantly different in at least one participant.  
 
5.3.5 | Stool, Plasma and Saliva Metabolome Changes 
 
Using negative mode LTQ-MS, principal component analysis was completed on saliva supernatant and 
raw saliva, Figure 5.12, and stool and blood plasma, Figure 5.13, with both participant and sampling 
month groupings displayed. In all four biofluids, no substantial separation can be seen in regards to 
either participant or sampling month groupings.  
  
FIGURE 5.11 | Principal Component Analysis of Stool Microbiome Composition 
Using the MG-RAST online platform, principal component analysis was completed, using taxonomy 
classifications from the RDP database, at a 97% alignment, with other parameters at default. Resulting 
plots show partial separation by (a) participant, particularly Participants A and C, but not by (b) 
sampling month. In (b), legend colour signifies activity of sampling period with orange showing 
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TABLE 5.2 | Phylum and Genus Level Differences Between Stool Microbiome of Participants 
A total of 38 genera, in four phyla, were shown to significantly differ between the five participants in 
the TAWT expedition. Significantly different genera are listed under their respective phyla (in bold) with 
groupings indicated by lowercase letters. Significant genera of unclassified taxonomy are not listed. 
 
Taxonomic Level A B C D E P Value 
Actinobacteria a a b a a < 0.001 
 
Bifidobacterium a a b a a < 0.001 
 
Collinsella a a,b b a a,b 0.001 
 
Enterorhabdus a a b a a,b 0.005 
 
Gordonibacter a a,b b a a 0.011 
 
Slackia a a b a a 0.001 
Bacteroidetes a a a b a < 0.001 
 
Bacteroides a a a b a < 0.001 
 
Barnesiella a a,b a a,c a 0.026 
 
Butyricimonas a a a a b 0.039 
 
Flavobacterium a a a a b < 0.001 
 
Odoribacter a a a b a < 0.001 
 
Parabacteroides a a a b a < 0.001 
 
Prevotella a a a,b a b 0.003 
Firmicutes a a b b b < 0.001 
 
Acetivibrio a a a a b < 0.001 
 
Aeribacillus a b a a a < 0.001 
 
Alkaliphilus a a a a b < 0.001 
 
Anaerostipes a a a a b < 0.001 
 
Blautia a,b b a a a 0.005 
 
Butyricicoccus a a a,b a b < 0.001 
 
Clostridium a a,b a,b b b 0.002 
 
Desulfosporosinus a a a,b a b 0.006 
 
Desulfotomaculum a a,b b a,b a,b 0.026 
 
Dialister a,b a a b c < 0.001 
 
Erysipelothrix a a a a b < 0.001 
 
Ethanoligenens a a,b b a a,b 0.005 
 
Eubacterium a b,c a,b c c < 0.001 
 
Faecalibacterium a,b a,b a b b 0.002 
 
Halobacillus a a b a a < 0.001 
 
Heliobacillus a a a a b 0.002 
 
Lactobacillus a a b a a 0.001 
 
Peptoniphilus a a,b b a,b a,b 0.013 
 
Roseburia a,b a,b b a,b a 0.042 
 
Ruminococcus a,d b,c b a,d d,c < 0.001 
 
Sarcina a a a a b 0.002 
 
Selenomonas a a,b a,b a b 0.027 
 
Tepidimicrobium a a a a b 0.007 
 
Thermoactinomyces a b a a a,b 0.017 
 
Tissierella a a a a b 0.003 
Proteobacteria a a a a b < 0.001 
 
Rhodospirillum a a a b a 0.015 
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FIGURE 5.12 | Principal Component Analysis of Saliva Supernatant and Raw Saliva 
Principal component analysis of negative mode LTQ-MS metabolite profiles was completed in PyChem, 
with samples classified by participant (left) and sampling month (right), for saliva supernatant (top) and 
raw saliva (bottom). Minimal variation was observed between participants, and no separation was 
observed between sampling months. In sampling month PCAs, legend colour signifies activity of 
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Participant Month
● A ● B ● C ● D ● E ● 0 ● 1 ● 2 ● 3 ● 4
● 5 ● 6 ● 7 ● 8
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FIGURE 5.13 | Principal Component Analysis of Stool and Plasma 
Principal component analysis of negative mode LTQ-MS metabolite profiles was completed in PyChem, 
with samples classified by participant (left) and sampling month (right), for stool (top) and plasma 
(bottom). For stool, some separation was evident between participants, but minimal variation was 
observed between sampling months. For plasma, some separation between participants was also 
observed, but not between sampling months. In sampling month PCAs, legend colour signifies activity 
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5.4 | Discussion 
 
The human microbiome and metabolome are both important factors in maintaining host homeostasis. 
Dysbiosis associated with either could be important indicators of disease, or factors in their aetiology. 
Therefore, understanding how both are altered by extreme environmental and physiological conditions 
could be important in understanding how the human body would be affected by prolonged space travel, 
such as a mission to Mars. In this portion of work, the expedition members of the terrestrial Trans-
Antarctic Winter Traverse, an analogous expedition to space travel, gave saliva, stool, and blood plasma 
samples over an eight month period, alongside an initial baseline sample. For all five participants, stool 
water content, biofluid pH, metabolome fingerprinting of biofluid, and bacterial load and diversity in 
saliva and stool was determined.  
 
5.4.1 | Stool Water Content and Biofluid pH 
 
Water is an essential nutrient in human health, and the most abundant compound in the human body. 
Water enters the human body through the consumption of fluid and solid food, and leaves via a number 
of pathways, including stool (Kleiner, 1999). Here, the water content of each monthly stool sample was 
determined by weight loss as a result of freeze drying. Overall, no significant differences were evident in 
regards to changes in stool water content between sampling months. Significant differences were 
however, seen between expedition members, suggesting individual differences in stool water content 
are maintained during physiological and environmental stress. The maintenance of hydration is 
important in health (Ritz and Berrut, 2005), and deviations from a person’s normal stool water content 
could be an indicator of constipation, which has important health implications (Arnaud, 2003). Although 
stool water content appears to be unconnected with sampling month, in this portion of work, it is 
possible that water loss was altered elsewhere, such as increased urine volume. 
 
As with stool water content, the pH of saliva supernatant, raw saliva, and blood plasma appears to 
maintain individual differences over the TAWT expedition, without being significantly affected by 
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sampling month. Significant differences were evident between the pH of participants’ saliva supernatant 
and raw saliva, but not blood plasma. Due to its importance in metabolic function, particularly in 
enzyme function, the lack of individual differences in blood plasma pH is not unexpected. Changes in 
salivary pH however, are linked to the activation of the sympathetic nervous system, which controls the 
fight-or-flight response (Khalaila, Cohen and Zidan, 2014). Individual differences in salivary pH were 
maintained through the TAWT expedition and no differences between sampling months were evident, 
suggesting that stress-associated changes may not have been a substantial factor. 
 
5.4.2 | Expedition Effects on the Salivary Microbiome 
 
The salivary microbiome has not been widely studied in regards to the effect that prolonged 
environmental and physiological stress may have. In this portion of work, the bacterial load and diversity 
of the salivary microbiome was determined. In regards to bacterial load, no significant individual 
differences were evident between TAWT expedition members. Significant differences were however, 
present between sampling months, with baseline samples showing a lower bacterial load than at all 
other time points. The salivary bacterial load has previously been suggested as an in vivo marker of 
immunity (Jones et al., 2014). At the time that baseline samples were donated, participants were not 
involved in the Antarctic traverse. By Month 1 however, the TAWT expedition had begun and 
participants were subjected to substantial environmental and physiological stress. The subsequent rise 
in salivary bacterial load could support the concept of it as an in vivo marker of immunity. However, 
because sample biofluids were unable to be stored at low ultralow temperatures, such as below -80°C, it 
was not plausible to accurately measure established markers of immunity, such as immunoglobulins or 
neutrophils (Vaught, 2006). If this had been possible, then establishing salivary bacterial load as an in 
vivo marker of immunity may have been possible. Salivary bacterial load has been linked, albeit not 
conclusively, to the onset of oral diseases (Dahan et al., 2004). Bacterial load has however, been linked 
to a range of respiratory diseases, including COPD (Wilkinson et al., 2003) and pneumonia (Muñoz-
Almagro et al., 2011). It may be that the increased bacterial load in saliva seen in this portion of work is 
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reflected in other portions of the respiratory tract. This could have potential implications for the health 
of participants in prolonged human space travel.  
 
The bacterial diversity of the human salivary microbiome was measured through sequencing of the V3 
to V4 region of the 16S rRNA gene. As a microbiome-wide measure of bacterial diversity, α-diversity 
values showed significant differences between participants, namely Participant A having an overall 
lower level of bacterial diversity, and sampling months, with baseline samples having lower bacterial 
diversity than all other time points. As with salivary bacterial load, the increase in bacterial diversity may 
be an indicator of altered immune function, particularly as the differences are seen in comparison to 
baseline samples and maintained through subsequent months of environmental and physiological 
stress. The role that bacterial diversity plays in the salivary microbiome is still to be established 
(Scannapieco, 2013). Some oral diseases, such as dental caries, have been linked to shifts in the 
taxonomic composition of the oral microbiome, rather than the emergence of distinct bacterial species 
(Yang et al., 2012). Therefore, the increase in bacterial diversity seen here may be an indicator of 
dysbiosis in the microbiome, which could have important implications in terms of disease, and the host’s 
health generally. 
 
Bacterial load and diversity analysis appears to suggest that sampling month is an important factor in 
determining the bacterial composition of the salivary microbiome. Therefore, changes in specific 
taxonomic classifications, namely phylum and genus, were analysed. This revealed one phylum and six 
genera which showed significantly different abundance levels between at least two time points. The 
phylum Bacteroidetes showed a significant and substantial increase from baseline samples to all other 
sampling months, from approximately 1.5% to over 10% in total abundance. The only genus of 
Bacteroidetes, to show significant differences in sampling month, was Prevotella, which also displayed a 
significant increase from baseline samples to all other sampling time points, rising from approximately 
1% to over 10% from baseline to Month 1 time points. Members of the Prevotella genus have been 
associated with a number of anaerobic infections, particularly in the oral cavity and respiratory tract 
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(Brook, 2007). Of the five other genera showing significant differences between sampling months, four 
are members of the Firmicutes phylum and one of the Actinobacteria phylum. The four members of the 
Firmicutes phylum, Desulfotomaculum, Veillonella, Megasphaera, and Bacillus, all show an increase in 
relative abundance from baseline samples to all other sampling months. The only genus to show a 
higher level of abundance in baseline samples was Rothia.  
 
This portion of work appears to be unique in that it has profiled the bacterial load and diversity of the 
salivary microbiome in participants exposed to substantial environmental and physiological stress. To 
date, the focus in this field has been on establishing microbiome changes in the gastrointestinal tract 
which may impact human health on prolonged space travel. Due to its potential to impact or reflect the 
health of the host, this portion of work suggests that the salivary microbiome of participants in 
analogous situations to human travel should also be analysed. 
 
5.4.3 | Maintenance of Individual Differences in Stool Microbiome 
 
The human stool microbiome has been the focus of studies involving analogous situations to prolonged 
human space travel, including both human and animal-model studies. The stool microbiome of 
participants in the Mars-500 study, similar to the TAWT expedition, showed a substantial degree of 
stability in terms of function and maintenance of host health, albeit with some taxonomic changes 
(Mardanov et al., 2013). 
 
In this portion of work, the stool microbiome in both bacterial load and diversity showed a similar 
degree of stability, with individual differences between expedition members appearing to outweigh any 
alteration caused by sampling month. In regards to stool bacterial load, no significant differences were 
evident between participants or sampling month. Bacterial diversity in the form of α-diversity measures 
however, did show significant differences between participants, though no such differences were 
evident between sampling months. Decreased diversity of the intestinal microbiome, as represented by 
stool in this portion of work, has been associated with increased risk of developing intestinal conditions 
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including diarrheal disease (Bik and Relman, 2014), inflammatory bowel disease (Kinross, Darzi and 
Nicholson, 2011), and Crohn’s disease (Clemente et al., 2012). Therefore, the maintenance of bacterial 
load and diversity in the stool microbiome during the TAWT expedition suggests that participants were 
not at an increased risk of developing gastrointestinal disorders. With prolonged human space travel, 
such as a manned mission to Mars, the gastrointestinal microbiome would be subjected to substantial 
amounts of radiation. In mice, this has been shown to significantly alter the host’s microbiome at both 
LD50 and LD30 levels (Karouia et al., 2014). Although TAWT expedition members were not subjected to 
such radiation, the maintenance of stool bacterial diversity displayed does suggest its stability under 
substantial environmental and physiological conditions. 
 
In addition to measures of bacterial diversity, namely α-diversity, macro level changes in the stool 
microbiome were modelled using principal component analysis. This supported previous results that 
individual differences are more substantial in determining the taxonomic composition of the stool 
microbiome than those resulting from sampling month. Principal component analysis by participant 
showed that Participants B and C were the most separate, though separations between Participants A, 
D, and E were also evident. 
 
Due to the stool microbiome showing significant differences between participants, rather than sampling 
month, individual taxonomic differences were explored at the phylum and genus level of classification. 
This revealed a total of 38 genera, in four phyla, which showed significantly different abundances in at 
least one member of the TAWT expedition when compared to other members. The Bacteroidetes and 
Firmicutes phyla, which are usually the main constituents of the human gut microbiome (Lozupone et 
al., 2012), displayed the greatest number of genera with significant differences between participants. 
The maintenance of these individual differences through the TAWT expedition suggest that they are an 
important component of stability and homeostasis in the gut microbiome, and that they are determined 
by other factors not including environmental and physiological stress.  
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Overall, the stool microbiome in the five TAWT expedition members appears to be highly stable, in 
terms of both bacterial load and diversity. Individual differences appear to be paramount in determining 
bacterial diversity, which persists even through sampling months where environmental and 
physiological stressors are extreme, with no overall difference in bacterial load between participants or 
sampling months. In a range of gastrointestinal diseases, and in general health, the human gut 
microbiome is clearly an important component. For some conditions, one of the key characteristics is a 
reduction in overall bacterial diversity in the gut (Kinross, Darzi and Nicholson, 2011). Here, bacterial 
diversity in the stool, shown through α-diversity, is significantly different between participants. The 
highest measure of α-diversity, in Participant C, was over twice that of the lowest measure, in 
Participant A. In terms of risk assessment for prolonged human space travel, the starting bacterial 
diversity in an individual’s gut could potentially be used as a discriminating factor in selection of 
participants to reduce the likelihood of gastrointestinal issues during the mission. 
 
5.4.4 | Stability of the Saliva, Stool and Plasma Metabolome 
 
The metabolome of the four biofluids studied in this portion of work, using negative mode LTQ-MS, 
suggest that there is no overall difference between participants or sampling month. This suggests that 
there was no substantial, macro-level change in the metabolome of saliva, stool, or blood plasma 
samples from the five TAWT expedition members. Previous studies of the plasma metabolome in 
particular have suggested changes in certain metabolites associated with age, sex and race (Lawton et 
al., 2008). Therefore, small level changes in the metabolome may have occurred as a result of the TAWT 
expedition, but because of the inherent similarities in participants, these were obscured. 
 
The plasma metabolome has been shown to be altered by levels of physical fitness (Chorell et al., 2012). 
Given that TAWT expedition members were of a similar level of physical fitness, to be able to meet the 
challenges posed by Antarctica, this could further obscure differences in the metabolome resulting from 
altered metabolism to maintain homeostasis. It may be that a more valid method of measuring changes 
in the human metabolome, either between participants or sampling month, would be to look at changes 
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in levels of individual metabolites. However, because of the sample size relative to the total number of 
metabolite peaks measured using negative mode LTQ-MS, the high rate of Type I statistical errors would 
make the subsequent findings unreliable (Broadhurst and Kell, 2006).  
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5.5 | Conclusions and Future Work 
 
This portion of work aimed to take advantage of the undertaking of the TAWT expedition, which served 
as a unique opportunity to study human microbiome and metabolome changes in an analogous 
situation to prolonged human space travel, such as a manned mission to Mars. The TAWT expedition 
was ultimately unsuccessful in its intention to cross Antarctica during the winter months. Nevertheless, 
the extreme environmental and physiological stressors that expedition members experienced were still 
useful in modelling human microbiome and metabolome changes. 
 
In regards to changes in the human microbiome, salivary bacterial load and diversity both increased 
markedly from baseline samples to the eight monthly samples collected during the TAWT expedition. 
Salivary bacterial load has previously been suggested as an in vivo marker of immune function, and it 
may be therefore, that immune function in TAWT expedition members was lowered, allowing for the 
observed increasing in bacterial load, and diversity. However, because the method of microbiome 
profiling employed here is unable to resolve taxonomic classification to the species level, it is difficult to 
conclude what effects these changes may have on host health and homeostasis. 
 
The metabolome of saliva, stool and blood plasma showed no substantial differences between 
participants or sampling month. Stool water content, and the pH of raw saliva and saliva supernatant 
showed significant individual differences. However, analysis of changes in the human metabolome may 
have been hampered by the small sample size associated with the TAWT expedition. 
 
Although this portion of work was limited by the relatively small sample size of participants, it has 
nevertheless created a framework on which subsequent studies into the real or analogous effect of 
prolonged human space travel can build upon. In regards to microbiome changes, subsequent work 
aiming to classify the saliva and stool microbiome in terms of its species-level composition and 
functional capacity could provide novel insights. Additionally, work on the analysis of individual 
metabolites, which would only be possible with larger sample sizes, is likely to provide useful insights.  
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CHAPTER 6 | General Discussion and Conclusions 
 
The human microbiome and metabolome have been shown to be important components in disease, 
from aetiology to diagnosis, monitoring to treatment. In this research project, the aims were to address 
unanswered questions in both fields; and to combine the two to establish whether changes in one could 
explain changes in the other. The portions of work completed here are clearly divided into ones with a 
clinical application, Chapters 2 and 3, and those which answer more basic research questions, Chapters 
4 and 5. Nevertheless, the tools and techniques which were developed during the Chapters with clinical 
applications could be easily applied to those answering basic research questions. 
 
6.1 | Novel Insights in the Diseased Lung Microbiome and Metabolome 
 
This research project was started with the intention of using metagenomic and metabolomic techniques 
to address unmet clinical needs that exist within the respiratory diseases lung cancer and COPD. The 
field of microbiomics is approximately ten years old, but little focus has been given to the lung 
microbiome; rather the gut microbiome has received the majority of the field’s attention (Dickson, Erb-
Downward and Huffnagle, 2013). Lung cancer in particular has only a few published studies on the lung 
microbiome in affected patients (Hosgood et al., 2014; Laroumagne et al., 2013; Koshiol et al., 2012).  
 
One of the primary aims of this research project was to address this using metagenomic sequencing, 
allowing the species-level resolution and functional capacity of the lung microbiome in lung cancer and 
COPD patients, represented by sputum samples, to be established. Additionally, sputum samples from 
lung cancer patients were to be analysed using metabolomic fingerprinting to identify non-invasive 
biomarkers for earlier detection of the disease. 
 
In these regards, the project was successful. Albeit using a relatively small sample size, significant 
differences in both taxonomic composition and functional capability between lung cancer positive and 
lung cancer negative patients were detected. The use of this patient group is one of the key strengths of 
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the study. Lung cancer can present with a range of non-specific symptoms, which are shared with other 
non-cancerous lung conditions. Therefore, the ability to distinguish between patients with similar 
symptoms, but dissimilar causes, could have significant clinical implications. This was shown to be 
possible through analysis of specific features of the lung microbiome and metabolome. The apparent 
ability of the lung cancer microbiome to mirror disease staging, through levels of G. adiacens relative to 
six other bacterial species, using a non-invasive sampling method could aide in the monitoring of the 
disease without additional invasive procedures. However, the small sample size of patients, all of whom 
had NSCLC types, used in this pilot study potentially limits its future applicability to SCLC types. Further 
metagenomic sequencing with a larger patient cohort would be required to confirm whether these 
microbiome changes hold true. Nevertheless, in a clinical application a technique, such as quantitative 
PCR, which requires less resources could be utilised as a diagnostic tool. If sputum were to continue as 
the sampling biofluid, rather than the more invasive BAL or biopsy method, this could act as a non-
invasive diagnostic or screening method; bringing the prospect of a targeted, at-risk population screen 
closer. 
 
Using a larger sample cohort, metabolomic fingerprinting, whereby the structures of individual 
metabolites are not determined, identified a range of metabolites which are able to differentiate 
between patients positive and negative for lung cancer, but presenting with suspected lung cancer 
symptoms. As with microbiome-derived biomarkers, metabolomic fingerprinting allows for a potentially 
high-throughput, non-invasive method of diagnosis and screening. Nevertheless, this portion of work 
used a relatively small sample size. To support the use of mass-spectrometry metabolomics, and the use 
of sputum as a diagnostic medium, applicability of these findings to a larger cohort would need to be 
determined. Furthermore, the cohort used in this study contained a mix of lung cancer types, NSCLC and 
SCLC, and sub-types thereof, of varying disease stages. By using a larger cohort in further studies, the 
ability of mass-spectrometry metabolomic fingerprinting to differentiate between disease type and 
stage could be established. Because the biomarkers discovered in this portion of work are derived from 
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sputum, it is possible that the two approaches can be combined to increase the sensitivity and 
specificity rates of using sputum as a non-invasive medium for diagnosis and screening.  
 
Chronic obstructive pulmonary disease is one of the few respiratory diseases that has received attention 
in regards to the lung microbiome in patients. However, these studies have used amplicon sequencing 
of the 16S rRNA gene to characterise the taxonomic composition of the microbiome (Erb-Downward et 
al., 2011; Pragman et al., 2012; Sze et al., 2012). Although amplicon sequencing can give an overview of 
microbiome composition, it is limited in its ability to resolve bacteria to the species level of taxonomy, 
nor is it able to identify the functional capability of the microbiome. In this research project, the lung 
microbiome of patients with and without COPD was sequenced using metagenomics. This revealed both 
taxonomic and functional characteristics which differentiated the COPD microbiome, which could 
explain some of the clinical features of the disease including the rapid increase in bacterial load during 
exacerbations. When individual features of the lung microbiome in COPD were correlated with COPD 
severity, sialic acid metabolism was shown to have a positive correlation with FEV1 % of predicted. Sialic 
acid is an important component of the inflammatory response, which is characteristic of COPD. This 
suggests that the lung microbiome in patients with COPD has a close interaction with the host’s sialic 
acid, which could be an important mechanism in the pathogenesis of the disease. It could also provide a 
novel mechanism for therapeutic interventions and disease monitoring. However, as with the lung 
cancer microbiome and metabolome work, this study used a relatively small sample size, and further 
metagenomic sequencing of the lung microbiome in more COPD patients is required. Additionally, an 
important component of COPD is exacerbation of the condition, which is the common cause of death 
and worsening morbidity. This was not measured during this study. Longitudinal sampling of COPD 
patients would however, be able to establish whether the lung microbiome, as suggested here, was able 
to influence the progression of the disease. For example, the lung microbiome’s capacity for rapid 
bacterial cell division and increased bacterial load could be used as a method for predicting a patient’s 
risk of exacerbation. 
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6.2 | Temporal Variability of the Salivary Microbiome and Metabolome 
 
One of the key questions in microbiome and metabolome research is whether they are stable over a 
prolonged period of time. This is of paramount importance where features of the microbiome and 
metabolome are used as biomarkers, for the screening, diagnosis, or monitoring of disease. In this 
portion of work, the salivary microbiome and metabolome, chosen because of the ease of sampling 
saliva, was monitored over a one year period, with samples taken every two months. Although other 
microbiome studies have studied the temporal variability of the human microbiome (Costello et al., 
2009), this has been over a relatively short period, frequently less than one month, or over long periods 
of time with large temporal gaps in sampling time points. However, if microbiome and metabolome 
biomarkers are to be used clinically, their variability over a yearly period needs to be determined. To this 
end, the portion of work outlined in Chapter 4 of this thesis has suggested that the salivary microbiome 
and metabolome is stable over a one year period, although bacterial load was significantly higher in the 
February sampling period than at all others.  
 
This portion of work appears to be the first in the literature to longitudinally track the salivary 
microbiome and metabolome over a one year period, and to suggest that it is stable, except from the 
one variation in bacterial load seen in February. Due to limited resources being available for sequencing 
of the microbiome, metagenomic sequencing of all samples was not possible and amplicon sequencing 
of the 16S rRNA gene was chosen. This still gives a novel insight into the salivary microbiome, and 
indeed is still the most common method of microbiome sequencing in the literature (Caporaso et al., 
2012). Nevertheless, amplicon sequencing is unable to resolve to the species-level of taxonomy and it 
may be that temporal differences in the salivary microbiome are evident. Additionally, a large number of 
sequences from the salivary microbiome were of unclassified taxonomy. This is likely an issue with the 
difficulty in culturing bacteria from the human microbiome, and thus whole genome sequencing of 
isolated species has not been possible, leaving gaps in sequence databases. Undoubtedly, this will be 
solved by advances in culturing methods of bacteria (Vartoukian, Palmer and Wade, 2010), and by 
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improvements in our bioinformatic ability to assemble the genomes of mixed cultures into individual 
bacterial species, possibly through the use of single-cell genomics (Chitsaz et al., 2011). 
 
6.3 | White Mars – Stressing the Microbiome and Metabolome 
 
Stress has a number of effects on the human body, and can be detrimental to health if homeostasis is 
unable to be maintained. An emerging area of research in the fields of microbiomics and metabolomics 
is how they are affected by stress, and if they are able to modulate the body’s response to it. One such 
application of this emerging field is to prolonged human space travel, such as a manned mission to 
Mars. As an analogy to such a mission, the microbiome and metabolome of members of the TAWT 
expedition was monitored. The salivary microbiome showed significant changes between sampling 
months, whilst the stool microbiome showed the maintenance of individual differences throughout the 
expedition. Changes in the metabolome of saliva, stool, and blood plasma were not evident.  
 
The seasonal variability of the salivary microbiome, as described in Chapter 4, suggests that the 
difference between sampling months during the TAWT expedition are as a consequence of the extreme 
physiological and environmental stress participants endured. To date, the focus of studies on how the 
human microbiome is affected by environmental and physiological stress has been the gastrointestinal 
tract. In this portion of work, spatial differences within the human microbiome have been shown 
suggesting the salivary microbiome changes as a result of environmental and physiological stress. 
Because the method of microbiome profiling employed, it is not possible to identify the species level 
changes within the microbiome; which may be able to reveal further novel information regarding the 
human microbiome’s response to stress. 
 
The TAWT expedition was a unique opportunity to monitor the effects of extreme physiological and 
environmental stress on the human microbiome and metabolome. Nevertheless, there were 
unavoidable weaknesses in its design; primarily the small, and limited to men, sample size. Additionally, 
the lack of resolution to the species-level of taxonomy, and the classification of the functional capability 
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of the microbiome may mean that changes in the stool microbiome, which appeared overall stable, 
were not possible to establish. Indeed, the functional capability of the stool may be a key component in 
the development of gastrointestinal disease (Qin et al., 2010). 
 
6.4 | Linking Microbiomics and Metabolomics 
 
One of the aims of this study was to combine profiling of the human microbiome and metabolome to 
reveal novel insights into both, and determine the extent to which changes in one could be explained by 
changes in the other. Overall, this has not been accomplished in this portion of work. 
 
In regards to the lung cancer and COPD microbiome and metabolome work, insufficient sample was 
available to allow for profiling of both. This meant that generating microbiome and metabolome profiles 
of sputum from the same patient was not possible, and therefore, any link between the two could not 
be established.  
 
When the generation of microbiome and metabolome profiles from the same sample, such as in 
Chapters 4 and 5, was possible, changes in the microbiome did not appear to be explained by changes in 
the metabolome. Whilst charting the seasonal variability of the salivary microbiome for example, only 
seven genera were correlated with at least one metabolite. Although significant, these correlations were 
likely artefacts of the genera’s low abundances. Within the White Mars portion of work, the sample size 
was determined to be too small to allow for statistically valid analysis between the microbiome and 
metabolome profiles generated.  
 
Now that the field of microbiomics is moving towards a stronger focus on characterising the functional 
capacity of microbiomes, it is likely that metabolomics as a tool will be widely used. One of the key roles 
that metabolomics will play in understanding the human microbiome will be in analysing its metabolic 
products. The gut microbiome in particular has been shown to be enriched with genes that are adapted 
to the specific sources of energy that will be found there. However, the production of specific 
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metabolites by bacteria or the modulation of the host’s metabolites may be an important component of 
diseases, such as Type II diabetes, which would not be realised through sequencing of the microbiome 
alone (Turnbaugh and Gordon, 2008). 
 
6.5 | Separating Correlation and Causation 
 
Changes in the taxonomic composition and functional capabilities of the human microbiome have been 
linked to a number of diseases (Cho and Blaser, 2012). In this research project, lung cancer has been 
linked to both and COPD to the microbiome. In COPD for example, the role that sialic acid metabolism 
may play is somewhat ambiguous, but could be fundamental in disease progression. However, because 
of the observational nature of both the lung cancer and COPD microbiome studies, only correlation and 
not causation can be established. 
 
The issue of separating correlation and causation is not unique to this research project. In fact, it is one 
of the main issues facing the field of microbiomics. Although some diseases have been clearly linked to a 
microbial cause, such as Helicobacter pylori infection and gastric cancer (Uemura et al., 2001), clearly 
linking disease-related changes in the microbiome with causing the disease itself is difficult without 
intervention studies. One approach which may prove effective is the use of model organisms. Although 
not all human diseases can be studied in a model organism, such as Mus musculus, many can. 
Additionally, the genetics of the model organism in relation to specific diseases is well understood, and 
the increasing commercial availability of germ-free M. musculus strains allows for intervention studies 
to be more widely completed. Nevertheless, intervention studies using model organisms may suffer 
from issues with translation to clinical intervention, but may still allow for a better understanding of 
disease dynamics (Cho and Blaser, 2012). 
 
One of the key principals in microbiology is that of Koch’s postulates, the four criteria which have to be 
met in order for the causative agent of a particular disease to be identified, and this will have to be 
applied to the field of microbiomics to fully separate cause and effect (de Vos and de Vos, 2012). 
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However, it may be that Koch’s postulates do not hold true in all diseases linked to the microbiome. 
Because of its foundation in infectious disease, Koch’s postulates focus on the identification of a single 
causative agent, such as a bacterium. It may be however, that certain diseases are caused by changes in 
more than one microbial species with a synergistic relationship. 
 
6.6 | The Effect of Sample Choice, Storage, and Extraction 
 
In studies of both the human microbiome and metabolome, the choice of sample is important. For 
example, it has been shown that sputum and BAL samples represent different spatial regions of the lung 
(Cabrera-Rubio et al., 2012b), and therefore comparisons drawn between studies employing different 
sampling biofluids are likely to be limited. 
 
Once the biofluid for sampling has been chosen, it may be that the methods for sample storage can 
impact upon the reliability and reproducibility of results. Analysis using NMR spectroscopy of the 
stability of human urine under room temperature (22°C), refrigeration (4°C), and deep-freeze (-80°C) has 
shown that approximately 50 metabolites change in concentration in room temperature and 
refrigerated samples, whilst those in samples in deep-freeze appear stable. This is may be as a result of 
bacterial contamination of the urine (Saude and Sykes, 2007). 
 
Unlike the urine metabolome which shows different temporal changes depending on storage 
temperature, the microbiome of sputum from cystic fibrosis patients appears to be stable when a 
sample is stored at 4°C, -20°C or -80°C, but variation is introduced when the sample is stored at room 
temperature (approximately 25°C) (Zhao et al., 2011). 
 
For both microbiome and metabolome studies, sample storage at below 0°C appears to preserve the 
integrity of the sample. As both fields move towards increased standardisation of methods, sample 
storage conditions are likely to be fundamental in ensuring reproducibility and comparisons between 
studies are possible. However, the effect of long-term sample storage has not been firmly established. 
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Some biological assays, such as those measuring levels of thyroid hormones, sex hormones, and 
cytokines, have been successfully carried out on serum samples which have been stored for between 30 
and 40 years (Jones and Golding, 2009). However, many longitudinal studies provide samples for 
analysis using technologies and techniques which were not available at its initiation. This may result in 
all of the samples from one longitudinal study being analysed in one batch, and therefore, any effect 
caused by sample storage duration would be difficult to establish. 
 
In the body of work detailed here, a number of potential biomarkers derived from both the lung 
microbiome and metabolome have been identified. Although it appears that in samples stored at low 
temperatures, such as -80°C, the metabolome and microbiome profile is stable, it may be that variation 
is introduced within a particular microbial taxon or metabolite. Therefore, for any potential biomarker 
to be introduced into a clinical setting, it may be that the stability of individual biomarkers during 
storage needs to be established to ensure the reliability of a biomarker assay. 
 
In studies of both the human microbiome and metabolome, the choice of extraction method for either 
DNA or metabolites respectively is important. For DNA extractions, a range of commercial kits and 
established laboratory techniques employing user-made buffers are available (Willner et al., 2012a). 
Commercially available DNA extractions kits have been shown to vary in the estimated recovery of total 
genomic DNA from as little as 1% to up to approximately 40%, though reproducible profiles of bacterial 
communities may be possible between kits that employ bead-beating and lysis extraction methods 
(Vishnivetskaya et al., 2014). Furthermore, analysis of bacterial community structure has been shown to 
be influenced by biological variation over technical variation in both human gut (Wagner Mackenzie, 
Waite and Taylor, 2015) and respiratory tract (Willner et al., 2012a) samples. However, for samples of 
microbial communities with low biomass, it may be that DNA contamination present within 
commercially available kits introduces a more significant degree of technical variation, which may hinder 
the reproducibility of a study, and its comparison to others (Salter et al., 2014) 
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Due to differences in sensitivity and detection range the choice of analysis method in metabolomic 
studies, such as between NMR or MS based approaches or different methods within each of these 
approaches, is likely to affect the view of the metabolome studied (Fiehn et al., 2007). However, before 
samples can be analysed using either NMR or MS based approaches, an extraction must be completed; 
and the extraction method employed may also affect the view of the metabolome studied (Vuckovic, 
2012). Extractions methodologies are usually based on solvents, such as ethanol, methanol, or 
chloroform, physical disruption, such as sonication or bead beating, or temperature, such as multiple 
freeze-thaw cycles. These various methods have been shown to not only extract differing numbers of 
metabolites, but also differing levels of the same metabolite from the same sample (Duportet et al., 
2011). This could have a significant effect on the biological interpretation of metabolomic based studies. 
 
In this body of work, a number of biomarkers derived from the lung sputum metabolome have been 
suggested as having the potential to clinically discriminate patients with and without lung cancer. 
However, it is possible that unless the same method of chemical extraction is used, these metabolites 
may not be extracted with the same level of efficiency, and therefore, their discriminatory power may 
be limited. As the field of metabolomics moves towards standardisation, it may be that findings need to 
be reproducible on more than one platform of metabolomic profiling, such as GC-MS and LC-MS (Fiehn 
et al., 2007). In addition to this, it may be that for findings to be valid the results have to be reproducible 
using more than one extraction methodology. 
 
6.7 | Opportunities from Emerging Technologies 
 
Advances in the capability of microbiome research can be directly correlated with advances in the 
capability of DNA sequencing, with the advent of high-throughput, next-generation sequencers, such as 
Roche’s 454, being the initial catalyst. It is likely therefore, that future advances in the capability of 
microbiome research will be as a result of advances in sequencing technology. For example, nanopore 
DNA sequencing, such as Oxford Nanopore’s pilot system, allows for substantially longer reads, with 
higher accuracy rates, than current sequencing systems (Bahassi and Stambrook, 2014). The use of this 
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system should allow for the sequencing of whole bacterial genomes, from a mixed microbial population, 
with sequence reads sufficient to allow for in silico genome assembly.  
 
As a field, microbiomics is usually studied through the sequencing of isolated DNA. However, sequencing 
only reveals the potential metabolic functions of the microbiome, and does not give an understanding of 
how these may be altered under periods of stress, or disease. By combining metagenomic sequencing 
with other ‘OMIC technologies, such as transcriptomics, proteomics, metabolomics, and lipidomics, for 
example, will allow for a measure of how the genetic and metabolic capacity of the microbiome 
translates in vivo (Serino, 2012). 
 
The majority of research conducted into the human microbiome focuses on its bacterial component. 
This approach, however, fails to appreciate other microbial constituents, including eukaryotic microbes, 
protozoa, archaea, and viruses. The study design and analysis pipeline for these microbes is somewhat 
different than for bacteria. In regards to eukaryotic microbes, for example, no standardised marker gene 
exists and sequence databases are somewhat limited. In viruses particularly, no gene or genomic region 
is found across all viruses. Therefore, sequencing them alongside other microbiome constituents is not 
possible, and fractionation of virus-like particles is required. Many of the issues associated with the non-
bacterial element of the microbiome will likely be solved through advances in sequencing, bioinformatic, 
and sequence repositories (Goodrich et al., 2014). 
 
6.8 | Developing Bioinformatic Capabilities and Techniques 
 
Advances in our understanding of the human microbiome have largely been as a result of developments 
in sequencing capability. However, the rapidly increasing amount of data generated through sequencing 
studies needs to be matched by our ability to computationally and statistically analyse it (Chan and 
Ragan, 2013). This requirement is leading to the development of novel analysis pipelines and 
approaches. For example, in microbiome studies relying on sequencing of the 16S rRNA gene for 
taxonomic assignment, the issue of gene copy number may affect the reliability of quantitative 
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information. As a result, the tool CopyRighter has been developed to correct 16S rRNA amplicon 
microbiota profiles and quantitative abundances. This has been suggested to improve the comparability 
between amplicon and metagenomic data sets, and to improve estimates of bacterial diversity (Angly et 
al., 2014). 
 
The bacterial diversity of the microbiome’s taxonomic composition has been one of the primary 
methods of analysis within the field. In this body of work, the measure of α-diversity, calculated by the 
MG-RAST pipeline using the Shannon diversity index, was frequently employed. This is a measure of the 
species richness within a given sample, namely, the higher the diversity value, the higher the number of 
bacterial species. For determining α-diversity, the Shannon and Simpson diversity indices are the two 
common methods employed. These two methods have been shown to have similar characteristics, but 
differ in the contribution of low-abundance taxa. Alternatives to these diversity indices include the Tail 
statistic, which shows greater sensitivity to low abundance taxa (Li et al., 2012). 
 
As with all other bioinformatic analysis techniques, choosing the appropriate tool is key in ensuring valid 
conclusions are drawn from a data set. In regards to diversity measurements, the Shannon and Simpson 
diversity indices may be more appropriate for some microbial communities, whilst the Tail statistic may 
be more useful when exploring communities with a high number of low abundance bacterial species. 
 
The focus of bacterial diversity in microbiomics has been on taxonomic composition of the microbiome. 
However, as metagenomic sequencing becomes more prominent within the field, measures of 
community diversity may need to be developed to take in to account the greater detail and scope 
achieved using metagenomics. For example, these data sets allow for the diversity of not only 
taxonomy, but also of gene diversity, genotype diversity, phylogenetic diversity, evolutionary diversity, 
functional diversity, and structural diversity (Xu, 2006). It may be that for some diseases associated with 
dysbiosis in the human microbiome, gene diversity is a better measure than taxonomic diversity in 
terms of disease diagnosis or risk assessment. 
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With the cost of metagenomic sequencing declining, it is becoming a more accessible tool for analysis of 
the human microbiome. As a result, very large datasets are being created for each study, which 
increases the computational burden of sequence analysis. In addition, because metagenome sequencing 
usually take a shotgun approach, host sequence contamination is a more substantial issue than in 
amplicon sequencing. As a result, tools such as BMTagger have been developed to remove human reads 
from metagenomic datasets, which reduces the size, and thus computational requirements, of sequence 
files, and protects the identify of study participants (Gevers et al., 2012). 
 
For analysis of metagenomic sequence data, the assembly process is arguably one of the key steps. The 
Human Microbiome Project initially compared six assembly strategies and failed to identify one method 
with superior results (Gevers et al., 2012). However, as the range of sequencing platforms has increased, 
each with its own advantages and drawbacks, assembly platforms have been developed to meet the 
specifications of each and the scope of the sequencing study. For example, the assembler Velvet has 
been developed for genome assemblies using Illumina, SOLiD, 454, and Sanger platforms, whilst 
ALLPATHS-LG is suited to Illumina and Pacific Biosciences platforms only. For metagenome assemblers, 
MetaVelvet, based on the Velvet genome assembler, has been developed for most sequencing 
platforms, whilst Genovo is specific to 454 pyrosequencing, and Meta-IDBA to Illumina only (The Human 
Microbiome Consortium, 2012a). 
 
In comparison to amplicon sequencing datasets, metagenomic sequencing projects are able to reveal 
the metabolic and functional capacity of the human microbiome. However, this requires differing 
analysis pipelines to amplicon sequences, though methods in metagenomic sequence analysis are 
similar, in part, to those employed in whole genome studies. There are four main categories of methods 
employed in metagenomic sequence analysis to identify the functional assignment of genes. Firstly, 
homology-based approaches, which are used by the MG-RAST pipeline (Meyer et al., 2008), are the 
most common. The other approaches include Motif- or pattern-based approaches, context-based 
annotation, and specific function approaches (Prakash and Taylor, 2012).  
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Metagenomic sequencing usually employs a shotgun-based approach, and because currently the widely 
used sequencing platforms, such as Illumina, are only able to generate short reads, the accuracy of gene 
prediction may be limited. With the increasing use of single cell genomics (Rinke et al., 2013) and whole 
genome sequencing of bacterial isolates, this issue should be addressed. As it stands, metagenomic 
sequencing using current technology is likely to only be able to give a snapshot of the functional capacity 
of the microbiome, and is unlikely to be able to assign gene function to bacterial species (Prakash and 
Taylor, 2012). 
 
Due to the limitations of the commonly employed sequencing platforms, which use short sequence 
reads, studies into the taxonomic composition of the human microbiome have been somewhat limited 
by the difficulty of resolving community structure to the species level. Indeed, this challenge is likely to 
be one of the key steps in moving beyond only the description of the microbiome and is becoming 
increasingly accessible through the use of metagenomic sequencing. The ability to resolve microbiome 
constituents to the species level of taxonomy will allow for a greater understanding of the evolutionary 
history of the microbiome. This will however, likely require a novel approach to the application of 
traditional evolutionary and ecological theory (Losos et al., 2013). 
 
During the analysis of metagenomic data sets, one of the key components is the prediction of gene 
function, and the assignment of the taxonomy of that gene. Currently, the main method of determining 
this is through similarity, such as using the BLAST algorithm. However, this approach can suffer from a 
number of drawbacks. For example, determining whether the sequence similarity between a gene of 
known function and a gene of unknown function is biologically significant is difficult. An alternative 
concept to assigning gene function based on similarity searches is that of using relatedness rather than 
similarity (Eisen and Wu, 2002). 
 
The application of phylogenomics, which is the study of evolutionary relationships based on the 
comparative analysis of whole genome data, offers an alternative to traditional alignment-based 
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approaches to improve our understanding of the microbiome in terms of species relatedness and 
evolution. However, because the bacterial genomes which have, to date, undergone whole genome 
sequencing have been chosen because of their physiology, a highly biased phylogenetic distribution 
exists. Further whole genome sequencing of bacterial isolates, chosen because they cover a wide range 
of phylogenies, has recently been shown to allow for the discovery of novel protein families, improved 
gene function prediction, and the reconstruction of phylogenetic histories (Wu et al., 2009). 
 
The application of phylogenomics to metagenomic datasets requires significant computational 
resources, and it is plausible that with next-generation sequencing technology, traditional 
phylogenomics techniques may no longer be feasible. However, as with other bioinformatics techniques 
in microbiomics, those employed in phylogenomics are being adapted and developed for the 
characteristics of next-generation sequencing platforms. For example, phylogenomics has traditionally 
focussed on the use of multiple sequencing alignments for analysis. However, this technique is 
computationally intensive and may be infeasible for large datasets. As an alternative, alignment-free 
methods are being developed, such as those which employ k-mers, to reduce the requirement for 
intensive computation (Chan and Ragan, 2013). 
 
To date, the field of microbiomics has developed concurrently with developments and advances in 
sequencing platforms. This is likely to continue to be the case for the foreseeable future, and 
additionally, the development of bioinformatic pipelines and analysis tools will be fundamental in 
exploiting advances in sequencing technologies. However, as the field expands to move beyond a 
descriptive account of the microbiome’s constitution and functional capacity, there is likely to be a much 
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7.1 | Chapter 2 Output 
 
A range of outputs were created as a result of the work detailed in Chapter 2. These are detailed here, 
including manuscript abstracts and graphical representations of posters for scientific conferences. 
 
7.1.1 | Lung Cancer Microbiome Publication 
 
Simon J. S. Cameron, Keir E. Lewis, Sharon A. Huws, Matthew J. Hegarty, Paul D. Lewis, Luis A. J. Mur, 
Justin A. Pachebat. (2015) Metagenomics of Lung Cancer Microbiome Suggests Granulicatella adiacens 
as a Biomarker for Status and Stage. Under Review at Scientific Reports. 
 
ABSTRACT | Little is known about bacterial species-level composition and the functional capacity of the 
microbiome in patients with lung cancer (LC). Spontaneous sputum samples were collected from ten 
patients referred with possible LC, of which four were eventually diagnosed with LC (LC+), and six had no 
LC after 1 year (LC-). Genomic DNA was isolated and Nextera® metagenomic libraries constructed and 
sequenced on the HiSeq 2500 platform, with resulting sequences analysed using the MG-RAST 
metagenomic pipeline. Principal component analysis of taxonomic alignments showed some separation 
between LC+ and LC-, and was not influenced by smoking status. Of the seven bacterial species found in 
all samples, Streptococcus viridans was significantly higher in LC+ samples. Seven further bacterial 
species were found only in controls, and 16 were found only in samples from LC+. Additional taxonomic 
differences were identified in regards to significant fold changes between LC and controls cases, with 
five species having significantly higher abundances in LC+. Functional differences, evident through 
significant fold changes, included polyamine metabolism and iron sidrephore receptors. Regression 
analyses correlated Granulicatella adiacens abundance with six other bacterial species in LC+ samples. 
Further, bacterial species could also be related to LC stage. This study offers a novel insight into the 
functional capacity and species-level taxonomy of the sputum microbiome in patients with LC. 
Furthermore, it suggests G. adiacens as a novel and clinically useful biomarker for LC diagnosis and 
possible staging.  
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7.1.2 | Lung Cancer Metabolome Publication 
 
Simon J. S. Cameron, Keir E. Lewis, Manfred Beckmann, Gordon G. Allison, Robin Ghosal, Paul D. Lewis, 
and Luis A. J. Mur. (2015) Metabolomic Fingerprinting of Clinical Sputum for Lung Cancer Biomarkers. 
Manuscript in Preparation. 
 
ABSTRACT | Developing novel screening and diagnosis methodologies will allow for earlier diagnosis of 
lung cancer, increasing the effectiveness of clinical interventions. We tested the potential of 
metabolomic fingerprinting on sputum to differentiate between patients with and without lung cancer. 
We collected and processed the spontaneous sputum of 34 patients with suspected lung cancer, 
alongside 33 healthy controls. Of the 34 patients, 23 were subsequently diagnosed with lung cancer (16 
NSCLC, six SCLC, and one radiological diagnosis) at various stages of disease progression. The 67 samples 
were analysed using linear quadrupole ion mass spectrometry (LTQ-MS) and gas-chromatography mass 
spectrometry (GC-MS). Principal component analysis clearly separated the clinically and non-clinically 
acquired samples using metabolites identified in negative LTQ-MS mode. Further, hierarchical cluster 
analysis, based on the top 25 metabolites identified through one-way ANOVAs in negative LTQ-MS 
mode, separated clinically and non-clinically acquired samples. Analysis based on area under the 
receiver operating characteristic curve (AUC) revealed differential metabolites for negative and positive 
lung cancer that had an AUC value of greater than 0.8. This preliminary analysis suggests sputum is a 
viable sample, and metabolomics has potential as a diagnostic and/or discriminator tool. Furthermore, it 
can identify specific key metabolites that could aid clinical intervention and targeted diagnosis of lung 
cancer within an ‘at risk’ population group. Metabolomics is a promising method for the identification of 
clinically useful biomarkers in the detection of lung cancer, but further work is required to establish 




[ 177 ] 
7.1.3 | Lung Cancer Diagnostic Patent Application 
 
A patent application was made by Aberystwyth University to the UK Intellectual Property Office covering 
the work detailed in Chapter 2 on the use of microbiome biomarkers for the diagnosis and lung cancer 
stage and status. The patent application was made on 19th December 2014, with reference number 
P102979GB01. 
 
PATENT APPLICATION ABSTRACT | The present invention relates to methods for the diagnosis of lung 
cancer (LC) status in a subject by determining the level of at least one specific 5 bacterial species relative 
to the level of at least one other bacterial species present in a sample which has been obtained from the 
subject (Fig. 3). The invention further provides a method of diagnosing LC stage in a subject by 
determining the level of at least one specific bacterial species in a sample which has been obtained from 
the subject, relative to the level of specific 10 bacterial species in a control. Also provided are kits, 
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1Institute of Biological, Environmental and Rural Sciences, Edward Llywd Building, Penglais Campus, Aberystwyth, SY23 3FG, UK. 2Department of Respiratory Medicine, Prince Phillip Hospital, Llanelli, SA14 8LY, UK. 3College of Medicine, 
Swansea University, Swansea, SA2 8PP, UK.
*sjc8@aber.ac.uk †lum@aber.ac.uk #jip@aber.ac.uk
(1) Jemal A et al., (2010) CA: A Cancer Journal for Clinicians 60: 277–300
(2) Young RP et al., (2010) The European Respiratory Journal 36: 1375–1382. (3) Erb-
Downward JR et al., (2011) PLoS ONE 6(2): e16384.
• Lung Cancer is the most prevalent cancer in the world, with 1.3 million deaths recorded each
year. However, unlike most other cancers, it has seen very little change in its overall five year
survival rate over the last 30 years1.
• Worldwide, lung cancer and Chronic Obstructive Pulmonary Disease (COPD), a condition
affecting the lungs ability to bring air in and out of the body, have a high level of morbidity and
mortality, and share common risk factors in terms of tobacco smoking and a genetic
predisposition2.
• The microbiome of patients with COPD has been investigated3, but as of yet, there has been no
reported study of the microbiome in patients with lung cancer. In this study we aimed to
address this lack of insight in to the lung microbiome of patients with lung cancer.
• This is the first piece of work to investigate the lung cancer microbiome, in addition
to expanding our knowledge of COPD via analysis of the microbiome function.
• The structure of the microbiome in the three disease groups is similar; with no taxon
being common amongst all samples in a group, and unique to that group.
• This work suggests that for COPD, the function of the microbiome is different to that
of lung cancer and control samples, although the structure is the same.
• COPD functional differences appear to focus on an increased percentage of
sequences related to cellular growth, indicating a potential for rapid colonisation,
which may be an important factor in COPD exacerbations.
Figures Key: Control Lung Cancer COPD
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PC1 ( 19.54% )
• MG-RAST was used to align metagenomic sequences to the M5NR database, at a
sequence identity of 97% and minimum alignment length of 15, to identify their
taxonomic origins.
• As with other studies looking at taxonomic changes to the microbiome structure of the
human respiratory system3, our results support the observation that there is no genus,
or species, that is common to all samples within a disease group, but unique to that
disease group.
• At the genus level, only Staphylococcus, Streptococcus, Ochrobactrum, Neisseria, and
Pseudomonas were found in all 30 samples. Enterococcus, Lactobacillus, Veillonella,
Fusobacterium, Brucella, Salmonella, Haemophilus, and Xanthomonas were found in at
least 90% of samples.
• Principal Component Analysis (PCA) suggests a partial separation between the control
and the clinically acquired samples, particularly COPD, but this is by no means absolute.
• There were no taxons at which there were significant differences in the percentage of
normalised reads between each disease group.
• Spontaneous sputum samples were collected from a total of 20 clinical patients with either
non-exacerbating-COPD (10) or lung cancer (10), and ten healthy age-matched individuals
with no history of clinical lung disease.
• After DNA extraction using 100 µL of raw sputum, 50 ng of each sample was multiplexed
using Illumina’s Nextera DNA kit.
• Libraries then underwent paired-end sequencing using the Illumina HiSeq2500 rapid run
platform with 2 x 151 bp reads, over two lanes. This generated approximately 10 million
paired end reads per sample, after quality control using the MG-RAST metagenomic
pipeline.
• Analysis of resulting sequencing statistics, post quality control, revealed no differences
between the base pair counts (p=0.418) and sequence counts (p=0.351) for each of the
three disease groups. The control group had significantly longer reads (p=0.000), by
approximately ten bases, and the lung cancer group had a higher average GC content
(p=0.037) by approximately 1.5 percentage points.
• To gauge the overall bacterial load in the sputum of participants, quantitative PCR, targeting
the 16S rDNA gene, using 2 µL of neat DNA was completed.
• No significant differences (p=0.726) were detectable between the three disease groups in
terms of bacterial load. Additionally, no correlation was evident (p=0.421) between the
concentration of extracted DNA and estimated 16S rDNA copy number.
• The ratio of DNA concentration to estimated 16S rDNA copy number is significantly
increased in COPD and lung cancer patients (p=0.004), suggesting that the increased DNA

























































































• MG-RAST was used to identify the functional role of metagenomic
sequences using the Subsystems annotation source, with a sequence
identity of 97% and minimum alignment length of 15.
• Although there appear to be no structural disease-caused changes to
the microbiome, functional changes appear evident.
• COPD samples have increased percentages of normalised reads for
Level 1 categories including those involved in nucleosides and
nucleotides, DNA metabolism, cofactors and vitamins, and
clustering-based subsystems.
• PCA suggests a partial separation between the control samples and
the clinically acquired samples, but this is by no means absolute.
• COPD samples have reduced percentages of genes involved in heavy
metal resistance, glycerol, lactose, and galactose utilisation, and
pyruvate metabolism.
• In general, COPD samples show a significantly higher percentage of
genes involved in growth, suggesting an increased capacity for
microbial cell turnover and growth in patients with COPD.
Figures Key: Control Lung Cancer COPD
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FIG 1: PRINCIPAL COMPONENT ANALYSIS (PCA) OF FINGERPRINTING METABOLITES
PCA plots were created for (a) negative and (b) positive LTQ-MS metabolites, and (c) GC-MS metabolites. The negative LTQ-MS
profile showed the best separation, with the non-clinical controls being clearly different to the clinically acquire d samples.
FIG 4: RECEIVER OPERATING CHARACTERISTIC CURVE ANALYSIS FOR BIOMARKER IDENTIFICATION
Using the online facility ROCCET, univariate receiver operating characteristic curves (ROC) were created, and plotted to create
area under the curve (AUC) figures for negative LTQ-MS metabolites. The top five AUC values for each comparison are given,
showing a number of metabolites that could have a role as clinically useful biomarkers.
Simon J. S. Cameron1*, Keir E. Lewis2, 3, Manfred Beckmann1, Gordon G. Allison1, Robin Ghosal2, Paul D. Lewis3, and Luis A. J. Mur1†.
1Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Ceredigion, SY23 3FG, UK. 2Department of Respiratory Medicine, Prince Phillip Hospital, Llanelli, SA14 8LY, UK. 3College of Medicine, Swansea University, Swansea, SA2 8PP, UK.
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Male 20 10 11
Female 13 1 12
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Current 15 3 10
Ex 0 8 10
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67.18/1479.81 1.00 4.47 x 10-15 -2.38
67.18/1560.81 1.00 3.10 x 10-15 -2.26
69.09/1479.81 0.99 6.09 x 10-15 -2.25
69.09/1560.81 0.99 3.64 x 10-15 -2.14








53.27/75.09 1.00 8.74 x 10-24 4.71
69.09/75.09 1.00 7.42 x 10-24 4.69
189.09 1.00 6.12 x 10-20 2.57
187.09 0.99 1.42 x 10-18 3.00







1496.72 0.85 2.93 x 10-3 -0.03
957.36 0.83 4.57 x 10-3 0.31
1382.45 0.83 5.93 x 10-4 0.07
1396.27 0.82 1.28 x 10-2 0.00



















































PC1 ( 40.0 % )
FIG 3: BIOMARKER DETECTION USING RANDOM FOREST
A Random forest plot was constructed, using
MetaboAnalyst 2.0 for negative LTQ-MS metabolites,
which revealed a number of metabolites, which may have
potential in terms of diagnostic markers, particularly
those that are either higher or lower in the LC+ group.
FIG 2: HIERARCHICAL CLUSTERING AND HEATMAP
Hierarchical cluster analysis, based on the top 25
negative LTQ-MS metabolites, identified by one-way
ANOVAs, shows a similar degree of clustering as the
PCA plot, with the clinical samples separating from
non-clinical samples.




































SPONTANEOUS SPUTUM COLLECTION: 34 clinical
patients (23 LC positive (LC+) (16 NSCLC, six SCLC, and
one radiological diagnosis), and 11 negative (LC-)), in
addition to 33 non-clinical controls (CON), (details in
table, standard deviation in brackets, NC = not
collected), gave sputum samples.
LTQ-MS PROFILING: A 50 % dilution of sputum
underwent protein precipitation with acetone, then
mixed with 70 % methanol before injection, in a
randomised order, into a LTQ linear ion trap, in
alternating positive and negative modes.
GC-MS PROFILING: For duplicate samples, protein
precipitation was completed, as above. Derivitization
was completed with methoxyamine and BSTFA, and
run on an Agilent 6890N GC linked to a 5973N mass-
spectrometer.
DATA ANALYSIS: Data was normalised, and analysed
using PyChem3, MetaboAnalyst 2.04, and ROCCET5.
LC is the most prevalent cancer in the world, and responsible for 1.3 million deaths each
year1. The key to improving the five-year survival rate is the development of novel
screening and diagnostic methodologies which allow for patients to be identified at an
earlier stage in the disease, thereby increasing the clinical effectiveness of interventions.
Previous work by this research group has involved evaluating Fourier Transform infrared
spectroscopy (FTIR), as a screening platform. FTIR was shown to differentiate between
sputum from patients with and without LC. Furthermore, it supported the role that
sputum could play as a biofluid for use in LC screening2.
The aim of this study was to employ metabolomic fingerprinting to identify clinically
relevant biomarkers, that could be used for the early detection of LC. This work is a
foundation from which other studies, using larger numbers, could be based.
(1) WHO, 2013. Cancer Factsheet. WHO Fact Sheets, Number 2970. (2) Lewis, P.D., et al.,
(2010). BMC Cancer. (3) Jarvis, R.M., et al., (2006). Bioinformatics 22, 2565-6. (4) Xia, J.,
et al., (2012). Nucleic Acid Research. 40, W127-33. (5) Xia, J., et al., (2012).
Metabolomics 9, 280-299. (6) Rivera et al., (2013). Chest Journal 143, e142S-e165S.
* sjc8@aber.ac.uk or sjcameron@gmail.com † lum@aber.ac.uk
INTRODUCTION: Developing novel screening and diagnosis methodologies will allow
earlier diagnosis of lung cancer (LC), increasing the effectiveness of clinical interventions.
We tested the potential of the metabolomic approach known as metabolite fingerprinting
of sputum to differentiate between patients with and without LC. Fingerprinting
techniques use rapid high-throughput screening to identify variables which discriminate
between samples without necessarily identifying them.
METHODS: Patients: We collected and processed the spontaneous sputum of 34 patients
with suspected LC, alongside 33 healthy controls from staff at Swansea University, with no
history of lung disease. Of the 34 patients, 23 were subsequently diagnosed with lung
cancer (16 NSCLC, six SCLC, and one radiological diagnosis) at various stages of disease
progression. Procedure: The 67 samples were profiled using linear quadrupole ion trap
mass spectrometry (LTQ-MS) and gas-chromatography mass spectrometry (GC-MS).
RESULTS: Principal component analysis clearly separated the clinically and non-clinically
acquired samples using metabolites in negative LTQ-MS mode. Further, hierarchical
cluster analysis, based on the top 25 metabolites identified through one-way ANOVAs in
negative LTQ-MS mode, separated clinically and non-clinically acquired samples. Analysis
based on area under the receiver operating characteristic curve (AUC) revealed
differential metabolites for negative and positive LC, with AUC values of greater than 0.8.
CONCLUSION: This preliminary analysis suggests that metabolomics could be used as a
diagnostic and/or discriminator tool for LC diagnosis. Ultimately, it will identify key
metabolites that could aid our understanding of the molecular pathogenesis of LC and








COMPARISON OF LTQ-MS AND GC-MS FINGERPRINTING APPROACHES: Metabolite
fingerprints were modelled using principal component analysis (FIG 1), with metabolites
in negative LTQ-MS mode (FIG 1a), showing the greatest degree of separation, though
predominately between the clinically and non-clinically acquired samples. Metabolites
identified in positive LTQ-MS (Fig 1b) and GC-MS (FIG1c) showed some degree of
separation, though not as markedly as negative LTQ-MS metabolites. Similar separations
were seen in hierarchical cluster analysis (FIG 2) with negative LTQ-MS metabolites.
TARGETING OF CLINICALLY RELEVANT METABOLOMIC BIOMARKERS: Because of the
greater degree of separation shown using negative LTQ-MS metabolites, only these
metabolites were used for the identification of potential biomarkers. A range of negative
LTQ-MS metabolites (FIG 3 and 4) were suggested as potential biomarkers for LC status.
Metabolites with very high AUC values, approximately 1.0, were differential between
clinical and non-clinical samples. Additionally, metabolites with AUC values of greater
than 0.8 were identified as differentials between LC+ and LC- groups.
DISCUSSION: Here we have reported on preliminary analysis suggesting that sputum is a
viable diagnostic medium from which metabolite biomarkers could be used in the
detection of LC. Specifically, we have identified a number of metabolites, with AUC values
above 0.8, that are able to differentiate between positive and negative LC cases, in a
clinical group of patients presenting with suspected LC. This suggests that this method
may have a similar level of sensitivity and specificity as other methods, such as sputum
cytology and bronchoscopy6, without the need for an invasive procedure. This may make
metabolomics an ideal, high-throughput tool for a preliminary negative/positive screen of
‘at-risk’ patients, which would identify them for further clinical diagnosis.
FUTURE PLANS: This preliminary study has suggested the potential application of
metabolomics as a novel screening/diagnosis methodology for LC. Future work will
concentrate on a larger number of clinical patients to establish whether metabolomics
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7.2 | Chapter 3 Output 
 
A range of outputs were created as a result of the work detailed in Chapter 3. These are detailed here, 
including manuscript abstracts and graphical representations of posters for scientific conferences. 
 
7.2.1 | COPD Metagenomics Publication 
 
Simon J. S. Cameron, Keir E. Lewis, Sharon A. Huws, Matthew J. Hegarty, Paul D. Lewis, Luis A. J. Mur, 
Justin A. Pachebat. (2014) The Structure and Function of the Upper Respiratory Microbiome in Patients 
with Chronic Obstructive Pulmonary Disease Revealed Through Metagenomic Sequencing. Under Review 
at Scientific Reports. 
 
ABSTRACT | The lung microbiome in COPD has been well-characterised, but little is known about the 
functional capacity of the microbiome that can be revealed by metagenomics. Genomic DNA was 
isolated from spontaneous sputa (sampling the upper respiratory tract) from ten control participants 
and eight patients with moderate to severe COPD. Barcoded Nextera® libraries were constructed from 
each sample and sequenced on the HiSeq 2500 platform. Resulting sequences were then analysed using 
the MG-RAST pipeline; an automated analysis platform for metagenomes. Principal component analyses 
showed partial separation for COPD based on for bacterial taxonomy and to a lesser extent based on 
function.  Significant differences were observed in the abundance of bacterial species, particularly 
within the Streptococcus genus in COPD patients. The pathogenic species Staphylococcus aureus, 
Stenotrophomonas maltophilia, Streptococcus agalactiae and Streptococcus pyogenes were found in all 
COPD samples, but not all Control samples. Functional differences in the metagenomes from COPD 
patients were consistent with a greater bacterial growth capacity.  Regression analyses correlated COPD 
severity with differences within the Streptococcus genus, specifically Streptococcus pneumonia.  
Metagenomic functional classifications indicated reduced bacterial sialic acid metabolism as COPD 
progressed. This pilot study has linked COPD severity to changes in abundance of S. pneumonia and 
reduced bacterial sialic acid metabolism which would allow host recognition to influence the 
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inflammatory response in the lung. Thus, the functional capacity of the COPD microbiome may be a 
factor in bacterial-associated progression and raises a number of avenues for further study including the 
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7.2.2 | Midlands Molecular Microbiology Meeting (15th to 16th September 2014) 
 
 
Simon J. S. Cameron1*, Keir E. Lewis2,3, Sharon A. Huws1, Matthew J. Hegarty1, Paul D. Lewis3, Luis A. J. Mur1† and Justin A. Pachebat1
1 Institute of Biological, Environmental and Rural Sciences, Edward Llywd Building, Penglais Campus, Aberystwyth, SY23 3FG, UK. 2 Department of Respiratory Medicine, Prince Phillip Hospital, Llanelli, SA14 8LY, UK. 3 College of 
Medicine, Swansea University, Swansea, SA2 8PP, UK. *Presenting Author: sjc8@aber.ac.uk †Communicating Author: lum@aber.ac.uk
(1) Lopez AD et al., (2006) Eur Respir J 27: 397-412. (2) Han MK et al.,
(2012) Thorax 67: 456-463. (3) Bittar F and Rolain JM, (2010) Clin Microbiol Infect 16:
809-820. (4) Borges TJ et al., (2012) Front Immunol 3: 95. (5) Cao H et al., (2011)
Immunology 132: 18-26.
• Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of death and
morbidity worldwide, leading to an estimated 2.75 millions deaths worldwide
in 20061.
• COPD is usually caused by smoking, and is an umbrella term for a multi-
systemic inflammatory state, including diseases such as emphysema.
• Patients experience acute exacerbations, which may be triggered by infection
or environmental pollutants. Around 75% are attributed to viral or bacterial
infection, or a combination of both2.
• The majority of microbiome work in COPD has employed sequencing of the
16S rRNA gene. However, minimal work has been undertaken to understand
the function of the microbiome, and its species-level structure.
• Spontaneous sputum samples were collected from eight COPD patients
(three moderate (GOLD II) and five severe (GOLD III)), and ten age-matched,
controls, either present or ex smokers, with no history of lung disease.
• After DNA extraction using 100 µL of raw sputum, 50 ng of each sample was
multiplexed using Illumina’s Nextera DNA kit.
• Libraries then underwent paired-end sequencing using the Illumina
HiSeq2500 rapid run platform with 2 x 151 bp reads, over two lanes. This
generated approximately 10 million paired end reads per sample, after
quality controls using the MG-RAST metagenomic pipeline.
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FEV1 % of Predicted Smoking Pack Years Age
R2 R2 - adj P R2 R2 - adj P R2 R2 - adj P
Streptococcus + 51.8 43.7 0.044 23.1 10.3 0.228 20.6 7.3 0.259
Streptococcus pneumonia + 63.6 57.6 0.018 8.4 0.0 0.487 40.1 30.1 0.092
Di- and oligosaccharides + 50.8 42.6 0.047 1.8 0.0 0.752 29.7 18.0 0.162
Sialic Acid Metabolism + 51.1 42.9 0.046 18.1 4.5 0.293 40.0 30.0 0.092
Figure 2 | Significant changes in species abundance
Figure 3 | Significant changes in 
functional classification abundance
Figure 1 | Variations in species abundance in the ‘Core Microbiome’
Table 1 | Regression analysis for COPD patients using FEV1% of predicted, smoking pack years and age
• We found eight bacterial genera which were present in all 18 samples:
Haemophilus, Lactobacillus, Neisseria, Ochrobactrum, Pseudomonas,
Staphylococcus, Streptococcus, and Veillonella.
• At the species level (Figure 1), there are four species present in all 18
samples.
• Four additional species were found in all of the COPD samples but not all
control samples – Streptococcus aureus, Stenotrophomonas maltophilia,
Streptococcus agalactiae, and Streptococcus pyogenes, suggesting their
potential to act as biomarkers of the disease.
• Significantly, all of these species are human pathogens, with S. pyogenes
being the most pathogenic Streptococcal bacterium.
• Some non-human eukaryotic sequences were
identified, but no significant differences in
species abundance were detected.
• Some species which exhibited statistically
significant fold changes in abundance between
COPD and controls were detected (Figure 2).
• The Streptococcus genus in particular appeared
to exhibit many changes in abundance in COPD
patient samples, with both increases and
decreases compared to the Control group.
• These changes suggest that the lung microbiome
in COPD is in flux, which may be characteristic of
the altered environment in the lung.
• Significant increases in functional alignments appear
to centre on those involved in bacterial growth,
nucleosides and nucleotides, and amino acid,
protein and RNA metabolism (Figure 3).
• Similar bacterial genomic flux also appears to be a
feature of cystic fibrosis patients3.
• Significant increase in alignments to the heat shock
dnaK gene cluster, which in bacteria, is responsible
for producing the heat shock protein Hsp70.
• Analogues of which have been shown to have
significant anti-inflammatory responses5, and could
provide a mechanism for bacterial defence from the
environment of the COPD lung.
• Significant positive correlations were found between COPD severity, based on FEV1 % of predicted, with the
Streptococcus genus, and more specifically Streptococcus pneumonia. Additional, functional positive correlations
were observed with the Level 2 classification of di- and oligosaccharides, and at Level 3 with sialic acid metabolism.
• Additionally, these correlations were not observed in regards to smoking pack years, or age.
• S. pneumonia is commonly cultured from the sputum of patients during exacerbations, and is the main initial target
of treatment with penicillin. Detecting changes in S. pneumonia load may allow for prediction of COPD progression
and allow earlier interventions.
• Sialic acid are monosaccharides found commonly on the outside of vertebrate, and some microbial cells. Sialic acid
interactions serve to maintain a baseline, non-activated state of innate immune cells, and limit inflammatory
responses activation through PAMP/DAMP recognition5.
• Here, sialic acid metabolism is correlated with decreasing FEV1 scores which would indicate a shift towards a lesser
capacity to avoid recognition and thus suppress inflammation – a key feature of COPD. Thus, a reduction in sialic acid
metabolising bacteria could be an important pathological feature in COPD progression.
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7.3 | Chapter 4 Output 
 
The outputs from the work detailed in Chapter 4 of this thesis are detailed here. 
 
7.3.1 | Human Salivary Microbiome Paper 
 
Simon J. S. Cameron, Matthew J. Hegarty, Dan Smith, Luis A. J. Mur. (2015) The Human Salivary 
Microbiome Shows Temporal Stability in Bacterial Diversity but not Load. Manuscript in Preparation. 
 
ABSTRACT | The human microbiome and metabolome are both important components of homeostasis, 
and in the monitoring of health and disease. However, the temporal stability of the human microbiome 
and metabolome has not been definitively established. Here, the saliva of 40 participants was collected 
every two months from October 2012 to October 2013, alongside lifestyle information. Samples were 
analysed through quantitative PCR to estimate bacterial load, measurement of pH, and metabolomic 
fingerprinting using negative mode LTQ-MS. A sub-group of ten participants with similar lifestyle 
information, underwent 16S rRNA (V3 to V4) amplicon sequencing. Estimated bacterial load was shown 
to be significantly (P < 0.001) higher in February 2013 than at all other sampling time points, with 
individuals’ changes between time points displaying significant (P = 0.003) flux. Salivary pH levels were 
shown to be significantly (P < 0.001) higher in December 2012 than in October 2012 and February 2013, 
with significant (P < 0.001) individual variations seen across the sampling period. In regards to the 
stability of the taxonomic composition of the salivary microbiome, α-diversity values showed significant 
differences between participants (P < 0.001), but not between sampling periods (P = 0.801), and a small, 
but significant positive correlation with salivary pH (R2 = 7.8%; P = 0.019). At the phylum level of 
classification, significant differences were evident between participants. The salivary metabolome also 
showed a strong degree of temporal stability. The salivary microbiome shows temporal stability in terms 
of bacterial taxonomic diversity, but not load, over a one year period, suggesting that comparing the 
human salivary microbiome and metabolome at different time points is valid.  
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7.4 | Chapter 5 Output 
 
The outputs from the work detailed in Chapter 5 of this thesis are detailed here. 
 
7.4.1 | White Mars Microbiome and Metabolome Paper 
 
Simon J. S. Cameron, Arwyn Edwards, Matthew J. Hegarty, Mike A. Stroud, Alexander Kumar, Robert 
Lambert, Luis A. J. Mur. (2015) Humans and Their Hidden Companions Cross Antarctica: The Microbiome 
and Metabolome Effects of White Mars. Manuscript in Preparation. 
 
ABSTRACT | The human microbiome and metabolome are important components of health and disease. 
The effects that prolonged human space travel could have on these are unclear, and could potentially 
impact the successful outcome of manned space travel, such as one to Mars. Here, we report on the 
microbiome and metabolome effects of the Trans-Antarctica Winter Traverse. Expedition members gave 
eight monthly stool, saliva, and blood plasma samples, and a preliminary baseline sample. Significant (P 
< 0.001) differences were seen between baseline salivary load and all other time points, but not 
between participants. Bacterial diversity was significantly (P = 0.002) lower in baseline samples than all 
other sampling months, though individual differences were also significant (P = 0.016). At the taxonomic 
level of classification, one phylum and six genera showed significantly different abundances between 
sampling months. The stool microbiome showed no difference in bacterial load between participants or 
sampling month, but bacterial diversity was significantly (P < 0.001) different between participants. 
Stool water content also showed significant (P < 0.001) differences between participants, as did pH of 
raw saliva (P < 0.001) and saliva supernatant (P = 0.001). In regards to metabolome changes, no 
difference was evident in any of the four biofluids profiled by either participant or sampling month. 
Overall, the human salivary microbiome shows significant and substantial changes in bacterial load and 
diversity as a result of the environmental and physiological stresses of the TAWT expedition. Thus, the 
human microbiome and metabolome is differentially affected based on site, which could have important 
implications for future, prolonged manned space travel to Mars.  
[ 185 ] 
7.5 | Non-Thesis Related Output 
 
In addition to the work detailed within this thesis, additional work was also completed that has been 
published in peer-reviewed journals. These are outlined below, alongside a description of the 
contribution given to each. 
 
7.5.1 | Jones et al., (2014) 
 
This research project investigated the physiological and immunological effects of supplementation with 
bovine colostrum in active males. Author contribution consisted of microbiome and metabolome work, 
including DNA extractions, 16S rRNA quantitative PCR, terminal restriction fragment length 
polymorphism analysis, metabolomic sample preparation, mass-spectrometry and analysis, subsequent 
data analysis and manuscript preparation. 
 
 
Jones, A.W., Cameron, S.J.S., Thatcher, R., Beecroft, M.S., Mur, L.A.J. and Davison, G. (2014). Effects of 
Bovine Colostrum Supplementation on Upper Respiratory Illness in Active Males. Brain, Behaviour, and 
Immunity 39, pp. 194–203. 
 
 
ABSTRACT | Bovine colostrum (COL) has been advocated as a nutritional countermeasure to exercise-
induced immune dysfunction and increased risk of upper respiratory illness (URI) in athletic populations, 
however, the mechanisms remain unclear. During winter months, under double-blind procedures, 53 
males (mean training load±SD, 50.5±28.9 MET-hweek(-1)) were randomized to daily supplementation of 
20g of COL (N=25) or an isoenergetic/isomacronutrient placebo (PLA) (N=28) for 12weeks. Venous blood 
was collected at baseline and at 12weeks and unstimulated saliva samples at 4 weeks intervals. There 
was a significantly lower proportion of URI days and number of URI episodes with COL compared to PLA 
over the 12weeks (p<0.05). There was no effect of COL on in vitro neutrophil oxidative burst, salivary 
secretory IgA or salivary antimicrobial peptides (p>0.05), which does not support previously suggested 
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mechanisms. In a subset of participants (COL=14, PLA=17), real-time quantitative PCR, targeting the 16S 
rRNA gene showed there was an increase in salivary bacterial load over the 12 weeks period with PLA 
(p<0.05) which was not as evident with COL. Discriminant function analysis of outputs received from 
serum metabolomics showed changes across time but not between groups. This is the first study to 
demonstrate that COL limits the increased salivary bacterial load in physically active males during the 
winter months which may provide a novel mechanism of immune-modulation with COL and a relevant 
marker of in vivo (innate) immunity and risk of URI. 
 
7.5.2 | Edwards et al., (2014) 
 
This research project investigated the microbial and metabolomic component of cryoconite holes found 
on polar glacial surfaces and alpine regions. Author contribution consisted of sequence analysis 




Edwards, A., Mur, L.A.J., Girdwood, S.E., Anesio, A.M., Stibal, M., Rassner, S.M.E., Hell, K., Pachebat, J.A., 
Post, B., Bussell, J.S., Cameron, S.J.S., Griffith, G.W., Hodson, A.J. and Sattler, B. (2014). Coupled 
Cryoconite Ecosystem Structure-Function Relationships are Revealed by Comparing Bacterial 
Communities in Alpine and Arctic Glaciers. FEMS Microbiology Ecology 89(2), pp. 222–237. 
 
 
ABSTRACT | Cryoconite holes are known as foci of microbial diversity and activity on polar glacier 
surfaces, but are virtually unexplored microbial habitats in alpine regions. In addition, whether 
cryoconite community structure reflects ecosystem functionality is poorly understood. Terminal 
restriction fragment length polymorphism and Fourier transform infrared metabolite fingerprinting of 
cryoconite from glaciers in Austria, Greenland and Svalbard demonstrated cryoconite bacterial 
communities are closely correlated with cognate metabolite fingerprints. The influence of bacterial-
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associated fatty acids and polysaccharides was inferred, underlining the importance of bacterial 
community structure in the properties of cryoconite. Thus, combined application of T-RFLP and FT-IR 
metabolite fingerprinting promises high throughput, and hence, rapid assessment of community 
structure–function relationships. Pyrosequencing revealed Proteobacteriawere particularly abundant, 
with Cyanobacteria likely acting as ecosystem engineers in both alpine and Arctic cryoconite 
communities. However, despite these generalities, significant differences in bacterial community 
structures, compositions and metabolomes are found between alpine and Arctic cryoconite habitats, 
reflecting the impact of local and regional conditions on the challenges of thriving in glacial ecosystems. 
 
7.5.3 | Huws et al., (2014) 
 
This research project investigated the effect of flax and echium oil diet supplementation on the rumen 
lipidome and microbiome. Author contribution consisted of sequence analysis generated from 454 




Huws, S.A., Kim, E.J., Cameron, S.J.S., Girdwood, S.E., Davies, L., Tweed, J., Vallin, H. and Scollan, N.D. 
(2014). Characterization of the Rumen Lipidome and Microbiome of Steers Fed a Diet Supplemented 
with Flax and Echium Oil. Microbial Biotechnology. In Press. 
 
 
ABSTRACT | Developing novel strategies for improving the fatty acid composition of ruminant products 
relies upon increasing our understanding of rumen bacterial lipid metabolism. This study investigated 
whether flax or echium oil supplementation of steer diets could alter the rumen fatty acids and change 
the microbiome. Six Hereford × Friesian steers were offered grass silage/sugar beet pulp only (GS), or GS 
supplemented either with flax oil (GSF) or echium oil (GSE) at 3% kg−1 silage dry matter in a 3 × 3 
replicated Latin square design with 21-day periods with rumen samples taken on day 21 for the analyses 
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of the fatty acids and microbiome. Flax oil supplementation of steer diets increased the intake of 
polyunsaturated fatty acids, but a substantial degree of rumen biohydrogenation was seen. Likewise, 
echium oil supplementation of steer diets resulted in increased intake of 18:4n-3, but this was 
substantially biohydrogenated within the rumen. Microbiome pyrosequences showed that 50% of the 
bacterial genera were core to all diets (found at least once under each dietary intervention), with 
19.10%, 5.460% and 12.02% being unique to the rumen microbiota of steers fed GS, GSF and GSE 
respectively. Higher 16S rDNA sequence abundance of the 
genera Butyrivibrio, Howardella, Oribacterium, Pseudobutyrivibrio and Roseburia was seen post flax 
feeding. Higher 16S rDNA abundance of the genus Succinovibrio and Roseburia was seen post echium 
feeding. The role of these bacteria in biohydrogenation now requires further study. 
 
7.5.4 | Hadfield et al., (2015) 
 
This research project aimed to develop a method of obtaining whole genome sequences of 
Cryptosporidium isolates from clinical samples, without the requirement to grow the parasite in an 
animal model. Author contribution consisted of developing a 16S rRNA qPCR screen to detect levels of 
bacterial contamination, and efficacy of purification methods to remove bacterial contamination. 
 
 
Hadfield S.J., Pachebat J.A., Swain M.T., Robinson G., Cameron S.J.S., Alexander J.L., Hegarty M., Elwin 
K., Chalmers R.M. (2015). Generation of whole genome sequences of new Cryptosporidium hominis and 
Cryptosporidium parvum isolates directly from stool samples. Submitted to BMC Genomics. 
 
 
ABSTRACT | Whole genome sequencing (WGS) of Cryptosporidium spp. has previously relied on 
propagation of the parasite in animals to generate enough oocysts from which to extract DNA of 
sufficient quantity and purity for analysis. We have developed and validated a method for preparation 
of genomic Cryptosporidium DNA suitable for WGS directly from human stool samples and used it to 
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generate 10 high quality whole Cryptosporidium genome assemblies. Our method uses a combination of 
salt flotation, immunomagnetic separation (IMS), and surface sterilisation of oocysts prior to DNA 
extraction, with subsequent use of the transposon-based Nextera XT kit to generate libraries for 
sequencing on Illumina platforms. IMS was found to be superior to caesium chloride density 
centrifugation for purification of oocysts from small volume stool samples and for reducing levels of 
contaminant DNA. The IMS-based method was used initially to sequence whole genomes of 
Cryptosporidium hominis gp60 subtype IbA10G2 and Cryptosporidium parvum gp60 subtype IIaA19G1R2 
from small amounts of stool left over from diagnostic testing of clinical cases of cryptosporidiosis. The C. 
parvum isolate was sequenced to a mean depth of 51.8x with reads covering 100% of the bases of the C. 
parvum Iowa II reference genome (Bioproject PRJNA 15586), while the C. hominis isolate was sequenced 
to a mean depth of 34.7x with reads covering 98% of the bases of the C. hominis TU502 v1 reference 
genome (Bioproject PRJNA 15585). The method was then applied to a further 17 stools, successfully 
generating another eight new whole genome sequences, of which two were C. hominis (gp60 subtypes 
IbA10G2 and IaA14R3) and six C. parvum (gp60 subtypes IIaA15G2R1 from three samples, and one each 
of IIaA17G1R1, IIaA18G2R1, and IIdA22G1), demonstrating the utility of this method to sequence 
Cryptosporidium genomes directly from clinical samples. This development is especially important for C. 
hominis for which symptomatic animal models, producing large numbers of oocysts, are lacking. This 
represents the first report of high quality whole genome sequencing of Cryptosporidium isolates 
prepared directly from human stool samples. 
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Chapter 2 | Supplementary Information 
 
Supplementary Table 2.1 | Microbiomics Full Participant Information 
Full participant information for ten patients who donated samples as part of the lung cancer 
microbiome portion of this work. Full participant information includes individual MG-RAST metagenome 
ID, age, sex, drug and medical history, smoking history, presence of infection, FEV1 % of predicted, and 
lung cancer state and staging. 
 
Supplementary Table 2.2 | Metagenomic Sequence Read Analysis 
Average read statistics for pre- and post-quality control (QC), for each group, alongside one-way ANOVA 
P values. Analysis shows no significant differences in all bar one, identified rRNA features, suggesting 
that the sequencing approach, and subsequent analysis using the MG-RAST pipeline, used in this study 
has not introduced any discernible bias between the two groups. 
 
Supplementary Table 2.3 | Metabolomics Full Participant Information 
Full individualised patient clinical information, including drug and medical history for all clinical patients, 
alongside relevant clinical diagnosis and histology, and information for participants from Swansea 
University. 
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Chapter 3 | Supplementary Information 
 
Supplementary Table 3.1 | COPD Metagenomics Full Participant Information 
Full participant information for Control participants and COPD patients, showing age, gender, and 
smoking history. Additional clinical information for COPD patients includes drug history, medical history, 
FEV1 % of predicted, and whether the patient had an infection at the time of giving a sample. nc = not 
collected. 
 
Supplementary Table 3.2 | Metagenomic Sequence Read Analysis 
Average read statistics pre and post quality control (QC), after merging of paired-end reads, alongside 
corresponding one-way ANOVA P values. Analysis shows no significant differences in all but one read 
characteristic, average read length both pre and post QC, suggesting that the HiSeq 2500 sequencing 
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Chapter 4 | Supplementary Information 
 
Supplementary Table 4.1 | Illumina Adaptors Used in 16S rRNA Amplicon Sequencing 
To allow for multiplexing of all 70 samples in one Illumina MiSeq 2 x 300 bp run, unique barcode 
sequences were added to the first stage PCR products after amplification of the V3 to V4 region of the 
16S rRNA gene. Illumina Nextera XT adaptors were used, and the specific Index 1 (i7) and Index 2 (i5) for 
each sample is given here. 
 
Supplementary Table 4.2 | Seasonal Variation Full Participant Information 
Individual participant information, for each of the seven sampling periods, is given here, alongside 
additional information collected during the October 2013 sampling period. All data is link anonymised. 
The individual participant information for those participants whose samples underwent amplicon 
sequencing of the 16S rRNA gene is also given. 
 
Supplementary Table 4.3 | Sequence Statistics for 16S rRNA Amplicon Sequencing 
Sequence statistics for those ten participants whose samples underwent amplicon sequencing of the 
16S rRNA gene, grouped by participant and sampling month. All features, except sequence length, GC 
content, and identified rRNA features in participant groupings, show no significant differences. All values 
given as means in standard format, except for sequence length and GC content statistics, with standard 
deviations. 
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Chapter 5 | Supplementary Information 
 
Supplementary Table 5.1 | Illumina Adaptors Used in 16S rRNA Amplicon Sequencing 
To allow for multiplexing of all 90 samples in one Illumina MiSeq 2 x 300 bp run, unique barcode 
sequences were added to the first stage PCR products after amplification of the V3 to V4 region of the 
16S rRNA gene. Illumina Nextera XT adaptors were used, and the specific Index 1 (i7) and Index 2 (i5) for 
each sample is given here. 
 
Supplementary Table 5.2 | Full Participant Physiological Information 
Full participant physiological information, namely weight, body mass index, and body fat percentage is 
given for each sampling month, which corresponds with when stool, saliva, and blood plasma samples 
were taken. 
 
Supplementary Table 5.3 | Sequence Statistics for Saliva 16S rRNA Amplicon Sequencing 
Sequence statistics for the 45 saliva samples which underwent amplicon sequencing of the 16S rRNA 
gene, grouped by participant and sampling month. All features, except sequence length, and GC content 
in participant groupings, show no significant differences. All values given as means in standard format, 
except for sequence length and GC content statistics, with standard deviations. 
 
Supplementary Table 5.4 | Sequence Statistics for Stool 16S rRNA Amplicon Sequencing 
Sequence statistics for the 45 stool samples which underwent amplicon sequencing of the 16S rRNA 
gene, grouped by participant and sampling month. All features, except processed rRNA features and 
aligned rRNA features showed some degree of significant difference between participant groupings, but 
all showed no significant differences in regards to sampling month groupings. All values given as means 
in standard format, except for sequence length and GC content statistics, with standard deviations. 
 
